Pyrimidoheterocyclic compounds and their applications

Abstract

To provide compounds and pharmaceutical compositions for the treatment of KRAS-related diseases.SOLUTION: The present invention provides a class of pyrimidoheterocyclic compounds, and specifically a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None

Description

[Technical Field]

[0001] This application is CN202010172140.2 filed March 12, 2020; CN202010323035.4 filed on April 22, 2020; CN202010953203.8 filed September 11, 2020; CN202011593642.9 filed on December 29, 2020 Priority is claimed based on

[0002] FIELD OF THE INVENTION The present invention relates to a class of pyrimidoheterocyclic compounds, particularly compounds of formula (III): or a pharmaceutically acceptable salt thereof: [Background technology]

[0003] Background of the Invention RAS oncogene mutations are the most common activating mutations in human cancer, occurring in 30% of human tumors. The RAS gene family includes three subtypes (KRAS, HRAS, and NRAS), of which 85% of RAS-driven cancers are caused by mutations in the KRAS subtype. KRAS mutations are commonly found in solid tumors such as lung adenocarcinoma, pancreatic ductal carcinoma, and colorectal cancer. In KRAS-mutated tumors, 80% of oncogenic mutations occur at codon 12, with the most common mutations including p.G12D (41%), p.G12V (28%), and p.G12C (14%).

[0004] The official name of the KRAS gene is Kirsten rat sarcoma viral oncogene homolog. KRAS plays a pivotal role in regulating cell proliferation signaling. After receiving external signals, upstream cell surface receptors such as EGFR (ErbB1), HER2 (ErbB2), ErbB3, and ErbB4 transmit the signals downstream via RAS proteins. When inactivated, KRAS tightly binds to GDP (guanosine diphosphate). After activation by guanosine exchange factors such as SOS1, KRAS binds to GTP (guanosine triphosphate) and becomes kinase-active. Mutations in the KRAS gene can independently transmit growth and proliferation signals to downstream pathways, regardless of upstream growth factor receptor signals, potentially leading to uncontrolled cell proliferation and tumor progression. At the same time, whether or not the KRAS gene is mutated is also an important indicator of tumor prognosis.

[0005] KRAS was the first oncogene discovered, but for a long time it was considered an undruggable target. It wasn't until 2019 that Amgen and Mirati Therapeutics published successful clinical study results for the small molecule KRAS inhibitors AMG510 and MRTX849, which confirmed for the first time the clinical efficacy of KRAS inhibitors in the clinical treatment of tumors. Both AMG510 and MRTX849 are irreversible small molecule inhibitors that inhibit KRAS activity by forming irreversible covalent bonds with cysteine ​​residues in KRAS G12C mutant proteins.

[0006] Statistical results show that 12-36% of lung adenocarcinomas are driven by KRAS mutations; 27-56% of colon cancers are driven by KRAS; and 90% of pancreatic cancers, 21% of endometrial cancers, and 12-36% of lung adenocarcinomas are driven by KRAS, indicating a large patient population. Among KRAS gene mutations, 97% occur at amino acid residues 12 or 13. G12D, G12V, and G13D mutations have poor druggability, while the KRAS (G12C) mutation, in which glycine at position 12 is replaced by cysteine, offers a promising path for the development of covalent inhibitors. Summary of the Invention

[0007] The present invention relates to a compound represented by formula (III) [ka] or a pharmaceutically acceptable salt thereof,

[0008] where:

[0009] T1 is selected from O and N;

[0010] R1 is C 6-10 aryl and 5-10 membered heteroaryl, wherein C 6-10 Aryl and 5- to 10-membered heteroaryl may optionally have 1, 2, 3, 4, or 5 R a is replaced by;

[0011] When T1 is O, R2 is absent;

[0012] When T1 is N, R2 is H, C 1-3 Alkyl, -C(=O)-C 1-3 Alkyl and -S(=O)2-C 1-3 alkyl, wherein C 1-3 Alkyl, -C(=O)-C 1-3 Alkyl and -S(=O)2-C 1-3 Alkyl may have one, two or three R b is replaced by;

[0013] R3 is C 1-3 alkyl, where C 1-3 Alkyl may have one, two or three R c is replaced by;

[0014] R4 is H and C 1-3 alkyl, wherein C 1-3 Alkyl may have one, two or three R d is replaced by;

[0015] R5, R6 and R7 are each independently H, F, Cl, Br, I and C 1-3 alkyl, wherein C 1-3 alkyl is optionally substituted with 1, 2 or 3 F;

[0016] R8 is selected from H and CH3;

[0017] R a are each independently F, Cl, Br, I, OH, NH2, CN, C 1-3 Alkyl, C 1-3 Alkoxy, C 2-3 Alkynyl and C 2-3 alkenyl, wherein C 1-3 Alkyl, C 1-3 Alkoxy, C 2-3 Alkynyl and C 2-3 alkenyl optionally substituted with 1, 2 or 3 F;

[0018] R b are each independently selected from F, Cl, Br, I, OH, and NH;

[0019] R c are each independently selected from 4- to 8-membered heterocycloalkyl, wherein the 4- to 8-membered heterocycloalkyl is optionally substituted with 1, 2, or 3 R;

[0020] R d are each independently selected from F, Cl, Br, I, OH, NH and CN;

[0021] R is independently H, F, Cl, Br, OH, CN, or C 1-3 Alkyl, C 1-3 Alkoxy and -C 1-3 Alkyl-O-CO-C 1-3 alkylamino;

[0022] provided that when R1 is naphthyl, the naphthyl is optionally substituted with F, Cl, Br, OH, NH2, CF3, CH2CH3, and -C≡CH; and R5, R6, and R7 are each independently H.

[0023] In one embodiment of the present invention, the R a are each independently selected from F, Cl, Br, I, OH, NH, CN, CH, CHCH, OCH, OCHCH, -CH=CH, -CH-CH=CH and -C≡CH, where CH, CHCH, OCH, OCHCH, -CH=CH, -CH-CH=CH and -C≡CH are optionally substituted with 1, 2 or 3 F, and the remaining variables are as defined herein.

[0024] In one embodiment of the present invention, the R a are each independently selected from F, OH, NH2, CH3, CF3, CH2CH3, and -C≡CH, and the remaining variables are as defined herein.

[0025] In one embodiment of the invention, R1 is selected from phenyl, naphthyl, indolyl, and indazolyl, wherein phenyl, naphthyl, indolyl, and indazolyl are optionally joined by one, two, or three R a and the remaining variables are as defined herein.

[0026] In one embodiment of the present invention, R1 is [ka] and the remaining variables are as defined herein.

[0027] In one embodiment of the invention, R2 is selected from H, CH3, CH2CH3 and CH(CH3)2, where CH3, CH2CH3 and CH(CH3)2 are optionally joined by one, two or three R band the remaining variables are as defined herein.

[0028] In certain embodiments of the invention, R2 above is selected from H and CH3, with the remaining variables being as defined herein.

[0029] In one embodiment of the invention, each R is independently H, F, Cl, Br, OH, CN, CH3, CH2CH3, CH2CF3, OCH3, OCF3, and [ka] and the remaining variables are as defined herein.

[0030] In one embodiment of the present invention, the R c is selected from tetrahydropyrrolyl and hexahydro-1H-pyrrolidinyl, where tetrahydropyrrolyl and hexahydro-1H-pyrrolidinyl are optionally substituted with 1, 2, or 3 R, and the remaining variables are as defined herein.

[0031] In one embodiment of the present invention, the R c teeth [ka] and the remaining variables are as defined herein.

[0032] In one embodiment of the present invention, the R c teeth [ka] and the remaining variables are as defined herein.

[0033] In one embodiment of the present invention, R3 is CH3, wherein CH3 is optionally selected from one, two, or three R c and the remaining variables are as defined herein.

[0034] In one embodiment of the present invention, R3 is [ka] and the remaining variables are as defined herein.

[0035] In one embodiment of the present invention, R3 is [ka] and the remaining variables are as defined herein.

[0036] In one embodiment of the invention, R4 is selected from H and CH3, where CH3 is optionally substituted with one, two or three R d and the remaining variables are as defined herein.

[0037] In certain embodiments of the invention, R4 above is selected from H, CH3 and CH2CN, with the remaining variables being as defined herein.

[0038] The present invention relates to a compound represented by formula (III) [ka] or a pharmaceutically acceptable salt thereof,

[0039] where:

[0040] T1 is selected from O and N;

[0041] R1 is selected from phenyl, naphthyl and indazolyl, where phenyl, naphthyl and indazolyl are optionally substituted with 1, 2, 3, 4 or 5 R a is replaced by;

[0042] When T1 is O, R2 is absent;

[0043] When T1 is N, R2 is H, C 1-3 Alkyl, -C(=O)-C 1-3 Alkyl and -S(=O)2-C 1-3 alkyl, wherein C 1-3 Alkyl, -C(=O)-C 1-3 Alkyl and -S(=O)2-C 1-3 Alkyl may have one, two or three R b is replaced by;

[0044] R3 is C 1-3 alkyl, where C 1-3 Alkyl may have one, two or three R c is replaced by;

[0045] R4 is H and C 1-3 alkyl, wherein C 1-3 Alkyl may have one, two or three R d is replaced by;

[0046] R5, R6 and R7 are each independently selected from H, F, Cl, Br, I, OH and NH2;

[0047] R8 is selected from H and CH3;

[0048] R a are each independently selected from F, Cl, Br, I, OH, NH2, CN, CH3, CF3, and OCH3;

[0049] R b are each independently selected from F, Cl, Br, I, OH, and NH;

[0050] R c are each independently selected from tetrahydropyrrolyl and hexahydro-1H-pyrrolidinyl, wherein tetrahydropyrrolyl and hexahydro-1H-pyrrolidinyl are substituted with one, two or three R;

[0051] R d are each independently selected from F, Cl, Br, I, OH, NH and CN;

[0052] Each R is independently selected from H, F, Cl, Br, and CH3.

[0053] In one embodiment of the present invention, the present invention relates to the above compound or a pharmaceutically acceptable salt thereof, wherein the compound is [ka] is selected from

[0054] where:

[0055] R4 is C 1-3 alkyl, where C 1-3 Alkyl may have one, two or three R d is replaced by;

[0056] T1, R1, R2, R3, R5, R6, R7 and R d is as defined herein;

[0057] Carbon atoms marked with an "*" are chiral carbon atoms that exist in the form of either an (R) or (S) single enantiomer or are enriched in one enantiomer.

[0058] In one embodiment of the present invention, R1 is phenyl, naphthyl, and [ka] wherein phenyl, naphthyl, and [ka] may have one, two or three R a and the remaining variables are as defined herein.

[0059] In one embodiment of the present invention, R1 is [ka] and the remaining variables are as defined herein.

[0060] In one embodiment of the invention, R2 is selected from H, CH3, CH2CH3 and CH(CH3)2, where CH3, CH2CH3 and CH(CH3)2 are optionally joined by one, two or three R b and the remaining variables are as defined herein.

[0061] In certain embodiments of the invention, R2 above is selected from H and CH3, with the remaining variables being as defined herein.

[0062] In one embodiment of the present invention, the R c teeth [ka] and the remaining variables are as defined herein.

[0063] In one embodiment of the present invention, the R c teeth [ka] and the remaining variables are as defined herein.

[0064] In one embodiment of the present invention, R3 is CH3, wherein CH3 is optionally selected from one, two, or three R c and the remaining variables are as defined herein.

[0065] In one embodiment of the present invention, R3 is [ka] and the remaining variables are as defined herein.

[0066] In one embodiment of the present invention, R3 is [ka] and the remaining variables are as defined herein.

[0067] In one embodiment of the invention, R4 is selected from H and CH3, where CH3 is optionally substituted with one, two or three R d and the remaining variables are as defined herein.

[0068] In certain embodiments of the invention, R4 above is selected from H, CH3 and CH2CN, with the remaining variables being as defined herein.

[0069] The present invention relates to a compound represented by formula (III) [ka] or a pharmaceutically acceptable salt thereof,

[0070] where:

[0071] T1 is selected from O and N;

[0072] R1 is selected from phenyl, naphthyl and indazolyl, where phenyl, naphthyl and indazolyl are optionally substituted with 1, 2, 3, 4 or 5 R a is replaced by;

[0073] When T1 is O, R2 is absent;

[0074] When T1 is N, R2 is H, C 1-3 Alkyl, -C(=O)-C 1-3 Alkyl and -S(=O)2-C 1-3 alkyl, wherein C1-3 Alkyl, -C(=O)-C 1-3 Alkyl and -S(=O)2-C 1-3 Alkyl may have one, two or three R b is replaced by;

[0075] R3 is C 1-3 alkyl, where C 1-3 Alkyl may have one, two or three R c is replaced by;

[0076] R4 is H and C 1-3 alkyl, wherein C 1-3 Alkyl may have one, two or three R d is replaced by;

[0077] R5, R6 and R7 are each independently selected from H, F, Cl, Br, I, OH and NH2;

[0078] R8 is selected from H and CH3;

[0079] R a are each independently selected from F, Cl, Br, I, OH, NH2, CN, CH3, CF3, and OCH3;

[0080] R b are each independently selected from F, Cl, Br, I, OH, NH2, and CH3;

[0081] R c are each independently tetrahydropyrrolyl, wherein the tetrahydropyrrolyl is substituted with one, two, or three R;

[0082] R d are each independently selected from F, Cl, Br, I, OH, NH and CN;

[0083] Each R is independently selected from F, Cl, Br, and CH3.

[0084] In one embodiment of the present invention, the present invention relates to the above compound or a pharmaceutically acceptable salt thereof, wherein the compound is [ka] is selected from

[0085] wherein T1, R1, R2, R3, R4, R5, R6 and R7 are as defined herein;

[0086] Carbon atoms marked with an "*" are chiral carbon atoms that exist in the form of either an (R) or (S) single enantiomer or are enriched in one enantiomer.

[0087] In one embodiment of the present invention, R1 is phenyl, naphthyl, and [ka] wherein phenyl, naphthyl, and [ka] may have one, two or three R a and the remaining variables are as defined herein.

[0088] In one embodiment of the present invention, R1 is [ka] and the remaining variables are as defined herein.

[0089] In one embodiment of the invention, R2 is selected from H, CH3, CH2CH3 and CH(CH3)2, where CH3, CH2CH3 and CH(CH3)2 are optionally joined by one, two or three R b and the remaining variables are as defined herein.

[0090] In certain embodiments of the invention, R2 above is selected from H and CH3, with the remaining variables being as defined herein.

[0091] In one embodiment of the present invention, the R c teeth [ka] and the remainder of the variables are as defined herein.

[0092] In one embodiment of the present invention, R3 is CH3, wherein CH3 is optionally selected from one, two, or three R c and the remaining variables are as defined herein.

[0093] In one embodiment of the present invention, R3 is [ka] and the remainder of the variables are as defined herein.

[0094] In one embodiment of the present invention, R4 is CH3, wherein CH3 is optionally selected from one, two, or three R d and the remaining variables are as defined herein.

[0095] In certain embodiments of the invention, R4 above is CH2CN, and the remaining variables are as defined herein.

[0096] The present invention relates to a compound represented by formula (II) [ka] or a pharmaceutically acceptable salt thereof,

[0097] where:

[0098] T1 is selected from O and N;

[0099] R1 is selected from phenyl and naphthyl, where phenyl and naphthyl are optionally joined by one, two or three R a is replaced by;

[0100] When T1 is O, R2 is absent;

[0101] When T1 is N, R2 is C 1-3 Alkyl, -C(=O)-C 1-3 Alkyl and -S(=O)2-C 1-3 alkyl, wherein C 1-3 Alkyl, -C(=O)-C 1-3 Alkyl and -S(=O)2-C 1-3 Alkyl may have one, two or three R b is replaced by;

[0102] R3 is C 1-3 alkyl, where C 1-3 Alkyl may have one, two or three R c is replaced by;

[0103] R4 is C 1-3 alkyl, where C 1-3 Alkyl may have one, two or three R d is replaced by;

[0104] R5, R6 and R7 are each independently selected from H, F, Cl, Br, I, OH and NH2;

[0105] R a are each independently selected from F, Cl, Br, I, OH, NH2, CN, CH3, and OCH3;

[0106] R b are each independently selected from F, Cl, Br, I, OH, NH2, and CH3;

[0107] R care each independently tetrahydropyrrolyl, wherein the tetrahydropyrrolyl is substituted with one, two, or three R;

[0108] R d are each independently selected from F, Cl, Br, I, OH, NH and CN;

[0109] R is independently selected from F, Cl, Br, and CH;

[0110] Carbon atoms marked with an "*" are chiral carbon atoms that exist in the form of either an (R) or (S) single enantiomer or are enriched in one enantiomer.

[0111] In one embodiment of the invention, R1 is naphthyl, wherein naphthyl optionally contains one, two, or three R a and the remaining variables are as defined herein.

[0112] In one embodiment of the present invention, R1 is [ka] and the remaining variables are as defined herein.

[0113] In one embodiment of the invention, R2 is selected from CH3, CH2CH3 and CH(CH3)2, where CH3, CH2CH3 and CH(CH3)2 are optionally joined by one, two or three R b and the remaining variables are as defined herein.

[0114] In certain embodiments of the invention, R2 above is CH3, and the remaining variables are as defined herein.

[0115] In one embodiment of the present invention, the R c teeth [ka] and the remainder of the variables are as defined herein.

[0116] In one embodiment of the present invention, R3 is CH3, wherein CH3 is optionally selected from one, two, or three R c and the remaining variables are as defined herein.

[0117] In one embodiment of the present invention, R3 is [ka] and the remainder of the variables are as defined herein.

[0118] In one embodiment of the present invention, R4 is CH3, wherein CH3 is optionally selected from one, two, or three R d and the remaining variables are as defined herein.

[0119] In certain embodiments of the invention, R4 above is CH2CN, and the remaining variables are as defined herein.

[0120] The present invention relates to a compound of formula (I) [ka] or a pharmaceutically acceptable salt thereof,

[0121] where:

[0122] R1 is selected from phenyl and naphthyl, where phenyl and naphthyl are optionally joined by one, two or three R a is replaced by;

[0123] R2 is C 1-3 Alkyl, -C(=O)-C 1-3 Alkyl and -S(=O)2-C 1-3 alkyl, wherein C1-3 Alkyl, -C(=O)-C 1-3 Alkyl and -S(=O)2-C 1-3 Alkyl may have one, two or three R b is replaced by;

[0124] R3 is C 1-3 alkyl, where C 1-3 Alkyl may have one, two or three R c is replaced by;

[0125] R4 is C 1-3 alkyl, where C 1-3 Alkyl may have one, two or three R d is replaced by;

[0126] R5, R6 and R7 are each independently selected from H, F, Cl, Br, I, OH and NH2;

[0127] R a and R b are each independently selected from F, Cl, Br, I, OH, NH2, and CH3;

[0128] R c are each independently tetrahydropyrrolyl, wherein the tetrahydropyrrolyl is substituted with one, two, or three R;

[0129] R d are each independently selected from F, Cl, Br, I, OH, NH and CN;

[0130] R is independently selected from F, Cl, Br, and CH;

[0131] Carbon atoms marked with an "*" are chiral carbon atoms that exist in the form of either an (R) or (S) single enantiomer or are enriched in one enantiomer.

[0132] In certain embodiments of the invention, R1 above is naphthyl, and the remaining variables are as defined herein.

[0133] In one embodiment of the present invention, R1 is [ka] and the remainder of the variables are as defined herein.

[0134] In one embodiment of the invention, R2 is selected from CH3, CH2CH3 and CH(CH3)2, where CH3, CH2CH3 and CH(CH3)2 are optionally joined by one, two or three R b and the remaining variables are as defined herein.

[0135] In certain embodiments of the invention, R2 above is CH3, and the remaining variables are as defined herein.

[0136] In one embodiment of the present invention, the R c teeth [ka] and the remainder of the variables are as defined herein.

[0137] In one embodiment of the present invention, R3 is CH3, wherein CH3 is optionally selected from one, two, or three R c and the remaining variables are as defined herein.

[0138] In one embodiment of the present invention, R3 is [ka] and the remainder of the variables are as defined herein.

[0139] In one embodiment of the present invention, R4 is CH3, wherein CH3 is optionally selected from one, two, or three R d and the remaining variables are as defined herein.

[0140] In certain embodiments of the invention, R4 above is CH2CN, and the remaining variables are as defined herein.

[0141] In one embodiment of the present invention, the present invention relates to the above compound or a pharmaceutically acceptable salt thereof, wherein the compound is [ka] is selected from

[0142] where R1, R5 and R c is as defined herein;

[0143] R4 is C 1-3 alkyl, where C 1-3 Alkyl may have one, two or three R d is replaced by;

[0144] R d are each independently selected from F, Cl, Br, I, OH, NH and CN;

[0145] Carbon atoms marked with an "*" are chiral carbon atoms that exist in the form of either an (R) or (S) single enantiomer or are enriched in one enantiomer.

[0146] In one embodiment of the present invention, the present invention relates to the aforementioned compound or a pharmaceutically acceptable salt thereof, wherein the compound is: [ka] is selected from

[0147] where:

[0148] R1, R2, R4, R5, R6, R7, R8 and R are as defined herein.

[0149] The present invention also includes certain embodiments resulting from any combination of the above variables.

[0150] The present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof: [ka]

[0151] In one embodiment of the present invention, the present invention relates to the above compound or a pharmaceutically acceptable salt thereof, wherein the compound is [ka] [ka] is selected from.

[0152] In one embodiment of the present invention, the present invention relates to the above compound or a pharmaceutically acceptable salt thereof, wherein the compound is [ka] [ka] [ka] is selected from.

[0153] The present invention also provides the use of the above compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease associated with a KRASG12C mutant protein. [Effects of the Invention]

[0154] Technical effects The compounds of the present invention have good cell growth inhibitory activity against KRASG12C mutant MIA-PA-CA-2 cell line and NCI-H358 cells.The compounds of the present invention have good stability in liver microsomes, hepatocytes, plasma and whole blood, good PK properties and significant antitumor effects.

[0155] Related Definitions Unless otherwise specified, the following terms and phrases as used herein are intended to have the following meanings: A particular term or phrase should not be considered unclear or indefinite by the absence of a specific definition, but should be understood in its customary sense. When a trade name is used herein, it is intended to refer to the corresponding commercial product or active ingredient thereof.

[0156] The term "pharmaceutically acceptable" is used herein in reference to compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with human and animal tissues and without undue toxicity, irritation, allergic response or other problem or complication commensurate with a reasonable benefit / risk ratio.

[0157] The term "pharmaceutically acceptable salt" refers to a salt of a compound disclosed herein prepared by reacting a compound having certain substituents disclosed herein with a relatively non-toxic acid or base. When a compound disclosed herein contains a relatively acidic functional group, a base addition salt can be obtained by contacting the compound with a sufficient amount of base in a pure solution or in a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine, or magnesium salts or similar salts. When a compound disclosed herein contains a relatively basic functional group, an acid addition salt can be obtained by contacting the compound with a sufficient amount of acid in a pure solution or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts (wherein inorganic acids include, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, phosphorous acid, and the like); and organic acid salts (wherein organic acids include, for example, acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, methanesulfonic acid, and the like); and salts of amino acids (e.g., arginine, and the like) and organic acids such as glucuronic acid. Certain compounds disclosed herein contain both basic and acidic functional groups and can be converted into either base or acid addition salts.

[0158] The pharmaceutically acceptable salts disclosed herein can be prepared from a parent compound that contains an acidic or basic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base form of the compound with a stoichiometric amount of the appropriate base or acid in water or an organic solvent, or a mixture thereof.

[0159] The compounds disclosed herein may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereoisomers, (D)-isomers, (L)-isomers, and racemic and other mixtures, e.g., mixtures enriched in an enantiomer or diastereoisomer, all of which are encompassed within the scope of the present disclosure. Substituents such as alkyl can have additional asymmetric carbon atoms. All such isomers and mixtures thereof are encompassed within the scope of the present disclosure.

[0160] The compounds disclosed herein may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compounds. For example, the compounds may contain tritium ( 3 H), iodine-125( 125 I) or C-14( 14 The compounds may be labeled with a radioactive isotope, such as 1,2-dichloro- ...

[0161] The terms "optional" or "optionally" mean that the subsequently described event or circumstance may, but need not, occur, and are intended to include instances where the event or circumstance occurs and instances where the event or circumstance does not occur.

[0162] The term "substituted" means that one or more hydrogen atoms on a particular atom are replaced with a substituent, including deuterium and hydrogen variants, as long as the valence of the particular atom is normal and the substituted compound is stable. When the substituent is oxo (i.e., =O), it means that two hydrogen atoms are replaced. Aromatic ring positions cannot be substituted with oxo. The term "optionally substituted" means that an atom may or may not be substituted with a substituent unless otherwise specified, and the type and number of substituents are optional as long as they are chemically achievable.

[0163] When any variable (e.g., R) appears more than once in a compound configuration or structure, the definition of the variable at each occurrence is independent. Thus, for example, if a group is substituted with 0 to 2 R, the group may be optionally substituted with up to 2 R, where the definition of R at each occurrence is independent. Furthermore, combinations of substituents and / or variants thereof are permissible only if such combinations result in stable compounds.

[0164] When the number of linking groups is 0, such as -(CRR)0-, it means that the linking group is a single bond.

[0165] When one of the variables is a single bond, it means that the two groups linked by the single bond are directly connected. For example, when L in ALZ represents a single bond, the structure of ALZ is actually AZ.

[0166] When the linking direction is not indicated for the linking group, the linking direction is arbitrary. For example, [ka] When the linking group L is -MW-, -MW- is linked to ring A and ring B in the same direction as the reading order from left to right, [ka] or concatenate rings A and B in reverse left-to-right reading order, [ka] Combinations of linking groups, substituents and / or variants thereof are permissible only if such combinations result in stable compounds.

[0167] Unless otherwise specified, when a group has one or more connectable sites, any one or more sites of the group can be connected to other groups via chemical bonds. When the connection position of the chemical bond is variable and there is an H atom at the connectable site, when the connectable site having an H atom is connected to a chemical bond, the number of H atoms at this site decreases corresponding to the increase in the number of connected chemical bonds, and the group becomes a group with the corresponding valence. The chemical bond between the site and other groups is [ka] For example, the straight solid bond in -OCH3 indicates that the group is connected to another group through the oxygen atom of the group; [ka] means that the group is connected to another group through two ends of the nitrogen atom of the group; [ka] The wavy lines indicate that the group is connected to another group through the 1- and 2-carbon atoms of the phenyl group; [ka] indicates that any connectable site on the piperidinyl group can be connected to another group via one chemical bond, and there are at least four ways of connecting the two groups. [ka] even if an H atom is depicted above -N-, [ka] Hanao [ka] The only difference is that when one chemical bond is attached, one H is removed from that site and the group becomes the corresponding monovalent piperidinyl group.

[0168] Solid wedge connections unless otherwise specified [ka] and wedge-shaped dashed bond [ka] indicates the absolute configuration of a stereocenter; a straight solid bond [ka] and straight dashed bond [ka] indicates the relative configuration of stereocenters; wavy line [ka] is a solid wedge connection [ka] or wedge-shaped dashed bond [ka] or wavy line [ka] is a straight solid line connection [ka] and straight dashed bond [ka] For example, [ka] teeth [ka] represents [ka] teeth [ka] Represents.

[0169] Unless otherwise specified, the terms "enriched in one isomer," "isomer-enriched," "enriched in one enantiomer," or "enantiomer-enriched" mean that the amount of one isomer or enantiomer is less than 100%, but that the amount of said isomer or enantiomer is 60% or more, or 70% or more, or 80% or more, or 90% or more, or 95% or more, or 96% or more, or 97% or more, or 98% or more, or 99% or more, or 99.5% or more, or 99.6% or more, or 99.7% or more, or 99.8% or more, or 99.9% or more.

[0170] Unless otherwise specified, the terms "isomeric excess" or "enantiomeric excess" refer to the relative percentage difference between two isomers or two enantiomers. For example, when one isomer or enantiomer is present in an amount of 90% and the other isomer or enantiomer is present in an amount of 10%, the isomeric or enantiomeric excess (ee value) is 80%.

[0171] Optically active (R)- and (S)-isomers, or D- and L-isomers, can be prepared using chiral synthesis or chiral reagents, or other conventional techniques. When one enantiomer of a compound disclosed herein is to be obtained, the pure desired enantiomer can be obtained by asymmetric synthesis or derivatization with a chiral auxiliary, followed by separation of the resulting diastereomeric mixture and cleavage of the auxiliary. Alternatively, when the molecule contains a basic (e.g., amino) or acidic (e.g., carboxyl) functional group, the compound can be reacted with an appropriate optically active acid or base to form a diastereomeric salt, which can then be subjected to diastereomeric resolution via methods conventional in the art to obtain the pure enantiomers. Furthermore, enantiomers and diastereoisomers are typically isolated by chromatography using chiral stationary phases, optionally in combination with chemical derivatization methods (e.g., carbamates generated from amines).

[0172] Unless otherwise specified, the term "C 1-6 "Alkyl" is used to mean a straight or branched chain saturated hydrocarbon group of 1 to 6 carbon atoms. 1-6 Alkyl is C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C6 and C5 alkyl, etc. It can be monovalent (e.g., methyl), divalent (e.g., methylene), or polyvalent (e.g., methenyl). 1-6 Examples of alkyl include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, s-butyl and t-butyl), pentyl (including n-pentyl, isopentyl and neopentyl), hexyl, and the like.

[0173] Unless otherwise specified, the term "C 1-3 "Alkyl" is used to mean a straight or branched chain saturated hydrocarbon group of 1 to 3 carbon atoms. 1-3 Alkyl is C 1-2 Alkyl, C2-3 alkyl, etc. It can be monovalent (e.g., methyl), divalent (e.g., methylene), or polyvalent (e.g., methenyl). 1-3 Examples of alkyl include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like.

[0174] Unless otherwise specified, the term "C 1-3 "Alkoxy" means an alkyl group containing 1 to 3 carbon atoms and attached to the remainder of the molecule by an oxygen atom. 1-3 The alkoxy group is C 1-2 , C 2-3 , C3 and C2 alkoxy groups, etc. 1-3 Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), and the like.

[0175] Unless otherwise specified, the term "C 1-3 "Alkylamino" means an alkyl group containing 1 to 3 carbon atoms and attached to the remainder of the molecule by an amino group. 1-3 The alkylamino group is C 1-2 , C3 and C2 alkylamino groups, etc. 1-3 Examples of alkylamino groups include, but are not limited to, -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH3)CH2CH3, -NHCH2CH2CH3, -NHCH2(CH3)2, and the like.

[0176] Unless otherwise specified, "C 2-3 "Alkenyl" is used to mean a straight or branched chain hydrocarbon group of 2 to 3 carbon atoms containing at least one carbon-carbon double bond, where the carbon-carbon double bond may be located at any position within the group. 2-3 Alkenyl includes C3 and C2 alkenyl. 2-3 Alkenyl can be monovalent, divalent or polyvalent. 2-3 Examples of alkenyl include, but are not limited to, vinyl, propenyl, and the like.

[0177] Unless otherwise specified, "C 2-3 "Alkynyl" is used to mean a straight or branched chain hydrocarbon group of 2 to 3 carbon atoms containing at least one carbon-carbon triple bond, where the carbon-carbon triple bond may be located at any position within the group. 2-3 Alkynyl includes C3 and C2 alkynyl. 2-3 Examples of alkynyl include, but are not limited to, ethynyl, propynyl, and the like.

[0178] Unless otherwise specified, the term "C 6-10 Aromatic ring" and "C 6-10 The terms "aryl" and "aryl" may be used interchangeably herein. 6-10 Aromatic ring" or "C 6-10 "Aryl" means a cyclic hydrocarbon group having a conjugated pi-electron system and consisting of 6 to 10 carbon atoms. It may be a monocyclic, fused bicyclic, or fused tricyclic ring system, in which each ring is aromatic. It may be monovalent, divalent, or polyvalent. C 6-10 Aryl is C 6-9 , C9, C 10 and C6 aryl. 6-10 Examples of aryl include, but are not limited to, phenyl, naphthyl (including 1-naphthyl and 2-naphthyl, etc.).

[0179] Unless otherwise specified, the terms "5- to 10-membered heteroaromatic ring" and "5- to 10-membered heteroaryl" may be used interchangeably. The term "5- to 10-membered heteroaryl" refers to a cyclic group having a conjugated pi-electron system and consisting of 5 to 10 ring atoms, where 1, 2, 3, or 4 ring atoms are heteroatoms independently selected from O, S, and N, and the remainder are carbon atoms. It may be a monocyclic, fused bicyclic, or fused tricyclic ring system, where each ring is aromatic, the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O)). pwhere p is 1 or 2. A 5- to 10-membered heteroaryl can be attached to the remainder of the molecule via a heteroatom or a carbon atom. 5- to 10-membered heteroaryl groups include 5- to 8-membered, 5- to 7-membered, 5- to 6-membered, 5-membered and 6-membered heteroaryl groups. Examples of 5- to 10-membered heteroaryls include pyrrolyl (including N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5-oxazolyl, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1,2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl, etc.), thiazolyl (2-thiazolyl, 4-thiazolyl and 5-thiazolyl, etc.). and the like), furyl (including 2-furyl and 3-furyl, and the like), thienyl (including 2-thienyl and 3-thienyl, and the like), pyridyl (including 2-pyridyl, 3-pyridyl, and 4-pyridyl, and the like), pyrazinyl or pyrimidinyl (including 2-pyrimidinyl and 4-pyrimidinyl, and the like), benzothiazolyl (including 5-benzothiazolyl, and the like), purinyl, benzimidazolyl (including 2-benzimidazolyl, and the like), benzoxazolyl, indolyl (including 5-indolyl, and the like), isoquinolyl (including 1-isoquinolyl, 5-isoquinolyl, and the like), quinoxalinyl (including 2-quinoxalinyl, 5-quinoxalinyl, and the like) or quinolyl (including 3-quinolyl, 6-quinolyl, and the like).

[0180] Unless otherwise specified, the term "4- to 8-membered heterocycloalkyl," alone or in combination with other terms, means a saturated cyclic group of 4 to 8 ring atoms, respectively, where 1, 2, 3, or 4 ring atoms are heteroatoms independently selected from O, S, and N, and the remainder are carbon atoms, where the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O)).p where p is 1 or 2. The ring includes monocyclic and bicyclic ring systems, where bicyclic ring systems include spiro, fused, and bridged rings. Additionally, for "4- to 8-membered heterocycloalkyl," a heteroatom can be present at the position of attachment of the heterocycloalkyl group to the remainder of the molecule. 4- to 8-membered heterocycloalkyl includes 4- to 6-membered, 5- to 6-membered, 4-membered, 5-membered, and 6-membered heterocycloalkyl, etc. Examples of 4- to 8-membered heterocycloalkyl include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothienyl (including tetrahydrothien-2-yl and tetrahydrothien-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl, and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl, hexahydropyridazinyl, homopiperazinyl, homopiperidinyl, or dioxepanyl, etc.

[0181] Unless otherwise specified, C n-n+m or C n -C n+m includes any particular case of n to n+m carbons, e.g., C 1-12 are C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 and C 12 and any range from n to n+m, for example, C 1-12 is C 1-3 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C 6-9 , C 6-12 and C 9-12and the like; similarly, n-membered to n+m-membered rings means that the number of atoms in the ring is n to n+m, for example, a 3- to 12-membered ring includes a 3-membered ring, a 4-membered ring, a 5-membered ring, a 6-membered ring, a 7-membered ring, an 8-membered ring, a 9-membered ring, a 10-membered ring, an 11-membered ring, and a 12-membered ring, and also includes any range of n to n+m, for example, a 3- to 12-membered ring includes a 3- to 6-membered ring, a 3- to 9-membered ring, a 5- to 6-membered ring, a 5- to 7-membered ring, a 6- to 7-membered ring, a 6- to 8-membered ring, and a 6- to 10-membered ring, etc.

[0182] The term "leaving group" refers to a functional group or atom that can be displaced by another functional group or atom via a substitution reaction (e.g., a nucleophilic substitution reaction). For example, representative leaving groups include triflate; chlorine, bromine, and iodine; sulfonate groups such as mesylate, tosylate, p-bromobenzenesulfonate, p-toluenesulfonate, and the like; acyloxy groups such as acetoxy, trifluoroacetoxy, and the like.

[0183] The term "protecting group" includes, but is not limited to, an "amino-protecting group," a "hydroxy-protecting group," or a "thio-protecting group." The term "amino-protecting group" refers to a protecting group suitable for blocking side reactions of an amino nitrogen. Representative amino-protecting groups include, but are not limited to, formyl; acyl such as alkanoyl (e.g., acetyl, trichloroacetyl, or trifluoroacetyl); alkoxycarbonyl such as tert-butoxycarbonyl (Boc); arylmethoxycarbonyl such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl such as benzyl (Bn), trityl (Tr), 1,1-bis-(4'-methoxyphenyl)methyl; silyl such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS). The term "hydroxy-protecting group" refers to a protecting group suitable for blocking side reactions of a hydroxy. Representative hydroxy protecting groups include, but are not limited to, alkyl, such as methyl, ethyl, and tert-butyl; acyl, such as alkanoyl (e.g., acetyl); arylmethyl, such as benzyl (Bn), p-methoxybenzyl (PMB), 9-fluorenylmethyl (Fm), and diphenylmethyl (benzhydryl, DPM); silyl, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS); and the like.

[0184] The compounds disclosed herein can be prepared by a variety of synthetic methods known to those skilled in the art, including the following embodiments, embodiments formed by combining the following embodiments with other chemical synthetic methods, and equivalent alternatives known to those skilled in the art. Alternative embodiments include, but are not limited to, the embodiments disclosed herein.

[0185] The structures of the compounds disclosed herein can be confirmed by conventional methods known to those skilled in the art. When the present invention relates to the absolute configuration of a compound, the absolute configuration can be confirmed by conventional techniques in the art, such as single crystal X-ray diffraction (SXRD). In single crystal X-ray diffraction (SXRD), diffraction intensity data of a grown single crystal is collected using a Bruker D8 venture diffractometer with a CuKα radiation source in a φ / ω scanning mode; after collecting the relevant data, the crystal structure is further analyzed by a direct method (Shelxs97) to confirm the absolute configuration.

[0186] The solvents used in the present invention are commercially available.

[0187] Compounds are named according to common naming principles in the art or by ChemDraw® software, commercially available compounds are named by supplier directory name. [Brief explanation of the drawings]

[0188] [Figure 1] The change in tumor volume over time at various doses is shown.

[0189] [Figure 2] The change in animal weight over time at various doses is shown. DETAILED DESCRIPTION OF THE INVENTION

[0190] Detailed Description of the Invention The present invention will be described in detail below by means of examples. However, these examples are not intended to impose any adverse limitations on the present invention. The present invention has been described in detail herein, and embodiments are also disclosed herein. It will be apparent to those skilled in the art that various changes and modifications can be made to the embodiments disclosed herein without departing from the spirit and scope of the disclosure.

[0191] Example 1 [ka] Step 1: Synthesis of Compound 1-2

[0192] Compound 1-1 (10 g, 64.03 mmol, 8.70 mL, 1 equiv.) and tert-butylsulfinamide (7.76 g, 64.03 mmol, 1 equiv.) were dissolved in tetrahydrofuran (100 mL), and tetraethyl titanate (29.21 g, 128.06 mmol, 26.56 mL, 2 equiv.) was then added. The mixture was stirred at 25 °C for 10 h. After the reaction was completed, 10 g of ice was added in an ice-water bath to precipitate a large amount of solid. Tetrahydrofuran (100 mL) was then added, and the mixture was filtered. The filtrate was collected and concentrated to give compound 1-2, which was used directly in the next reaction step. 1 H NMR (400 MHz, CDCl3) δ = 9.17 (s, 1H), 9.05 (d, J = 8.5 Hz, 1H), 8.05 (dd, J = 7.9, 10.8 Hz, 2H), 7.94 (d, J = 8.1 Hz, 1H), 7.72 - 7.63 (m, 1H), 7.59 (t, J = 7.6 Hz, 2H), 1.34 (s, 9H); LCMS m / z =260.1 [M+1] +

[0193] Step 2: Synthesis of Compounds 1-3

[0194] Methyl acetate (4.28 g, 57.83 mmol, 4.60 mL, 1.5 equiv) was dissolved in tetrahydrofuran (100 mL), and the mixture was cooled to −78°C under nitrogen. Lithium hexamethyldisilazide (1 M, 59.76 mL, 1.55 equiv) was slowly added dropwise to the reaction solution. After stirring at −78°C for 1 hour, compound 1-2 (10 g, 38.56 mmol, 1 equiv) was slowly added dropwise to the reaction solution, and the mixture was stirred at this temperature for another 1 hour. After the reaction was complete, the reaction solution was poured into saturated aqueous ammonium chloride solution (80 mL) and extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was collected and concentrated. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 50 / 1 to 1 / 1) to give compound 1-3.1 H NMR (400 MHz, CDCl3) δ = 8.17 (d, J = 8.4 Hz, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.57 (t, J = 6.8 Hz, 2H), 7.54 - 7.52 LCMS m / z = 334.1 [M+1] +

[0195] Step 3: Synthesis of Compounds 1-4

[0196] Compound methyl acetate (5.55 g, 74.98 mmol, 5.96 mL, 5 equiv.) was dissolved in tetrahydrofuran (50 mL), and the mixture was cooled to -78 °C under nitrogen. Sodium hexamethyldisilazide (1 M, 74.98 mL, 5 equiv.) was added to the reaction solution. After stirring at -78 °C for 1 hour, compound 1-3 (5 g, 15.00 mmol, 1 equiv.) was slowly added dropwise to the reaction solution, and the mixture was stirred at this temperature for another 1 hour. After the reaction was completed, the reaction solution was poured into saturated aqueous ammonium chloride solution (50 mL) and extracted with ethyl acetate (50 mL x 3). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was collected and concentrated to give compound 1-4, which was used directly in the next reaction step. LCMS m / z = 376.1 [M+1] +

[0197] Step 4: Synthesis of Compounds 1-5

[0198] Compound 1-4 (5 g, 13.32 mmol, 11.92 mL, 1 equiv.) was dissolved in toluene (50 mL), and N,N-dimethylformamide dimethyl acetal (15.87 g, 133.16 mmol, 17.69 mL, 10 equiv.) was added. The mixture was stirred at 19 °C for 10 hours to allow the reaction to proceed. After completion of the reaction, the reaction solution was poured into saturated aqueous ammonium chloride solution (80 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was collected and concentrated. The crude product was purified by column chromatography (dichloromethane / methanol = 100 / 1 to 10 / 1) to give compound 1-5. LCMS m / z = 431.1 [M+1] +

[0199] Step 5: Synthesis of Compounds 1-6

[0200] Compound 1-5 (2.4 g, 5.57 mmol, 1 eq) was dissolved in hydrochloride / dioxane (4 M, 60.00 mL), and the mixture was stirred at 18 °C for 10 hours. After completion of the reaction, the reaction solution was directly concentrated to give the hydrochloride salt of compound 1-6, which was used directly in the next reaction step. LCMS m / z = 282.1 [M+1] +

[0201] Step 6: Synthesis of Compounds 1-7

[0202] Compound 1-6 hydrochloride (2 g, 6.29 mmol, 1 equiv.) was dissolved in N,N-dimethylformamide (20 mL), followed by the successive addition of potassium carbonate (6.15 g, 18.88 mmol, 3 equiv.) and iodomethane (1.79 g, 12.59 mmol, 783.65 μL, 2 equiv.) and stirring at 18 °C for 10 h. After completion of the reaction, the reaction solution was poured into water (30 mL) and extracted with ethyl acetate (30 mL × 2). The combined organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give the crude product. The crude product was purified by column chromatography (dichloromethane / methanol = 50 / 1 to 10 / 1) to give compound 1-7. 1H NMR (400 MHz, CDCl3) δ = 8.47 (s, 1H), 7.96 - 7.88 (m, 2H), 7.85 (d, J = 8.4 Hz, 1H), 7.62 - 7.51 (m, 2H), 7.48 - 7.41 (m, 1H), 7.35 (d, J = 7.0 Hz, 1H), 5.52 - 5.39 (m, 1H), 3.83 (s, 3H), 3.19(s, 3H),3.23 - 3.14 (m, 1H), 2.98 - 2.87 (m, 1H)

[0203] Step 7: Synthesis of Compounds 1-8

[0204] Compound 1-7 (20 mg, 67.72 μmol, 1 equiv.) was dissolved in ethanol (0.2 mL) and 1,4-dioxane (1 mL). Nickel chloride hexahydrate (19.32 mg, 81.26 μmol, 1.2 equiv.) was then added. After cooling to 5-10°C, sodium borohydride (1.28 mg, 33.86 μmol, 0.5 equiv.) was added, and the mixture was reacted at 10°C for 0.5 h. After the reaction was completed, the mixture was poured into saturated aqueous ammonium chloride solution (5 mL) and extracted with ethyl acetate (10 mL × 2). The combined organic phase was washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to obtain the crude product. The crude product was purified by thin-layer chromatography (TLC) using a 3 / 1 mixture of petroleum ether and ethyl acetate to obtain compound 1-8. 1 H NMR (400 MHz, CDCl3) δ = 11.99 - 11.85 (m, 1H), 8.67 - 8.49 (m, 1H), 7.92 - 7.85 (m, 1H), 7.85 - 7.77 (m, 1H), 7.57 - 7.41 (m, 4H), 3.82 (s, 3H), 3.56 - 3.51 (m, 1H), 3.16 - 2.95 (m, 2H), 2.68 - 2.47 (m, 1H), 2.15 (s, 3H)

[0205] Step 8: Synthesis of Compounds 1-9

[0206] Compound 1-8 (240 mg, 807.14 μmol, 1 eq.) and urea (242.36 mg, 4.04 mmol, 216.40 μL, 5 eq.) were dissolved in ethanol (5 mL), and sodium methoxide (130.80 mg, 2.42 mmol, 3 eq.) was added. After reacting at 85° C. for 10 hours, the reaction solution was slowly poured into water, followed by the addition of ethyl acetate (5 mL). A solid precipitated. The mixture was filtered, and the solid was collected to give compound 1-9. LCMS m / z=308.1 [M+1] +

[0207] Step 9: Synthesis of Compounds 1-10

[0208] Compound 1-9 (400 mg, 1.30 mmol, 1 equiv.) was dissolved in phosphorus oxychloride (132.00 g, 860.89 mmol, 80 mL). The mixture was heated to 105° C. and reacted for 10 hours, then concentrated under reduced pressure to remove excess phosphorus oxychloride. The residue was dissolved in ethyl acetate (50 mL), and the solution was then added to saturated aqueous sodium bicarbonate solution (20 mL). The aqueous phase was extracted with ethyl acetate (50 mL×3). The combined organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to obtain the crude product. The crude product was purified by thin-layer chromatography column (eluent: petroleum ether / ethyl acetate = 20 / 1 to 0 / 1) to obtain compound 1-10. LCMS m / z = 344.0 [M+1] +

[0209] Step 10: Synthesis of Compounds 1-11

[0210] Compound 1-10 (250 mg, 726.24 μmol, 1 equiv.) and intermediate 1-10A hydrochloride (279.24 mg, 944.12 μmol, 1.3 equiv.) were dissolved in isopropanol (2 mL), and N,N-diisopropylethylamine (375.44 mg, 2.90 mmol, 505.98 μL, 4 equiv.) was added. After reacting at 110 °C for 12 h, the reaction solution was directly concentrated. The residue was purified by column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1 to 1 / 1) to give compound 1-11.1 H NMR (400 MHz, CDCl3) δ = 8.60 - 8.48 (m, 1H), 7.93 - 7.87 (m, 1H), 7.86 - 7.80 (m, 1H), 7.58 - 7.34 (m, 9H), 5.21 (m, 2H), 4.77 - 4.61 (m, 1H), 4.06 (m, 2H), 3.97 - 3.75 (m, 2H), 3.62 - 3.40 (m, 3H), 3.30 - 3.00 (m, 4H), 2.78 - 2.64 (m, 1H), 2.26 (s, 1.5H), 2.21 (s, 1.5H); LCMS m / z = 567.3 [M+1] +

[0211] Step 11: Synthesis of Compounds 1-12

[0212] Compound 1-11 (100 mg, 176.34 μmol, 1 equiv.) and 1-11A (60.93 mg, 529.03 μmol, 62.81 μL, 3 equiv.) were dissolved in 1,4-dioxane (1.5 mL), and cesium carbonate (172.37 mg, 529.03 μmol, 3 equiv.), 2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl (16.46 mg, 35.27 μmol, 0.2 equiv.), and tris(dibenzylideneacetone)dipalladium (32.30 mg, 35.27 μmol, 0.2 equiv.) were added. The mixture was reacted at 90 °C under nitrogen for 24 hours. After completion of the reaction, the reaction mixture was directly concentrated. The residue was purified by column chromatography (eluent: dichloromethane / methanol = 100 / 1 to 10 / 1) to give compound 1-12. LCMS m / z = 646.4 [M+1] +

[0213] Step 12: Synthesis of Compounds 1-13

[0214] Compound 1-12 (50 mg, 77.42 μmol, 1 equivalent) was dissolved in tetrahydrofuran (50 mL), and Pd / C (77.4 mg, 10% purity) was added. The reaction system was purged with H2 three times. The mixture was stirred at 15 psi and 20°C for 10 hours to react. After completion of the reaction, the mixture was filtered to obtain a tetrahydrofuran solution of compound 1-13 (70 mL), which was used directly in the next step. LCMS m / z=512.3 [M+1] +

[0215] Step 13: Synthesis of Compound 1

[0216] To a solution (70 mL) of compound 1-13 obtained in the previous step in tetrahydrofuran, N,N-diisopropylethylamine (17.18 mg, 132.90 μmol, 23.15 μL, 2 equivalents) was added. The mixture was then cooled to -20 to -30 °C, and acryloyl chloride (6.01 mg, 66.45 μmol, 5.42 μL, 1 equivalent) was added. After reacting at this temperature for 30 minutes, the reaction solution was poured into water (10 mL) and then extracted with ethyl acetate (10 mL). The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to obtain the crude product. The crude product was purified by high performance liquid chromatography column (column: Phenomenex Luna 80*30mm*3μm; mobile phase: [10mM NH4HCO3 aqueous solution-acetonitrile]; acetonitrile%: 30%-60%, 7min) to give compound 1, which consisted of two diastereomers as identified by SFC (Chiralcel OD-3 column, P1 Rt=1.93min, P2 Rt=2.08min, P1:P2=50.6:49.4). 1H NMR (400 MHz, CDCl3) δ = 8.66 - 8.53 (m, 1H), 7.93 - 7.87 (m, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.56 - 7.41 (m, 4H), 6.70 - 6.50 (m, 1H), 6.47 - 6.34 (m, 1H), 5.84 (d, J = 7.2 Hz, 1H), 4.38 (m, 1H), 4.27 - 4.09 (m, 2H), 4.05 - 3.78 (m, 4H), 3.60 - 3.35 (m, 3H), 3.23 - 3.01 (m, 4H), 2.84 - 2.60 (m, 3H), 2.50 - 2.41 (m, 3H), 2.30 - 2.21 (m, 4H), 2.10 - 1.98 (m, 1H), 1.90 - 1.66 (m, 4H). LCMS m / z = 566.4 [M+1] +

[0217] Examples 2 and 3 [ka] Step 1: Synthesis of Compound 2-2

[0218] Compound 2-1 (2.2 g, 9.11 mmol, 1 equiv.) was dissolved in anhydrous tetrahydrofuran (15 mL), and the mixture was cooled to −78°C under nitrogen. Then, n-BuLi (2.5 M, 3.64 mL, 1 equiv.) was added dropwise, and the mixture was stirred at −78°C for 1 h to allow the reaction to proceed. N,N-Dimethylformamide (3.33 g, 45.55 mmol, 3.50 mL, 5 equiv.) was added, and the mixture was stirred at −78°C for an additional 0.5 h. Saturated ammonium chloride solution (10 mL) was added to quench the reaction, followed by the addition of water (10 mL). The organic phase was separated and removed, and the aqueous phase was extracted with ethyl acetate (50 mL). The combined organic phase was dried over anhydrous sodium sulfate and filtered to remove the drying agent. The solvent was removed under reduced pressure to give the crude product. The crude product was purified by column chromatography (ethyl acetate / petroleum ether = 0-15%) to give compound 2-2. 1H NMR (400 MHz, CDCl3) δ =11.32 (s, 1H), 8.04 (dd, J=1.2, 8.0 Hz, 1H), 7.92 (dd, J=1.2, 7.2 Hz, 1H), 7.87 (dd, J=1.2, 8.4 Hz, 1H), 7.71 (dd, J=1.2, 7.2 Hz, 1H), 7.59 (t, J=7.6 Hz, 1H), 7.51 - 7.44 (m, 1H)

[0219] Step 2: Synthesis of Compound 2-3

[0220] Sodium hydride (248.01 mg, 6.20 mmol, 60% purity, 1.2 equiv.) was suspended in anhydrous tetrahydrofuran (5 mL). The mixture was cooled to 0 °C under nitrogen, and methyl acetoacetate (600 mg, 5.17 mmol, 555.56 μL, 1 equiv.) was then added dropwise. After stirring for 10 min, n-butyllithium (2.5 M, 2.27 mL, 1.1 equiv.) was added dropwise, and the mixture was stirred at 0 °C for an additional 20 min. The reaction mixture was then cooled to -78 °C in a dry ice-acetone bath, and a solution of compound 2-2 (1.08 g, 5.68 mmol, 1.1 equiv.) in tetrahydrofuran (6 mL) was added dropwise. The reaction mixture was stirred for 30 min, then slowly warmed to room temperature and stirred for 30 min. Water (30 mL) was added to quench the reaction, and the aqueous phase was extracted with ethyl acetate (50 mL × 2). The combined organic phase was dried over sodium sulfate and filtered to remove the drying agent. The solvent was removed from the filtrate under reduced pressure to give the crude product. The crude product was purified by column chromatography (ethyl acetate / petroleum ether = 0-20%) to give compound 2-3. 1H NMR (400 MHz, CDCl3) δ = 8.07 (d, J=7.6 Hz, 1H), 7.81 (d, J=8.0 Hz, 2H), 7.63 - 7.49 (m, 2H), 7.35 (t, J=8.0 Hz, 1H), 6.92 (br d, J=9.6 Hz, 1H), 3.75 (s, 3H), 3.55 (s, 2H), 3.37 (dd, J=1.6, 18.1 Hz, 1H), 3.24 (d, J=1.2 Hz, 1H), 2.86-2.77 (m, 1H)

[0221] Step 3: Synthesis of Compound 2-4

[0222] Compound 2-3 (520 mg, 1.70 mmol, 1 equiv.) was dissolved in dichloromethane (5 mL), followed by the addition of N,N-dimethylformamide dimethyl acetal (202.01 mg, 1.70 mmol, 225.20 μL, 1 equiv.). The resulting reaction solution was stirred at 25 °C for 1 h. Boron trifluoride etherate complex (240.60 mg, 1.70 mmol, 209.22 μL, 1 equiv.) was then added, and the reaction solution was stirred at 25 °C for 18 h. The reaction solution was concentrated under reduced pressure, and the residue was adjusted to pH 3-4 with 2 M hydrochloric acid. The mixture was then extracted with ethyl acetate (30 mL × 3). The combined organic phase was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (ethyl acetate / petroleum ether = 0-35%) to obtain compound 2-4. 1 H NMR (400 MHz, CDCl3) δ = 8.56 (d, J=0.8 Hz, 1H), 7.91 (t, J=8.0 Hz, 2H), 7.85 (dd, J=1.2, 8.4 Hz, 1H), 7.65 (dd, J=1.6, 7.6 Hz, 1H), 7.59 (t, J=8.0 Hz, 1H), 7.44 - 7.35 (m, 2H), 3.87 (s, 3H), 3.27 - 3.17 (m, 1H), 2.92-2.82 (m, 1H). LCMS m / z = 317.0 [M+H] +

[0223] Step 4: Synthesis of Compound 2-5

[0224] Compound 2-4 (780 mg, 2.46 mmol, 1 equiv.) was dissolved in tetrahydrofuran (3 mL), and the mixture was cooled to −78°C under nitrogen. Lithium tri-sec-butylborohydride (1 M, 2.46 mL, 1 equiv.) was then added dropwise, and the mixture was stirred at −78°C for 1 hour to allow the reaction to proceed. The reaction was quenched with saturated ammonium chloride (5 mL) and then extracted with ethyl acetate (50 mL × 3). The organic phases were combined and concentrated under reduced pressure to give the crude product. The crude product was purified by column chromatography (ethyl acetate / petroleum ether = 0-15%) to give compound 2-5. 1 H NMR (400 MHz, CDCl3) δ =11.81 (s, 1H), 7.99 (d, J=7.2 Hz, 1H), 7.85-7.80 (m, 2H), 7.63 - 7.53 (m, 2H), 7.36 (t, J=7.6 Hz, 1H), 6.30 (dd, J=2.8, 10.4 Hz, 1H), 4.68 - 4.62 (m, 1H), 4.56 - 4.47 (m, 1H), 3.82 (s, 3H), 3.07 - 2.98 (m, 1H), 2.57 - 2.46 (m, 1H)

[0225] Step 5: Synthesis of Compound 2-6

[0226] Compound 2-5 (497 mg, 1.56 mmol, 1 equiv.) was dissolved in methanol (2 mL), followed by the addition of 2-methylthiourea sulfate (528.27 mg, 2.81 mmol, 1.8 equiv.) and sodium methoxide (421.14 mg, 7.80 mmol, 5 equiv.). The resulting reaction solution was stirred at 25 °C under nitrogen for 18 h. Methanol was removed under reduced pressure, and water (1 mL) was added to the residue. The mixture was adjusted to pH 5-6 with 2 M hydrochloric acid, precipitating a large amount of white solid. The solid was collected by filtration and dried under reduced pressure to give compound 2-6. The crude product was used directly in the next reaction step. LCMS m / z = 359.1 [M+H] +

[0227] Step 6: Synthesis of Compounds 2-7

[0228] Compound 2-6 (440.00 mg, 1.23 mmol, 1 equiv.) and N,N-diisopropylethylamine (316.95 mg, 2.45 mmol, 427.15 μL, 2 equiv.) were added to anhydrous dichloromethane (5 mL), and the mixture was cooled to 0 °C. Triflic anhydride (449.74 mg, 1.59 mmol, 263.00 μL, 1.3 equiv.) was added. After the addition was complete, the mixture was stirred at 0 °C for 60 min to allow the reaction to proceed. The reaction solution was concentrated under reduced pressure to give the crude product, which was purified by column chromatography (ethyl acetate / petroleum ether = 0-6%) to give compound 2-7. 1 H NMR (400 MHz, CDCl3) δ = 7.99 (d, J=7.2 Hz, 1H), 7.90-7.82 (m, 2H), 7.66 - 7.54 (m, 2H), 7.44 - 7.33 (m, 1H), 6.46 (dd, J=2.4, 10.4 Hz, 1H), 5.12 - 5.04 (m, 1H), 4.97 - 4.89 (m, 1H), 3.63 (dd, J=2.0, 18.0 Hz, 1H), 3.05-2.90 (m, 1H), 2.57 (s, 3H). LCMS m / z = 491.0 [M+H] +

[0229] Step 7: Synthesis of Compound 2-8

[0230] Compound 2-7 (121 mg, 246.48 μmol, 1 equiv.) and N,N-diisopropylethylamine (95.57 mg, 739.45 μmol, 128.80 μL, 3 equiv.) were added to N,N-dimethylformamide (1.5 mL), followed by compound 1-10A hydrochloride (70.31 mg, 237.71 μmol, 1.1 equiv.). The gas in the reaction solution was replaced with nitrogen, and the reaction solution was stirred in an oil bath at 100 °C for 1 hour. The reaction solution was concentrated under reduced pressure to give the crude product, which was purified by column chromatography (ethyl acetate / petroleum ether = 0-30%) to give compound 2-8. LCMS m / z = 600.2 [M+H] +

[0231] Step 8: Synthesis of Compound 2-9

[0232] Compound 2-8 (125 mg, 208.29 μmol, 1 equivalent) was dissolved in dichloromethane (1 mL), and then m-chloroperoxybenzoic acid (84.57 mg, 416.58 μmol, 85% purity, 2 equivalents) was added. The resulting reaction solution was stirred at 20°C for 8 hours. The reaction solution was filtered to remove insoluble matter, and the filtrate was concentrated under reduced pressure to obtain the crude product. This was purified by column chromatography (ethyl acetate / petroleum ether = 0-60%) to obtain compound 2-9. LCMS m / z = 632.3 [M+H] +

[0233] Step 9: Synthesis of Compound 2-10

[0234] Compound 2-9 (101 mg, 159.78 μmol, 1 equiv.) and 1-11A (55.21 mg, 479.34 μmol, 56.91 μL, 3 equiv.) were dissolved in toluene (0.8 mL). The resulting solution was cooled to -5°C, and then t-BuONa (30.71 mg, 319.56 μmol, 2 equiv.) was added. The resulting reaction solution was stirred at -5 to 0°C for 1 hour. The reaction solution was diluted with 3 mL of ethyl acetate and washed with water (1 mL) and saturated brine (1 mL). The organic phase was concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography (methanol / dichloromethane = 0 to 8%) to obtain compound 2-10. LCMS m / z = 667.3 [M+H] +

[0235] Step 10: Synthesis of a mixture of compounds 2-11 and 3-1

[0236] Compound 2-10 (101 mg, 151.38 μmol, 1 equivalent) was dissolved in dichloromethane (1 mL), and then palladium acetate (6.80 mg, 30.28 μmol, 0.2 equivalent) and triethylsilane (88.01 mg, 756.90 μmol, 120.90 μL, 5 equivalents) were added. The resulting reaction solution was stirred at room temperature for 1 hour to allow the reaction to proceed. The reaction solution was concentrated under reduced pressure to give a mixture of compounds 2-11 and 3-1, which was used directly in the next reaction step without purification. Compound 2-11: LCMS m / z = 555.3 [M+Na] + ; Compound 3-1:LCMS m / z=521.3 [M+Na] +

[0237] Step 11: Synthesis of Compounds 2 and 3

[0238] A mixture of compounds 2-11 and 3-1 was dissolved in dichloromethane (1 mL), and then triethylamine (45.95 mg, 454.14 μmol, 63.21 μL, 3 equivalents) was added. The reaction solution was cooled to 0°C, and then acryloyl chloride (20.55 mg, 227.07 μmol, 18.52 μL, 1.5 equivalents) was added. The mixture was stirred for 30 minutes to react. The reaction solution was concentrated under reduced pressure to give the crude product, which was separated by preparative high-performance liquid chromatography (separation conditions: column: Welch Xtimate C18 150*30 mm*5 μm; mobile phase: [water (0.225% formic acid)-acetonitrile]; acetonitrile %: 15% to 55%, 8 min) to give compounds 2 and 3. Compounds 2 and 3 were a pair of diastereoisomers. Compound 2: LCMS m / z = 587.3 [M+H] + ; Compound 3:LCMS m / z=553.3 [M+H] +

[0239] Example 4 [ka] [ka]

[0240] Synthesis of intermediate 4-14A Step 1: Synthesis of Compound 4-21

[0241] Compound 4-20 (3 g, 8.35 mmol, 1 eq) was dissolved in tetrahydrofuran (30 mL) and wet palladium on carbon (1.2 g, 10% by weight) was added. The atmosphere was replaced with hydrogen three times (562.02 μg, 278.23 μmol, 1 eq), and the mixture was reacted at room temperature of 25 °C and 15 Psi for 2 hours. The reaction solution was filtered, and the mother liquor was collected and concentrated to give compound 4-21. LCMS m / z = 170.1 [M -55 + H] +

[0242] Step 2: Synthesis of Compound 4-22

[0243] Compound 4-21 (0.2 g, 887.76 μmol, 1 equiv.) was dissolved in tetrahydrofuran (5 mL), and triethylamine (269.50 mg, 2.66 mmol, 370.70 μL, 3 equiv.) was added. The mixture was cooled to 0°C under nitrogen, and trifluoroacetic anhydride (205.10 mg, 976.53 μmol, 135.83 μL, 1.1 equiv.) was added. The mixture was reacted at 0°C for 0.5 h. The mixture was poured into saturated aqueous ammonium chloride solution (10 mL), and ethyl acetate (5 mL*2) was added. The mixture was washed with saturated brine (5 mL) and purified by column chromatography (petroleum ether / ethyl acetate = 10 / 1 to 1 / 1, TLC: petroleum ether / ethyl acetate = 3 / 1) to give compound 4-22. 1 H NMR (400 MHz, CDCl3) δ = 4.86 (s, 1H), 4.51 - 4.06 (m, 2H), 3.88 (d, J = 14.0 Hz, 1H), 3.52 - 3.33 (m, 1H), 3.24 (dd, J = 4.0, 14.2 Hz, 1H), 3.12 - 2.92 (m, 1H), 2.91 - 2.73 (m, 1H), 2.67 (s, 1H), 1.50 (s, 9H); LCMS: MS m / z = 222.0 [M-100+H] +

[0244] Step 3: Synthesis of Compound 4-14A

[0245] Compound 4-22 (150 mg, 466.86 μmol, 1 eq) was dissolved in hydrochloride / dioxane (5 M, 8 mL, 85.68 eq). The mixture was reacted at 18° C. under nitrogen for 1 hour, then directly rotary evaporated to dryness to give compound 4-14A hydrochloride. LCMS: MS m / z=222.0 [M+H] +

[0246] Synthesis of Example 4

[0247] Step 1: Synthesis of Compound 4-2

[0248] Water (210 mL) and hydrochloric acid (210 mL, 36-38% mass content) were mixed, and then compound 4-1 (36.00 g, 176.44 mmol, 1 equivalent) was added. The mixture was heated to 65 °C and reacted for 1 hour, then cooled to 0-5 °C. A solution of sodium nitrite (14.61 g, 211.72 mmol, 1.2 equivalents) in water (70 mL) was added dropwise, and the mixture was stirred for 15 minutes. Cuprous chloride (26.20 g, 264.65 mmol, 6.33 mL, 1.5 equivalents) was dissolved in hydrochloric acid (350 mL, 36-38% mass content), and the solution was cooled to 0-5 °C. The above solution was added dropwise to the reaction solution, and the mixture was reacted for an additional 6 hours. 750 mL of dichloromethane was added to the reaction system, and the mixture was stirred for 20 minutes. The layers were separated. The organic phase was washed once with 350 mL of saturated brine, dried over 30.00 g of anhydrous sodium sulfate, and filtered. The filtrate was rotary evaporated under reduced pressure at 45° C. to give compound 4-2. 1 H NMR (400 MHz, CDCl3) δ = 7.24 - 7.21 (m, 1H), 6.94 (dd, J = 2.8, 8.8 Hz, 1H), 2.43 (s, 3H)

[0249] Step 2: Synthesis of Compound 4-3

[0250] Tetrahydrofuran (395 mL) and compound 4-2 (39.50 g, 176.76 mmol, 1 equiv.) were added to a clean reaction flask and stirred. The mixture was cooled to -70 to -65 °C. Lithium diisopropylamide (2 M, 106.05 mL, 1.2 equiv.) was added dropwise, and the mixture was allowed to react for an additional hour. N,N-dimethylformamide (18.76 g, 256.70 mmol, 19.75 mL, 1.45 equiv.) was then added, and the mixture was allowed to react for an additional hour. 500 mL of saturated ammonium chloride solution was added to the reaction, and the layers were then separated. The organic phase was washed once with 300 mL of saturated brine, then dried over 20 g of anhydrous sodium sulfate, and filtered. The filtrate was rotary evaporated under reduced pressure at 45 °C to give compound 4-3. 1 H NMR (400 MHz, CDCl3) δ = 10.28 (s, 1H), 7.08 (d, J = 10.8 Hz, 1H), 2.51 (s, 3H); LCMS m / z = 245.0[M+H] + , 247.0[M+3H] +

[0251] Step 3: Synthesis of Compound 4-4

[0252] Dimethyl sulfoxide (300 mL) and compound 4-3 (20.00 g, 79.53 mmol, 1 equiv.) were added to a clean reaction flask prepared in advance and stirred. Hydrazine hydrate (48.75 g, 954.35 mmol, 47.33 mL, 98% mass content, 12 equiv.) was then added, and the mixture was heated to 130 °C and reacted for 3 h. The reaction solution was combined with the small-scale reaction solution, and then the mixture was poured into 700 mL of water. The mixture was filtered, and the filter cake was washed with water (100 mL x 3). The resulting filter cake was dissolved in 300 mL of ethyl acetate, and the layers were separated. The organic phase was dried over 50.00 g of anhydrous sodium sulfate and filtered. The filtrate was rotary evaporated under reduced pressure at 45 °C to give compound 4-4. 1H NMR (400 MHz, CDCl3) δ = 10.38 (brs, 1H), 8.03 (s, 1H), 7.33 (s, 1H), 2.57 (s, 3H); LCMS m / z = 245.1[M+H] + , 247.1[M+3H] +

[0253] Step 4: Synthesis of Compound 4-5

[0254] Dichloromethane (200 mL) and compound 4-4 (20.00 g, 81.47 mmol, 1 equiv.) were added to a clean reaction flask and stirred. Then, pyridinium p-toluenesulfonate (2.05 g, 8.15 mmol, 0.1 equiv.) and 2-methylhydroxy-3,4-dihydropyran (20.56 g, 244.40 mmol, 3 equiv.) were added sequentially. The mixture was reacted at 20 °C for 12 h. After adding 200 mL of water to the reaction system, the layers of the reaction solution were directly separated. The organic phase was dried over 20.00 g of anhydrous sodium sulfate and filtered. The filtrate was rotary evaporated under reduced pressure at 45 °C to obtain the crude compound. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 100 / 0 to 70 / 30, TLC: petroleum ether / ethyl acetate = 5 / 1) to obtain compound 4-5. 1 H NMR (400 MHz, CDCl3) δ = 7.95 (s, 1H), 7.44 (s, 1H), 5.67 (dd, J = 2.8, 8.8 Hz, 1H), 4.02 - 3.98 (m, 1H), 3.79 - 3.71 (m, 1H), 2.57 (s, 3H), 2.54 - 2.46 (m, 1H), 2.18 - 2.05 (m, 2H), 1.80 - 1.66 (m, 3H); LCMS m / z = 329.0[M+H] + , 331.0[M+3H] +

[0255] Step 5: Synthesis of Compounds 4-6

[0256] Tetrahydrofuran (160 mL) and compound 4-5 (16 g, 48.54 mmol, 1 equiv.) were added to a clean reaction flask and stirred. After cooling the mixture to -70 to -65 °C, n-butyllithium (2.5 M, 21.36 mL, 1.1 equiv.) was slowly added dropwise, and the mixture was allowed to react for an additional 1 h. N,N-dimethylformamide (35.48 g, 485.41 mmol, 37.35 mL, 10 equiv.) was then added, and the mixture was allowed to react for an additional 0.5 h. After adding 250 mL of saturated ammonium chloride solution, the layers were separated. The organic phase was washed once with 150 mL of saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was rotary evaporated under reduced pressure at 45 °C to give an oil. The oil was mixed with 7 mL of ethyl acetate. The mixture was slurried for 20 min and then filtered. The filter cake was rotary evaporated under reduced pressure at 45° C. to give compound 4-6. 1 H NMR (400 MHz, CDCl3) δ = 10.72 (s, 1H), 8.63 (s, 1H), 7.74 (s, 1H), 5.70 (dd, J = 2.8, 8.8 Hz, 1H), 3.98 - 3.94 (m, 1H), 3.75 - 3.68 (m, LCMS m / z = 279.1[M+H] +

[0257] Step 6: Synthesis of Compounds 4-7

[0258] Tetrahydrofuran (54 mL) and compound 4-6 (5.4 g, 19.37 mmol, 1 equiv.) were added to a clean reaction flask and stirred. tert-Butylsulfinamide (2.58 g, 21.31 mmol, 232.15 μL, 1.1 equiv.) and tetraisopropyl titanate (8.84 g, 38.75 mmol, 8.04 mL, 2 equiv.) were then added, and the mixture was reacted at 20 °C for 12 h. 50 mL of saturated ammonium chloride solution was added to the reaction mixture, and the layers were separated. The organic phase was dried over 3.00 g of anhydrous sodium sulfate and then filtered. The filtrate was rotary evaporated under reduced pressure at 45 °C. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 100 / 0 to 50 / 50, TLC: petroleum ether / ethyl acetate = 10 / 1) to give compound 4-7. LCMS m / z = 382.2 [M+H] +

[0259] Step 7: Synthesis of Compounds 4-8

[0260] Tetrahydrofuran (35 mL) and sodium hydride (829.50 mg, 20.74 mmol, 60% mass content, 1.2 equiv.) were added to a clean reaction flask and stirred. The mixture was then cooled to 0-5 °C, and methyl acetoacetate (2.41 g, 20.74 mmol, 2.23 mL, 1.2 equiv.) was added dropwise. The mixture was allowed to react for 20 min. n-Butyllithium (2.5 M, 7.60 mL, 1.1 equiv.) was then added dropwise, and the mixture was allowed to react for an additional 20 min. The mixture was then cooled to -70 to -65 °C, and a solution of compound 4-7 (6.60 g, 17.28 mmol, 1 equiv.) in tetrahydrofuran (35 mL) was added dropwise, and the mixture was allowed to react for an additional 20 min. The mixture was slowly warmed to room temperature (20 °C) and allowed to react for an additional 0.5 h. The reaction solution was poured into 100 mL of saturated ammonium chloride solution. After combining with the 1 g batch, the layers were separated. The organic phase was dried over 3.00 g of anhydrous sodium sulfate and filtered. The filtrate was rotary evaporated under reduced pressure at 45 °C. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 100 / 0 to 20 / 80, TLC: PE / EtOAc = 0:1) to give compound 4-8. 1H NMR (400 MHz, CDCl3) δ = 8.20 (s, 1H), 7.44 (d, J = 5.6 Hz, 1H), 5.72 - 5.64 (m, 2H), 4.04 - 3.99 (m, 1H), 3.77 - 3.69 (m, 4H), 3.57 - 3.46 (m, 2H), 3.15 - 3.08 (m, 1H), 2.59 - 2.52 (m, 4H), 2.16 - 2.05 (m, 2H), 1.83 - 1.65 (m, 4H), 1.20 - 1.18 (m, 9H); LCMS m / z = 498.2[M+H] +

[0261] Step 8: Synthesis of Compounds 4-9

[0262] Toluene (66 mL) and compound 4-8 (6.60 g, 13.25 mmol, 1 equiv.) were added to a clean reaction flask and stirred. N,N-dimethylformamide dimethyl acetal (4.74 g, 39.76 mmol, 5.28 mL, 3 equiv.) was then added, and the mixture was allowed to react at room temperature of 20 °C for 12 h. 60 mL of water and 60 mL of ethyl acetate were added to the reaction system, and the mixture was stirred for 5 min. The layers were separated. The organic phase was washed once with 60 mL of saturated brine, dried over 5.00 g of anhydrous sodium sulfate, and filtered. The filtrate was rotary evaporated under reduced pressure at 50 °C to give compound 4-9, which was used directly in the next step.

[0263] Step 9: Synthesis of Compounds 4-10

[0264] Compound 4-9 (50 mg, 90.40 μmol, 1 eq) was dissolved in hydrochloride / ethyl acetate (3 mL). The mixture was stirred at 18° C. for 20 minutes. The reaction solution was directly concentrated to give the crude product as compound 4-10 hydrochloride. LCMS m / z=320.0 [M+H] +

[0265] Step 10: Synthesis of Compounds 4-11

[0266] Compound 4-10 (5.00 g, 14.04 mmol, 1 equiv., HCl) was dissolved in dichloromethane (50 mL), and triethylamine (5.97 g, 58.96 mmol, 8.21 mL, 4.2 equiv.), tert-butyl dicarbonate (12.25 g, 56.15 mmol, 12.90 mL, 4 equiv.), and 4-dimethylaminopyridine (1.71 g, 14.04 mmol, 1 equiv.) were added. The reaction mixture was stirred at 18 °C for 10 hours. The reaction mixture was combined with a 0.5 g batch and treated. The mixture was quenched with saturated aqueous ammonium chloride solution (100 mL) and extracted with dichloromethane (30 mL x 2). The combined organic phase was dried over anhydrous sodium sulfate and concentrated to give the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate=50 / 1 to 0 / 1, TLC: petroleum ether / ethyl acetate=1 / 1) to give compound 4-11. 1 H NMR (400 MHz, CDCl3) δ = 9.02 (s, 1H), 8.12 (s, 1H), 7.89 (s, 1H), 6.16 (dd, J = 5.2, 8.8 Hz, 1H), 3.77 (s, 3H), 3.10 (dd, J = 8.4, 16.0 Hz, 1H), 2.82 (m, 1H), 2.48 (s, 3H), 1.63 (s, 9H), 1.18 (s, 9H). LCMS m / z = 520.1[M+H] +

[0267] Step 11: Synthesis of Compound 4-12

[0268] Compound 4-11 (3.00 g, 5.77 mmol, 1 equiv.) was dissolved in tetrahydrofuran (30 mL), and the solution was cooled to -78 °C. Lithium tri-sec-butylborohydride (1 M, 5.77 mL, 1 equiv.) was added dropwise to the reaction solution under nitrogen, and the mixture was stirred for 0.5 h. The reaction mixture was quenched with saturated aqueous ammonium chloride solution (30 mL) and extracted with ethyl acetate (20 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to give crude compound 4-12. LCMS m / z = 522.2 [M+H] +, 466.1[M-56+H] +

[0269] Step 12: Synthesis of Compound 4-13

[0270] Compound 4-12 (2.30 g, 4.41 mmol, 1 equiv.) and 2-methyl-2-thiopseudourea disulfate (1.66 g, 8.81 mmol, 2 equiv., H2SO4) were dissolved in methanol (430 mL), and sodium methoxide (476.05 mg, 8.81 mmol, 2 equiv.) was added. The mixture was stirred at 18 °C for 1.5 h. Sodium methoxide (357.04 mg, 6.61 mmol, 1.5 equiv.) was then added to the reaction solution, and the mixture was stirred at 18 °C for 10 h. The mixture was rotary evaporated to dryness, and water (50 mL) was added. The mixture was adjusted to pH 2-3 with 1 M dilute hydrochloric acid, and a white solid precipitated. The solid was collected by filtration. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 10 / 1 to 0 / 1, TLC: petroleum ether / ethyl acetate = 1 / 1) to give compound 4-13. LCMS m / z=562.1[M+H] +

[0271] Step 13: Synthesis of Compounds 4-14

[0272] Compound 4-13 (0.328 g, 583.55 μmol, 1 equiv.) and N,N-diisopropylethylamine (377.09 mg, 2.92 mmol, 508.21 μL, 5 equiv.) were dissolved in dichloromethane (10 mL), and triflic anhydride (246.96 mg, 875.32 μmol, 144.42 μL, 1.5 equiv.) was added at 0° C. The mixture was stirred at 0° C. for 1 h. The mixture was combined with a 0.56 g batch and treated. The mixture was poured into saturated aqueous ammonium chloride solution (50 mL) and extracted with ethyl acetate (20 mL x 3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate=20 / 1 to 5 / 1, TLC: petroleum ether / ethyl acetate=5 / 1) to give compound 4-14. 1H NMR (400 MHz, CDCl3) δ = 8.21 - 8.11 (m, 1H), 8.00 - 7.90 (m, 1H), 5.86 - 5.69 (m, 1H), 5.25 - 5.09 (m, 1H), 4.68 - 4.46 (m, 1H), 3.57 - 3.42 (m, 1H), 3.27 - 3.08 (m, 1H), 2.66 - 2.41 (m, 6H), 1.79 - 1.67 (m, 9H), 1.21 - 1.07 (m, 9H); LCMS m / z = 637.9[M-56+H] + , 639.8[M-56+3H] +

[0273] Step 14: Synthesis of Compounds 4-15

[0274] Compound 4-14 (630 mg, 907.60 μmol, 1 equiv.) and compound 4-14A (420.90 mg, 1.63 mmol, 1.8 equiv., HCl) were dissolved in N,N-dimethylformamide (15 mL), and N,N-diisopropylethylamine (469.19 mg, 3.63 mmol, 632.33 μL, 4 equiv.) was added. The mixture was stirred at 20 °C for 2 h. The mixture was poured into water (30 mL) and extracted with ethyl acetate (20 mL × 3). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give the crude product, which was purified by column chromatography (petroleum ether / ethyl acetate = 50 / 1 to 1 / 1, TLC: petroleum ether / ethyl acetate = 0 / 1) to give compound 4-15. 1H NMR (400 MHz, CDCl3) δ = 8.18 - 8.05 (m, 1H), 8.04 - 7.93 (m, 1H), 5.75 - 5.45 (m, 1H), 5.06 - 4.89 (m, 1H), 4.66 - 4.35 (m, 1H), 4.19 - 3.84 (m, 3H), 3.82 - 3.45 (m, 1H), 3.43 - 3.12 (m, 2H), 3.06 - 2.75 (m, 6H), 2.61 - 2.38 (m, 5H), 1.79 - 1.60 (m, 9H), 1.14 - 0.85 (s, 9H); LCMS m / z = 765.0[M+H] +

[0275] Step 15: Synthesis of Compound 4-16

[0276] Compound 4-15 (400.00 mg, 522.71 μmol, 1 equiv.) was dissolved in dichloromethane (8 mL), and m-chloroperoxybenzoic acid (200.00 mg, 985.11 μmol, 85% mass content, 1.88 equiv.) was added. The mixture was stirred at 20° C. for 2 hours. The mixture was combined with a 200 mg batch and processed. The reaction solution was washed with aqueous sodium sulfite (20 mL, 10%), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give the crude product. The crude product was purified by column chromatography (SiO2 100 mesh, petroleum ether / ethyl acetate = 50 / 1 to 1 / 1, TLC: petroleum ether / ethyl acetate = 2 / 1) to give compound 4-16. LCMS m / z = 697.1 [M-100+H] +

[0277] Step 16: Synthesis of Compound 4-17

[0278] Compound 1-11A (57.79 mg, 501.73 μmol, 59.57 μL, 4 equiv.) was dissolved in toluene (1 mL), and sodium tert-butoxide (42.19 mg, 439.01 μmol, 3.5 equiv.) was added at 0° C. The mixture was stirred for 15 minutes. Then, a 0.1 mL toluene solution of compound 4-16 (100.00 mg, 125.43 μmol, 1 equiv.) was slowly added to the reaction solution, and the mixture was reacted at 0° C. for 30 minutes. The reaction mixture was quenched with water (5 mL) and extracted with ethyl acetate (5 mL×2). The organic phases were combined to give compound 4-17. LCMS m / z=636.1 [M+H] +

[0279] Step 17: Synthesis of Compound 4-18

[0280] Compound 4-17 (79.80 mg, 125.44 μmol, 1 equiv.) was dissolved in dichloromethane (2 mL), and N,N-diisopropylethylamine (81.06 mg, 627.18 μmol, 109.24 μL, 5 equiv.) was added at 18 °C. The mixture was cooled to -78 °C. Acryloyl chloride (4.54 mg, 50.17 μmol, 4.09 μL, 0.4 equiv.) was slowly added to the reaction solution, and the mixture was reacted at -78 °C for 0.5 h. An additional 8.00 mg of acryloyl chloride was added, and the mixture was reacted for an additional 1 h. The reaction mixture was quenched with saturated aqueous ammonium chloride (5 mL) and extracted with dichloromethane (5 mL * 2). The organic phases were combined. The crude product was added to potassium carbonate (1.7 M, 1 mL) in methanol (1 mL), and the mixture was stirred at 18 °C for 1 h. The product was measured (time = 0.943) to give compound 4-18. LCMS m / z = 690.3 [M+H] +

[0281] Step 18: Synthesis of Compounds 4A and 4B

[0282] Compound 4-18 (100 mg, 144.88 μmol, 1 equiv.) was dissolved in dichloromethane (2 mL), trifluoroacetic acid (3.08 g, 27.01 mmol, 2.00 mL, 186.45 equiv.) was added, and the mixture was reacted at 18°C ​​for 1 hour. The mixture was concentrated to give compound 4-19. Compound 4-19 was purified using a high-performance liquid chromatography column (column: Phenomenex Luna C18 100*40 mm*5 μm; mobile phase: [HO (0.1% TFA)-acetonitrile]; acetonitrile %: 5% to 30%, 8 min). 0.05 mL of diluted hydrochloric acid (0.2 mL) was added to the sample. The mixture was concentrated under reduced pressure to give compound 4A hydrochloride (time to peak: 2.417 min, LCMS m / z = 590.1 [M+H]). + , 295.9[M / 2+H] + ) and compound 4B hydrochloride (time to peak: 2.388 min, LCMS m / z = 590.1 [M+H] + , 295.9[M / 2+H] + ) was obtained.

[0283] Example 5 [ka] Step 1: Synthesis of Compound 5-1

[0284] Tetrahydrofuran (27 mL) and sodium hydride (789.28 mg, 19.73 mmol, 60% mass content, 2 equiv.) were added to a clean reaction flask and stirred. The mixture was then cooled to 0-5 °C, and methyl acetoacetate (2.29 g, 19.73 mmol, 2.12 mL, 2 equiv.) was added dropwise. The mixture was allowed to react for 30 min. n-Butyllithium (2.5 M, 7.50 mL, 1.9 equiv.) was then added dropwise, and the mixture was allowed to react for an additional 30 min. The mixture was then cooled to -70 to -65 °C. A solution of compound 4-6 (2.75 g, 9.87 mmol, 1 equiv.) in tetrahydrofuran (27 mL) was added dropwise, and the mixture was allowed to react for an additional 0.5 h. The reaction solution was quenched by pouring it into 50 mL of saturated ammonium chloride solution. The organic phase was dried over 1.50 g of anhydrous sodium sulfate and filtered. The filtrate was rotary evaporated under reduced pressure at 45° C. The crude product was purified by column chromatography (petroleum ether / ethyl acetate=100 / 0 to 70 / 30, TLC: petroleum ether / ethyl acetate=1 / 1) to give compound 5-1. 1 H NMR (400 MHz, CDCl3) δ = 8.40 (d, J = 2.8 Hz, 1H), 7.41 (d, J = 11.6 Hz, 1H), 5.95 - 5.91 (m, 1H), 5.69 - 5.64 (m, 1H), 4.04 - 3.98 (m, 1H), 3.78 - 3.70 (m, 4H), 3.56 (d, J = 0.8 Hz, 2H), 3.37 (d, J = 3.2, 8.4 Hz, 1H), 3.08 - 2.99 (m, 2H), 2.61 - 2.54 (m, 1H), 2.50 (s, 3H), 2.18 - 2.04 (m, 2H), 1.81 - 1.70 (m, 2H). LCMS: MS m / z = 395.0[M+H] +

[0285] Step 2: Synthesis of Compound 5-2

[0286] Dichloromethane (25 mL) and compound 5-1 (1.6 g, 4.05 mmol, 1 equiv.) were added to a clean reaction flask and stirred. N,N-dimethylformamide dimethyl acetal (724.30 mg, 6.08 mmol, 807.47 μL, 1.5 equiv.) was then added, and the mixture was reacted at room temperature of 20 °C for 12 h. The mixture was then cooled to 0-5 °C. Boron trifluoride etherate (575.13 mg, 4.05 mmol, 500.11 μL, 1 equiv.) was added. The mixture was reacted at room temperature of 20 °C for an additional 1 h. The reaction solution was rotary evaporated under reduced pressure at 30 °C to give compound 5-2, which was used directly in the next step.

[0287] Step 3: Synthesis of Compound 5-3

[0288] Tetrahydrofuran (58 mL) and compound 5-2 (3.9 g, 8.40 mmol, 87.233% mass content, 1 equiv.) were added to a clean reaction flask prepared in advance and stirred. The mixture was cooled to -70 to -65 °C, and lithium tri-sec-butylborohydride (1 M, 9.24 mL, 1.1 equiv.) was added dropwise. The mixture was allowed to react for 0.5 h. The reaction solution was poured into 50 mL of saturated ammonium chloride solution. The organic phase was dried over 2.00 g of anhydrous sodium sulfate and filtered. The filtrate was rotary evaporated under reduced pressure at 45 °C. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 100 / 0 to 70 / 30, TLC: petroleum ether / ethyl acetate = 5 / 1) to give compound 5-3. LCMS: MS m / z = 407.0 [M+H] +

[0289] Step 4: Synthesis of Compound 5-4

[0290] Methanol (4 mL), compound 5-3 (0.65 g, 1.60 mmol, 1 equiv.), and methylisothiourea sulfate (1.22 g, 6.39 mmol, 4 equiv., H2SO4) were added to a pre-prepared reaction flask and stirred. Sodium methoxide (172.61 mg, 3.20 mmol, 2 equiv.) was then added, and the mixture was allowed to react at room temperature for 1 hour at 25 °C. After further addition of sodium methoxide (172.62 mg, 3.20 mmol, 2 equiv.), the mixture was allowed to react for an additional 15 hours. The reaction solution was rotary evaporated under reduced pressure at 45 °C. 10 mL of water was added to the resulting white solid, and the mixture was extracted with 10 mL of ethyl acetate. The layers were separated. The organic phase was washed once with 10 mL of saturated brine, dried over 0.50 g of anhydrous sodium sulfate, and filtered. The filtrate was rotary evaporated under reduced pressure at 45 °C. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 100 / 0 to 40 / 60, TLC: petroleum ether / ethyl acetate = 1 / 1) to give compound 5-4. LCMS: MS m / z = 447.0 [M+H] +

[0291] Step 5: Synthesis of Compound 5-5

[0292] Dichloromethane (20 mL) and compound 5-4 (610 mg, 1.36 mmol, 1 equiv.) were added to a clean reaction flask and stirred. After the mixture was cooled to 0-5 °C, N,N-diisopropylethylamine (617.36 mg, 4.78 mmol, 832.02 μL, 3.5 equiv.) and triflic anhydride (770.13 mg, 2.73 mmol, 450.37 μL, 2 equiv.) were added sequentially. The mixture was allowed to react for 0.5 h. The reaction solution was poured into 20 mL of saturated ammonium chloride solution, and the layers were then separated. The organic phase was washed once with 10 mL of saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was rotary evaporated under reduced pressure at 45 °C. The crude product was purified by column chromatography (petroleum ether / ethyl acetate=100 / 0 to 70 / 30, TLC: petroleum ether / ethyl acetate=5 / 1) to give compound 5-5. 1H NMR (400 MHz, CDCl3) δ = 8.26 (d, J = 5.2 Hz, 1H), 7.48 (d, J = 14.4 Hz, 1H), 5.73 - 5.67 (m, 1H), 5.53 - 5.49 (m, 1H), 5.15 (dd, J = 3.2, 15.6 Hz, 1H), 4.88 (d, J = 15.6 Hz, 1H), 4.06 - 3.99 (m, 1H), 3.80 - 3.72 (m, 1H), 3.30 - 3.25 (m, 1H), 3.12 - 3.04 (m, 1H), 2.61 - 2.49 (m, 7H), 2.19 - 2.07 (m, 2H), 1.83 - 1.68 (m, 3H)

[0293] Step 6: Synthesis of Compound 5-6

[0294] N,N-Dimethylformamide (5 mL) and compound 5-5 (0.33 g, 569.94 μmol, 1 equiv.) were added to a clean reaction flask and stirred. N,N-Diisopropylethylamine (368.29 mg, 2.85 mmol, 496.35 μL, 5 equiv.) and compound 5-5a (143 mg, 1.14 mmol, 2.00 equiv., 2HCl) were then added sequentially. The mixture was heated to 100 °C and reacted for 1 h. The reaction solution was poured into 20 mL of saturated ammonium chloride solution, and the mixture was then added to 10 mL of ethyl acetate. The layers were separated. The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was rotary evaporated under reduced pressure at 45 °C. The crude product was purified by column chromatography (dichloromethane / methanol=100 / 0 to 85 / 15, TLC: dichloromethane / methanol=15 / 1) to give compound 5-6. 1 H NMR (400 MHz, CDCl3) δ = 8.22 (d, J = 4.4 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H), 5.71 - 5.66 (m, 1H), 5.57 - 5.53 (m, 1H), 4.89 - 4.80 (m, 2H), 4.05 - 3.86 (m, 2H), 3.77 - 3.32 (m, 1H), 3.60 - 3.57 (m, 1H), 3.39 - 3.38 (m, 1H), 3.31 - 3.26 (m, 1H), 3.23 - 3.17 (m, 1H), 3.12 - 3.09(m, 1H), 3.02 - 2.96 (m, 3H), 2.93 - 2.83 (m, 2H), 2.57 - 2.56 (m, 1H), 2.54 - 2.52 (m, 7H), 2.16 - 2.04 (m, 2H), 1.79 - 1.71 (m, 3H). LCMS: MS m / z = 554.0[M+H] +

[0295] Step 7: Synthesis of Compound 5-7

[0296] Compound 5-6 (190 mg, 342.90 μmol, 1 equiv.) was dissolved in tetrahydrofuran (2 mL) and stirred. The mixture was then cooled to 0-5°C, and trifluoroacetic anhydride (108.03 mg, 514.34 μmol, 71.54 μL, 1.5 equiv.) and triethylamine (121.44 mg, 1.20 mmol, 167.04 μL, 3.5 equiv.) were added. The mixture was reacted for 0.5 h. The reaction solution was poured into 10 mL of saturated ammonium chloride solution and then extracted with 10 mL of dichloromethane. The organic phase was washed once with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was rotary evaporated under reduced pressure at 45°C to give compound 5-7. LCMS: MS m / z=650.2 [M+H] +

[0297] Step 8: Synthesis of Compound 5-8

[0298] Dichloromethane (5 mL) and compound 5-7 (0.2 g, 290.04 μmol, 94.281% mass content, 1 equivalent) were added to a clean reaction flask prepared in advance and stirred. m-Chloroperoxybenzoic acid (143.96 mg, 667.37 μmol, 80% mass content, 2.30 equivalents) was then added, and the mixture was reacted at room temperature at 25 °C for 0.5 h. The reaction solution was poured into 20 mL of sodium thiosulfate solution (10%), and the mixture was extracted with 15 mL of dichloromethane. The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was rotary evaporated under reduced pressure at 45 °C. The crude product was purified by column chromatography (dichloromethane / methanol = 100 / 0 to 85 / 15, TLC: dichloromethane / methanol = 15 / 1) to give compound 5-8. LCMS: MS m / z=682.0[M+H] +

[0299] Step 9: Synthesis of Compound 5-9

[0300] Toluene (5 mL) and compound 1-11A (148.59 mg, 1.29 mmol, 153.18 μL, 4 equiv.) were added to a clean reaction flask and stirred. The mixture was then cooled to 0-5 °C, and sodium tert-butoxide (123.98 mg, 1.29 mmol, 4 equiv.) was added. The mixture was allowed to react for 15 min. A solution of compound 5-8 (0.22 g, 322.53 μmol, 1 equiv.) in 0.2 mL of toluene was quickly added, and the mixture was allowed to react for 0.5 h. The reaction solution was poured into 10 mL of saturated ammonium chloride solution, and the mixture was extracted with 10 mL of dichloromethane. The organic phase was washed once with 10 mL of saturated brine, dried over 0.50 g of anhydrous sodium sulfate, and filtered. The filtrate was rotary evaporated under reduced pressure at 45 °C to give compound 5-9. LCMS: MS m / z=621.4[M+H] +

[0301] Step 10: Synthesis of Compounds 5-10

[0302] Dichloromethane (5 mL) and compound 5-9 (98.26 mg, 125.80 μmol, 79.529% mass content, 1 equiv.) were added to a pre-prepared reaction flask and stirred. The mixture was then cooled to -60 °C, and N,N-diisopropylethylamine (162.59 mg, 1.26 mmol, 219.12 μL, 10 equiv.) was added. A solution of acryloyl chloride (17.08 mg, 188.70 μmol, 15.39 μL, 1.5 equiv.) in 0.3 mL of dichloromethane was added dropwise, and the mixture was allowed to react for 10 min. The reaction solution was poured into 5 mL of saturated ammonium chloride solution, and the layers were separated. The organic phase was washed once with 5 mL of saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was rotary evaporated under reduced pressure at 35 °C to give compound 5-10, which was used directly in the next step. LCMS: MS m / z=675.1[M+H] +

[0303] Step 11: Synthesis of Compounds 5A and 5B

[0304] Dichloromethane / trifluoroacetic acid (4 mL, 5 / 3) and compound 5-10 (0.1 g, 148.10 μmol, 1 equivalent) were added to a reaction flask, and the mixture was reacted at room temperature of 25 °C for 0.5 h. The reaction solution was slowly added dropwise to 15 mL of saturated sodium bicarbonate solution, and then the mixture was extracted with 10 mL of dichloromethane. The organic phase was washed once with 10 mL of saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was rotary evaporated under reduced pressure at 30 °C. The crude product was purified using a high-performance liquid chromatography column (column: Phenomenex Gemini-NX 150*30 mm*5 μm; mobile phase: [HO (0.1% TFA)-acetonitrile]; acetonitrile%: 20% to 50%, 9 min) to obtain compound 5-11. Compounds 5-11 were resolved by SFC (DAICEL CHIRALPAK AS (250 mm*30 mm, 10 μm); mobile phase: [0.1% NH3H2O ​​EtOH]; ethanol: 50%-50%, 15 min).

[0305] 5A was obtained (time to peak on chiral column: 1.516). SFC separation method: column: Chiralpak AD-3, 50 x 4.6 mm, ID: 3 μm; mobile phase: A (CO2) and B (isopropanol with 0.05% diethanolamine); gradient: B% = 5-50%, 3 min; flow rate: 3.4 mL / min; wavelength: 220 nm; pressure: 1800 psi. Optical purity: 91.04%. 1H NMR (400 MHz, CDCl3) δ = 8.26 (s, 1H), 7.37 (s, 1H), 6.62 - 6.56 (m, 1H), 6.42 - 6.38 (m, 1H), 5.84 (d, J = 11.6 Hz, 1H), 5.58 (dd, J = 4.0, 11.2 Hz, 1H), 4.94 (s, 2H), 4.55 - 4.43 (m, 1H), 4.27 - 4.18 (m, 1H), 4.02 - 3.87 (m, 1H), 3.76 - 3.73 (m, 1H), 3.23 - 3.18 (m, 4H), 3.07 - 2.98 (m, 2H), 2.87 - 2.74 (m, 3H), 2.56 - 2.53 (m, 6H), 2.13 - 2.07 (m, 1H), 1.82 - 1.76 (m, 3H), 1.37 - 1.29 (m, 3H). LCMS: MS m / z = 591.2[M+H] +

[0306] 5B was obtained (time to peak on chiral column: 1.800). SFC separation method: column: Chiralpak AD-3, 50 x 4.6 mm, ID: 3 μm; mobile phase: A (CO2) and B (isopropanol containing 0.05% diethanolamine); gradient: B% = 5-50%, 3 min; flow rate: 3.4 mL / min; wavelength: 220 nm; pressure: 1800 psi. Optical purity: 99.74%. 1H NMR (400 MHz, CDCl3) δ = 8.31 (s, 1H), 7.36 (s, 1H), 6.63 - 6.53 (m, 1H), 6.42 - 6.37 (m, 1H), 5.83 (d, J = 11.6 Hz, 1H), 5.59 (dd, J = 4.0, 11.2 Hz, 1H), 4.98 - 4.88 (m, 2H), 4.55 - 4.80 (m, 1H), 4.24 - 4.19 (m, 1H), 4.01 - 3.97 (m, 1H), 3.93 - 3.85 (m, 1H), 3.74 - 3.69 (m, 1H), 3.56 - 3.52 (m, 1H), 3.28 - 3.05 (m, 3H), 3.03 - 2.95 (m, 1H), 2.83 - 2.69 (m, 3H), 2.58 - 2.53 (m, 6H), 2.43 - 2.33 (m, 1H), 2.12 - 2.06 (m, 1H), 1.91 - 1.86 (m, 1H), 1.81 - 1.79 (m, 2H), 1.45 - 1.30 (m, 2H). LCMS: MS m / z = 591.2[M+H] +

[0307] Example 6 [ka] Step 1: Synthesis of Compound 6-1

[0308] Compound 4-17 (190 mg, 298.65 μmol, 1 eq.) and N,N-diisopropylethylamine (192.99 mg, 1.49 mmol, 260.10 μL, 5 eq.) were dissolved in dichloromethane (5 mL), and trifluoroacetic anhydride (94.09 mg, 447.98 μmol, 62.31 μL, 1.5 eq.) was added at 0° C. The mixture was reacted at 0° C. for 0.5 hours. The reaction mixture was quenched with saturated aqueous ammonium chloride (5 mL) and extracted with dichloromethane (5 mL*2). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give compound 6-1. LCMS: MS m / z=732.3 [M+H] +

[0309] Step 2: Synthesis of Compound 6-2

[0310] Compound 6-1 (200 mg, 273.15 μmol, 1 equiv.) was dissolved in dichloromethane (4 mL), and trifluoroacetic acid (3.08 g, 27.01 mmol, 2 mL, 98.89 equiv.) was added at 0 °C. The mixture was reacted at 18 °C for 0.5 h. The mixture was directly rotary evaporated to dryness to obtain the crude product, which was purified by high-performance liquid chromatography column (Phenomenex Gemini-NX 150*30 mm*5 μm; mobile phase: [HO (0.1% TFA)-acetonitrile]; acetonitrile%: 30%-60%, 9 min) to obtain compound 6-2. LCMS: MS m / z=632.3 [M+H] +

[0311] Step 3: Synthesis of Compound 6-3

[0312] Compound 6-2 (110 mg, 174.03 μmol, 1 equiv.) and paraformaldehyde (88.91 mg, 1.74 mmol, 10 equiv.) were dissolved in 1,2-dichloroethane (1 mL) and methanol (1 mL). Glacial acetic acid (1.05 mg, 17.40 μmol, 9.95 e-1 μL, 0.1 equiv.) was added, and the mixture was stirred for 30 minutes. Sodium cyanoborohydride (21.87 mg, 348.06 μmol, 2 equiv.) was added, and the mixture was stirred at 25 °C for 10 hours. The mixture was poured into saturated aqueous ammonium chloride (10 mL), and dichloromethane (5 mL × 3) was added. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 6-3. LCMS: MS m / z = 646.1 [M+H] + , 647.7[M+2H] +

[0313] Step 4: Synthesis of Compound 6-4

[0314] Compound 6-3 (90 mg, 139.30 μmol, 1 equiv.) was dissolved in methanol (3 mL), and potassium carbonate (1.7 M, 2.70 mL, 32.95 equiv.) was added. The mixture was reacted at 18° C. for 1 hour. The reaction mixture was quenched with saturated aqueous ammonium chloride (5 mL) and extracted with ethyl acetate (5 mL×2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give compound 6-4. LCMS: MS m / z=550.2 [M+H] + , 551.8[M+2H] +

[0315] Step 5: Synthesis of Compounds 6A and 6B

[0316] Compound 6-4 (76 mg, 138.16 μmol, 1 equiv.) was dissolved in dichloromethane (20 mL), and N,N-diisopropylethylamine (267.83 mg, 2.07 mmol, 360.96 μL, 15 equiv.) was added. Acryloyl chloride (12.50 mg, 138.16 μmol, 11.27 μL, 1 equiv.) was added at −60° C. The mixture was reacted at −60° C. for 0.5 h. The mixture was quenched with saturated aqueous ammonium chloride (5 mL) and extracted with ethyl acetate (5 mL × 2). The organic phases were combined and concentrated to give compound 6-5, which was purified by high performance liquid chromatography column (column: Phenomenex Gemini-NX C18 75*30mm*3μm; mobile phase: [H2O (0.04%NH3H2O ​​+ 10mM NH4HCO3)-ACN]; acetonitrile%: 25%~55%, 6 min) to give compound 6-5, which was isolated by SFC (column: Phenomenex Gemini-NX C18 75*30mm*3μm; mobile phase: [H2O (0.04%NH3H2O ​​+ 10mM NH4HCO3)-ACN]; acetonitrile%: 25%~55%, 6 min) to give compound 6A (time to peak on chiral column = 1.435 min), SFC analytical method (column: Chiralpak AD-3, 50×4.6mm, ID, 3 μm; mobile phase: A (CO2) and B (isopropanol with 0.05% diethanolamine); gradient: B% = 5-50%, 3 min; flow rate: 3.4 mL / min; wavelength: 220 nm; pressure: 1800 psi. Optical purity: 87.38%. LCMS: MS m / z = 604.1 [M+H]+) and compound 6B ((time to peak on chiral column = 1.643)), SFC analytical method (column: Chiralpak AD-3, 50 × 4.6 mm, ID, 3 μm; mobile phase: A (CO2) and B (isopropanol with 0.05% diethanolamine); gradient: B% = 5-50%, 3 min; flow rate: 3.4 mL / min; wavelength: 220 nm; pressure: 1800 psi. Optical purity: 100%. LCMS: MS m / z=604.1 [M+H]+) was obtained.

[0317] Example 7 [ka] Step 1: Synthesis of Compound 7-1

[0318] N,N-Dimethylformamide (6 mL) and compound 5-9 (150 mg, 193.18 μmol, 80% mass content, 1 equivalent) were added to a pre-prepared reaction flask and stirred. The mixture was then cooled to 0-5 °C. 2-Fluoroacrylic acid (26.10 mg, 289.78 μmol, 3.08 μL, 1.5 equivalents), 2-(7-azabenzotriazole)-N,N,N,N-tetramethyluronium hexafluorophosphate (110.18 mg, 289.78 μmol, 1.5 equivalents), and N,N-diisopropylethylamine (74.90 mg, 579.55 μmol, 100.94 μL, 3 equivalents) were then added sequentially, and the mixture was allowed to react for 0.5 h. The reaction solution was poured into 15 mL of saturated ammonium chloride solution and extracted with 20 mL of ethyl acetate. The aqueous phase was washed once with 15 mL of ethyl acetate. The organic phases were combined and washed once with 15 mL of saturated brine, then dried over anhydrous sodium sulfate and filtered. The filtrate was rotary evaporated under reduced pressure at 45°C. The crude product was purified by column chromatography (dichloromethane / methanol = 50 / 1, 30 / 1, 20 / 1, 15 / 1, 10 / 1, TLC: dichloromethane / methanol = 10 / 1) to give compound 7-1. 1H NMR (400 MHz, CDCl3) δ = 8.24 - 8.21 (m, 1H), 7.48 - 7.43 (m, 1H), 5.71 - 5.65 (m, 1H), 5.61 - 5.55 (m, 1H), 5.27 - 5.23 (m, 1H), 4.97- 4.84 (m, 2H), 4.60- 4.56 (m, 2H), 4.06- 4.00 (m, 2H), 3.76 - 3.67 (m, 5H), 3.57 - 3.37 (m, 2H), 3.21 - 3.15 (m, 4H), 3.04 - 2.97 (m, 4H), 2.93 - 2.81 (m, 3H), 2.54 (s, 3H), 2.38 - 2.33 (m, 1H), 2.19 - 2.05 (m, 6H), 1.79 - 1.66 (m, 3H). LCMS: MS m / z = 693.2[M+H] +

[0319] Step 2: Synthesis of Compounds 7A and 7B

[0320] Dichloromethane / trifluoroacetic acid (7 mL, 5 / 3) and compound 7-1 (70 mg, 100.98 μmol, 1 equivalent) were added to a reaction flask, and the mixture was reacted at room temperature of 25 °C for 3 hours. The reaction solution was slowly added dropwise to 15 mL of saturated sodium bicarbonate solution and then mixed with the small-scale reaction solution. The mixture was extracted with 10 mL of dichloromethane. The organic phase was washed once with 10 mL of saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was rotary evaporated under reduced pressure at 30 °C to give the crude product, which was purified by high-performance liquid chromatography (HPLC) column (column: Phenomenex luna C18 100*40 mm*5 μm; mobile phase: [HO (0.1% TFA)-acetonitrile]; acetonitrile%: 10%~35%, 8 min) to give compound 7-2, which was isolated by SFC (column: DAICEL CHIRALCEL OJ (250 mm*30 mm, 10 μm); mobile phase: [0.1% NH3HO EtOH]; EtOH%: 40%~40%, 15 min).

[0321] Compound 7A was obtained (time to peak on chiral column: 1.263 min). SFC separation method: column: Chiralcel OJ-3, 50 × 4.6 mm ID, 3 μm; mobile phase: A (CO2) and B (ethanol, containing 0.05% diisopropylamine); gradient: B% = 5–50%, 3 min; flow rate: 3.4 mL / min; wavelength: 220 nm; pressure: 1800 psi. Optical purity: 91.94%. 1 H NMR (400 MHz, CDCl3) δ=8.29 (s, 1H), 7.35 (s, 1H), 5.61 - 5.57 (m, 1H), 5.48 - 5.32 (m, 1H), 5.28 - 5.24 (m, 1H),4.95 - 4.86 (m, 3H), 4.44 - 4.43 (m, 1H), 4.20 - 4.16 (m, 2H), 3.97 - 3.93 (m, 1H), 3.80 - 3.78 (m, 1H), 3.50 - 3.48 (m, 1H), 3.27 - 3.22 (m, 1H), 3.14 - 2.95 (m, 4H), 2.81 - 2.71 (m, 3H), 2.52 - 2.50 (m, 7H), 2.34 - 2.28 (m, 1H), 2.08 - 2.02 (m, 1H), 1.91 - 1.84 (m, 2H). LCMS: MS m / z=609.2[M+H] +

[0322] Compound 7B was obtained (time to peak on chiral column: 1.393 min). SFC separation method: Column: Chiralcel OJ-3, 50 × 4.6 mm ID, 3 μm; Mobile phase: A (CO2) and B (ethanol, containing 0.05% diisopropylamine); Gradient: B% = 5–50%, 3 min; Flow rate: 3.4 mL / min; Wavelength: 220 nm; Pressure: 1800 psi. Optical purity: 82.48%. 1H NMR (400 MHz, CDCl3) δ=8.26 (s, 1H), 7.35 (s, 1H), 5.59 - 5.55 (m, 1H), 5.48 - 5.36 (m, 1H), 5.29 - 5.24 (m, 1H), 4.93 (s, 2H), 4.42 - 4.40 (m, 1H), 4.24 - 4.20 (m, 2H), 3.73 - 3.70 (m, 1H), 3.24 - 2.98 (m, 8H), 2.90 - 2.71 (m, 3H), 2.53 - 2.48 (m, 7H), 2.33 - 2.31 (m, 1H), 2.09 - 2.04 (m, 1H), 1.89 - 1.85 (m, 2H). LCMS: MS m / z=609.1[M+H] +

[0323] Example 8

change

[0324] In a dry 2 L three-neck flask (anhydrous and oxygen-free environment), sodium hydride (39.12 g, 978.08 mmol, 60% mass content, 2.4 equiv.) was added to N,N-dimethylformamide (510 mL), resulting in a heterogeneous, gray reaction. The mixture was cooled to 0 °C, and a solution of compound 8-1 (51 g, 407.53 mmol, 1 equiv.) in N,N-dimethylformamide (200 mL) was added dropwise under nitrogen. The mixture was allowed to react at 0 °C for 0.5 h. p-Methoxybenzyl chloride (140.41 g, 896.57 mmol, 122.10 mL, 2.2 equiv.) was added, and the reaction was allowed to warm slowly to 20 °C. The reaction turned crimson red and was allowed to react under nitrogen for 7.5 h. The reaction solution was slowly added to 200 mL of saturated ammonium chloride and extracted with methyl tert-butyl ether (200 mL × 2). The organic phases were combined, washed with 200 mL of saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was then concentrated to obtain the crude product. The crude product was separated by a chromatographic purification system COMBI-FLASH (gradient elution: petroleum ether: ethyl acetate = 10:0 to 10:1, petroleum ether: ethyl acetate = 10:1) to obtain compound 8-2. 1 H NMR (400 MHz, CDCl3) δ = 7.23-7.18 (m, 4H), 6.91-6.87(m, 1H), 6.82-6.76 (m, 4H), 6.65 -6.59(m, 2H), 4.20 (s, 4H), 3.79(s, 6H), 2.19 (s, 3H). LCMS: MS m / z = 366.1 [M+H] +

[0325] Step 2: Synthesis of Compound 8-3

[0326] 2,2,6,6-Tetramethylpiperidine (31.31 g, 221.65 mmol, 37.63 mL, 3 equiv) was added to anhydrous tetrahydrofuran (300 mL), and the mixture was cooled to -5 °C. n-Butyllithium (2.5 M, 94.57 mL, 3.2 equiv) was added dropwise, and the mixture was reacted at -5 to 0 °C for 15 min. The mixture was cooled to -60 °C, and a solution of compound 8-2 (27 g, 73.88 mmol, 1 equiv) in tetrahydrofuran (60 mL) was added. The mixture was reacted at -60 °C for 0.5 h. N,N-Dimethylformamide (108.00 g, 1.48 mol, 113.69 mL, 20 equiv) was added quickly, and the mixture was reacted at -60 °C for 10 min. 400 mL of saturated ammonium chloride was added to the reaction solution, and the mixture was extracted with 200 mL × 2 of methyl tert-butyl ether. The combined organic phases were washed with 200 mL of saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give the crude product, which was slurried in 70 mL of a solvent mixture of petroleum ether and methyl tert-butyl ether (petroleum ether:methyl tert-butyl ether = 5:1) for 0.5 hours and then filtered. The filter cake was rotary evaporated to dryness, and the filtrate was stirred and purified by column chromatography (petroleum ether:ethyl acetate = 100:0 to 10:1) to give compound 8-3. 1 H NMR (400MHz, CDCl3) δ = 10.43 - 10.35 (m, 1H), 7.21-7.18 (m, 5H), 6.92 - 6.81 (m, 5H), 4.25 (s, 4H), 3.80 (s, 6H), 2.23 (s, 3H). LCMS:MS m / z = 394.2[M+H] +

[0327] Step 3: Synthesis of Compound 8-4

[0328] Compound 8-3 (17.8 g, 45.24 mmol, 1 equiv.) was added to N,N-dimethylformamide (170 mL). Bromosuccinimide (8.05 g, 45.24 mmol, 1 equiv.) was added, and the mixture was allowed to react at 20 °C for 20 min. The reaction solution was added to 300 mL of water and extracted with 150 mL × 2 of methyl tert-butyl ether. The organic phases were combined, washed with 100 mL × 2 of saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated. The crude product was slurried in a solvent mixture of ethyl acetate and methyl tert-butyl ether (ethyl acetate:methyl tert-butyl ether = 1:1) for 0.5 h and then filtered. The filter cake was rotary evaporated to dryness to give compound 8-4. 1 H NMR (400MHz, CDCl3) δ = 10.39 (s, 1H), 7.17 (d, J = 8.8 Hz, 4H), 6.89 (d, J = 8.8 Hz, 1H), 6.85-6.82 (m, 4H), 4.22 (s, 4H), 3.79 (s, 6H), 2.28 (s, 3H). LCMS:MS m / z = 472.1[M+H] + , 474.1[M+3H] + .

[0329] Step 4: Synthesis of Compound 8-5

[0330] Compound 8-4 (19.3 g, 40.86 mmol, 1 equiv.) was added to N,N-dimethylformamide (190 mL). Cuprous iodide (15.56 g, 81.72 mmol, 2 equiv.) and methyl fluorosulfonyl difluoroacetate (39.25 g, 204.30 mmol, 25.99 mL, 5 equiv.) were added, and the mixture was reacted at 100 °C under nitrogen for 1 h. The reaction solution was filtered through a pad of diatomaceous earth. The filtrate was added to 300 mL of water and extracted with 2 x 150 mL of methyl tert-butyl ether. The combined organic phases were washed with saturated brine (200 mL x 2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 100:0 to 10:1, petroleum ether:ethyl acetate = 5:1) to give compound 8-5. 1H NMR (400MHz, CDCl3) δ = 10.37 (q, J = 4.0 Hz, 1H), 7.18 - 7.11 (m, 4H), 6.89 - 6.82 (m, 4H), 6.73 (d, J = 8.8 Hz, 1H), 4.36 (s, 4H), 3.81 (s, 6H), 2.37 - 2.29 (m, 3H). LCMS: MS m / z =484.0[M+Na] +

[0331] Step 5: Synthesis of Compound 8-6

[0332] Anhydrous tetrahydrofuran (50 mL) and sodium hydride (1.17 g, 29.26 mmol, 60% mass content, 3 equivalents) were added to a dry three-neck flask. The mixture was cooled to 0 °C. Methyl acetoacetate (3.40 g, 29.26 mmol, 3.15 mL, 3 equivalents) was added dropwise under nitrogen, and the mixture was reacted at 0 °C under nitrogen for 0.5 hours. n-Butyllithium (2.5 M, 11.70 mL, 3 equivalents) was added dropwise, and the mixture was reacted at 0 °C for 0.5 hours. The mixture was cooled to -60 °C. A solution of compound 8-5 (4.5 g, 9.75 mmol, 1 equivalent) in tetrahydrofuran (20 mL) was added dropwise, and the mixture was reacted at -60 °C for 0.5 hours. 100 mL of saturated ammonium chloride solution was added to the reaction solution, and the mixture was extracted with 30 mL of ethyl acetate. The organic phase was washed with 80 mL of saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give the crude product, which was combined and purified by column chromatography (petroleum ether:ethyl acetate=100:0-3:1, petroleum ether:ethyl acetate=3:1) to give compound 8-6 as a yellow oil. 1H NMR (400MHz, CDCl3) δ = 7.18-7.15 (m, 4H), 6.90 - 6.78 (m, 4H), 6.61 (d, J = 8.8 Hz, 1H), 5.72 - 5.57 (m, 1H), 4.31 (m, 4H), 3.81(s, 6H), 3.76(s, 3H), 3.56 (s, 2H), 3.50 - 3.38 (m, 1H), 2.98 - 2.93 (m, 1H), 2.38 - 2.26 (m, 3H). LCMS: MS m / z =578.1[M+H] +

[0333] Step 6: Synthesis of Compound 8-7

[0334] Compound 8-6 (3 g, 5.19 mmol, 1 equiv.) was added to anhydrous dichloromethane (30 mL), and N,N-dimethylformamide dimethyl acetal (742.74 mg, 6.23 mmol, 828.02 μL, 1.2 equiv.) was added. The mixture was reacted at 20 °C for 16 h. Boron trifluoride etherate (884.66 mg, 6.23 mmol, 769.27 μL, 1.2 equiv.) was added, and the mixture was reacted at 20 °C for 1 h. The reaction solution was added to 20 mL of saturated sodium bicarbonate solution. The layers were separated, and the aqueous phase was extracted with 20 mL of dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 100:0-3:1, petroleum ether:ethyl acetate = 3:1) to give compound 8-7. 1H NMR (400MHz, CDCl3) δ =8.43 (d, J = 0.8 Hz, 1H), 7.21 - 7.10 (m, 4H), 6.91 - 6.81 (m, 4H), 6.70 (d, J = 8.8 Hz, 1H), 5.93 (dd, J = 3.2, 14.8 Hz, 1H), 4.35 (s, 4H), 3.8(s, 3H), 3.81 (s, 6H), 3.38-3.29 (m, 1H), 2.68 (dd, J = 3.6, 16.8 Hz, 1H), 2.39 - 2.24 (m, 3H). LCMS: MS m / z =588.2[M+H] +

[0335] Step 7: Synthesis of Compound 8-8

[0336] Compound 8-7 (2.1 g, 3.57 mmol, 1 equiv.) was added to anhydrous tetrahydrofuran (21 mL). The mixture was cooled to -60 °C, and lithium tri-sec-butylborohydride (1 M, 4.29 mL, 1.2 equiv.) was added under nitrogen. The mixture was reacted at -60 °C for 0.5 h. The reaction solution was added to 30 mL of saturated ammonium chloride. After extraction, the layers were separated. The organic phase was washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give the crude product, which was purified by column chromatography (petroleum ether:ethyl acetate = 100:0 to 3:1, petroleum ether:ethyl acetate = 3:1) to give compound 8-8. 1 H NMR (400MHz, CDCl3) δ = 7.167-7.14(m, 4H), 6.87-6.83 (m, 4H), 6.63 (d, J = 8.8 Hz, 1H), 5.05-5.00 (m, 1H), 4.61-4.58 (m, 1H), 4.42 - 4.24 (m, 5H), 3.85-3.73 (m, 10H), 3.13-3.05 (m, 1H), 2.47 - 2.38 (m, 1H), 2.35-2.31 (m, 3H). LCMS: MS m / z = 600.1[M+H] +

[0337] Step 8: Synthesis of Compounds 8-9

[0338] Compound 8-8 (1.27 g, 2.15 mmol, 1 equiv.) was added to ethanol (15 mL), water (3 mL), sodium bicarbonate (3.62 g, 43.08 mmol, 1.68 mL, 20 equiv.) and methylisothiourea sulfate (4.05 g, 21.54 mmol, 10 equiv.) were added. The mixture was reacted at 50 °C for 4 hours. The reaction solution was added to 40 mL of water and extracted with 20 mL x 2 of ethyl acetate. The combined organic phases were washed with 20 mL x 2 of saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 100:0 to 1:1, petroleum ether:ethyl acetate = 1:1) to give compound 8-9. 1 H NMR (400MHz, CDCl3) δ = 7.22 - 7.14 (m, 4H), 6.91 - 6.82 (m, 4H), 6.65 (dd, J = 8.4 Hz 1H), 5.12-5.08 (m, 1H), 4.97-4.91 (m, 1H), 4.67 - 4.57 (m, 1H), 4.45 - 4.22 (m, 4H), 3.88 - 3.74 (m, 6H), 3.43-3.35 (m, 1H), 2.77-2.72 (m, 1H), 2.59 (m, 3H), 2.40-2.31 (m, 3H). LCMS:MS m / z =630.2[M+H] +

[0339] Step 9: Synthesis of Compounds 8-10

[0340] Compound 8-9 (0.57 g, 905.25 μmol, 1 equiv.) was added to anhydrous dichloromethane (6 mL), and N,N-diisopropylethylamine (409.48 mg, 3.17 mmol, 551.86 μL, 3.5 equiv.) and triflic anhydride (510.81 mg, 1.81 mmol, 298.72 μL, 2 equiv.) were added at 0°C. The mixture was reacted at 0-5°C for 5 h. The reaction solution was added to 20 mL of saturated ammonium chloride and extracted with 10 mL of dichloromethane. The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 100:0 to 5:1, petroleum ether:ethyl acetate = 3:1) to give compound 8-10. 1 H NMR (400MHz, CDCl3) δ = 7.21 - 7.11 (m, 4H), 6.90 - 6.80 (m, 4H), 6.66 (d, J = 8.4 Hz, 1H), 5.19-5.15 (m, 1H), 5.04 - 4.93 (m, 1H), 4.77-4.72 (m, 1H), 4.41 - 4.19 (m, 4H), 3.80 (s, 6H), 3.62-3.54 (m, 1H), 3.11 - 2.97 (m, 1H), 2.56 (s, 3H), 2.42 - 2.31 (m, 3H). LCMS:MS m / z =762.2[M+H] +

[0341] Step 10: Synthesis of Compounds 8-11

[0342] Compound 8-10 (0.45 g, 590.76 μmol, 1 equiv.) was added to N,N-dimethylformamide (5 mL), and N,N-diisopropylethylamine (229.05 mg, 1.77 mmol, 308.69 μL, 3 equiv.) and compound 1-10A (306.37 mg, 1.18 mmol, 2 equiv., HCl) were added successively. The mixture was reacted at 50 °C for 2 h. The reaction solution was poured into 20 mL of water and filtered. The filter cake was dissolved in 20 mL of methyl tert-butyl ether and washed with 20 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give compound 8-11.1 H NMR (400MHz, CDCl3) δ = 7.44 - 7.32 (m, 5H), 7.16-7.13 (m, 4H), 6.85-6.82 (m, 4H), 6.63 (d, J = 7.6 Hz, 1H), 5.21-5.15 (m, 2H), 4.80 - 4.66 (m, 3H), 4.39 - 4.22 (m, 4H), 3.93-3.88 (m, 1H), 3.80 (s, 6H), 3.71 - 3.55 (m, 1H), 3.52 - 3.29 (m, 2H), 3.25 - 3.08 (m, 3H), 3.06 - 2.96 (m, 2H), 2.91 - 2.77 (m, 1H), 2.71-2.68 (m, 1H), 2.52 (s, 3H), 2.35-2.30 (m, 3H). LCMS: MS m / z =871.4[M+H] +

[0343] Step 11: Synthesis of Compounds 8-12

[0344] Compound 8-11 (580.00 mg, 665.94 μmol, 1 equivalent) was added to anhydrous dichloromethane (6 mL), and m-chloroperoxybenzoic acid (359.13 mg, 1.66 mmol, 80% mass content, 2.5 equivalents) was added. The mixture was reacted at 25 °C for 0.5 hours. The reaction solution was poured into 20 mL of sodium thiosulfate solution (10%) and extracted with 10 mL of dichloromethane. The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was rotary evaporated under reduced pressure at 45 °C. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 100:0-1:1, petroleum ether:ethyl acetate = 1:1) to give compound 8-12. 1H NMR (400MHz, CDCl3) δ = 7.40-7.37 (m, 5H), 7.17-7.12 (m, 4H), 6.86-6.82 (m, 4H), 6.67-6.64 (d, J = 8.4 Hz, 1H), 5.19 (s, 2H), 4.86 - 4.79 (m, 2H), 4.71-4.63 (m, 1H), 4.35 - 4.24 (m, 4H), 3.82-3.81 (m, 1H), 3.80 (s, 6H), 3.64 - 3.50 (m, 2H), 3.46 - 3.33 (m, 2H), 3.30 - 3.27 (m, 4H), 3.25 - 3.11 (m, 3H), 2.71-2.65 (m, 1H), 2.52-2.45 (m, 1H), 2.38-2.30 (m, 3H). LCMS: MS m / z =903.3[M+H] +

[0345] Step 12: Synthesis of Compounds 8-13

[0346] Compound 1-11A (117.35 mg, 1.02 mmol, 120.98 μL, 4 equiv.) was added to dioxane (5 mL). The mixture was cooled to 0-5°C. Sodium tert-butoxide (97.91 mg, 1.02 mmol, 4 equiv.) was added, and the mixture was reacted for 10 minutes. A solution of compound 8-12 (230.00 mg, 254.72 μmol, 1 equiv.) in toluene (1 mL) was added, and the mixture was reacted for 0.5 hours. The reaction solution was added to 20 mL of saturated ammonium chloride and extracted with 2 x 10 mL of ethyl acetate. The organic phases were combined, washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 1:1-0:1, dichloromethane:methanol = 100:0-10:1, dichloromethane:methanol = 10:1) to give compound 8-13. LCMS: MS m / z = 938.2 [M+H] +

[0347] Step 13: Synthesis of Compounds 8-14

[0348] Compound 8-13 (0.15 g, 159.91 μmol, 1 equivalent) was added to anhydrous dichloromethane (5 mL), and trifluoroacetic acid (0.5 mL) was added. The mixture was reacted at 25° C. for 2.5 hours. The reaction solution was added to 10 mL of saturated sodium bicarbonate solution and extracted with 5 mL x 2 of dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give compound 8-14. LCMS: MS m / z=698.2 [M+H] +

[0349] Step 14: Synthesis of Compounds 8-15

[0350] Compound 8-14 (0.17 g, 243.65 μmol, 1 equivalent) was added to anhydrous methanol (2 mL) and anhydrous tetrahydrofuran (2 mL). Palladium on carbon (0.15 g, 10% mass content) was added, and the mixture was reacted at 25° C. under hydrogen (15 psi) for 0.5 hours. The reaction solution was directly filtered to recover the catalyst, and the filtrate was concentrated to obtain compound 8-15 as a yellow solid. LCMS: MS m / z=564.2 [M+H] +

[0351] Step 15: Synthesis of Compounds 8A and 8B

[0352] Compound 8-15 (60 mg, 106.46 μmol, 1 equiv.), 2-fluoroacrylic acid (11.50 mg, 127.75 μmol, 1.2 equiv.), and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (60.72 mg, 159.69 μmol, 1.5 equiv.) were added to N,N-dimethylformamide (1 mL). N,N-Diisopropylethylamine (41.28 mg, 319.38 μmol, 55.63 μL, 3 equiv.) was added, and the mixture was reacted at 25 °C for 0.5 h. The reaction solution was added to 10 mL of saturated ammonium chloride and extracted with 2 x 5 mL of ethyl acetate. The organic phases were combined, washed with 2 x 5 mL of saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give compound 8-16, which was purified by high-performance liquid chromatography (Phenomenex Gemini-NX 150*30 mm*5 μm column; mobile phase: [HO (0.1% TFA)-ACN]; acetonitrile %: 20%-50%, 9 min). The fractions were concentrated under reduced pressure. 5 mL of deionized water and 0.5 mL of acetonitrile were added, followed by 2 drops of 1 M hydrochloric acid solution. The mixture was concentrated under reduced pressure to give compound 8A hydrochloride (time to peak: 1.379 min). SFC separation method: Column: Chiralcel OD-3, 50 × 4.6 mm ID, 3 μm; Mobile phase: A (CO2) and B (methanol, containing 0.05% diisopropylamine); Gradient: B% = 5 to 50%, 3 min; Flow rate: 3.4 mL / min; Wavelength: 220 nm; Pressure: 1800 psi. Optical purity: 80.82%. LCMS: MS m / z = 636.4 [M+H] + ) and compound 8B hydrochloride (time to peak: 1.789 min). An SFC separation method (column: Chiralcel OD-3, 50 x 4.6 mm ID, 3 µm; mobile phase: A (CO2) and B (methanol, containing 0.05% diisopropylamine); gradient: B% = 5 to 50%, 3 min; flow rate: 3.4 mL / min; wavelength: 220 nm; pressure: 1800 psi. Optical purity: 75.56%) was obtained. 1H NMR (400MHz, CDCl3) δ = 6.59 (d, J = 8.4 Hz, 1H), 5.50 - 5.33 (m, 1H), 5.29 - 5.16 (m, 2H), 4.82 - 4.69 (m, 2H), 4.39 (dd, J=5.2, 10.8 Hz, 1H), 4.16 (dd, J=6.8, 10.4 Hz, 1H), 4.04 (s, 2H), 3.94 (d, J = 14.0 Hz, 1H), 3.68 (d, J = 11.6 Hz, 1H), 3.50 - 3.32 (m, 2H), 3.10 (br t, J = 7.2 Hz, 1H), 3.05 - 2.94 (m, 2H), 2.79 (br d, J = 7.2 Hz, 2H), 2.71-2.62 (m, 1H), 2.48 (s, 3H), 2.39 (q, J = 4.0 Hz, 3H), 2.32 - 2.22 (m, 1H), 2.11 - 1.99 (m, 1H), 1.93 - 1.66 (m, 6H). LCMS: MS m / z =636.4[M+H] +

[0353] Example 9 [ka] Step 1: Synthesis of Compound 9-3A

[0354] Anhydrous tetrahydrofuran (30 mL) was added to a dry reaction flask, followed by compound 9-6 (1.5 g, 6.07 mmol, 1 equiv). The reaction was cooled to 10 °C. Lithium aluminum hydride (690.66 mg, 18.20 mmol, 3 equiv) was added in several batches, and the reaction was allowed to react at 15 °C for 16 h. Sodium sulfate decahydrate (4 g) was added to the reaction solution, and the mixture was stirred for 1 h. The mixture was filtered. The filter cake was added to tetrahydrofuran (20 mL × 2), and the mixture was stirred for 0.5 h. The mixture was filtered separately. The filtrates were combined and concentrated under reduced pressure to give compound 9-3A, which was used directly in the next step without purification. 1H NMR (400 MHz, CDCl3) δ ppm 5.25 - 4.98 (m, 1 H) 3.75 - 3.65 (m, 1 H) 3.61 - 3.43 (m, 2 H) 2.83 - 2.74 (m, 1 H) 2.71 - 2.56 (m, 1 H) 2.39 (s, 3 H) 2.14 - 2.03 (m, 2 H). LCMS m / z =134.2[M+H] +

[0355] Step 2: Synthesis of Compound 9-2

[0356] N,N-Dimethylformamide (6 mL) was added to a dry reaction flask, followed by compound 8-10 (0.55 g, 722.04 μmol, 1 equiv.), N,N-diisopropylethylamine (279.95 mg, 2.17 mmol, 377.29 μL, 3 equiv.), and compound 9-1A (289.22 mg, 1.44 mmol, 2 equiv.). The reaction mixture was reacted at 50 °C under nitrogen for 50 min. Compound 9-1A (50 mg) was added, and the mixture was reacted for an additional 0.5 h. TLC (petroleum ether:ethyl acetate = 3:1) showed the disappearance of the raw material and the appearance of a new spot. After cooling the reaction mixture to room temperature (15 °C), the reaction solution was added to saturated ammonium chloride solution (30 mL) and extracted with methyl tert-butyl ether (10 mL × 2). The organic phases were combined, washed with saturated brine (20 mL × 2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give compound 9-2, which was used directly in the next step without purification. LCMS m / z=812.4 [M+H] +

[0357] Step 3: Synthesis of Compound 9-3

[0358] Dichloromethane (10 mL) was added to a dry reaction flask, followed by compound 9-2 (0.65 g, 800.57 μmol, 1 equiv.) and m-chloroperoxybenzoic acid (207.23 mg, 960.68 μmol, 80% purity, 1.2 equiv.). The reaction mixture was allowed to react at 15 °C for 0.5 h. The reaction solution was poured into water (20 mL). Sodium thiosulfate solution (20 mL, 10%) was added, and the mixture showed a negative reaction with starch-KI paper. The mixture was then extracted with dichloromethane (20 mL). The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure at 40 °C to give the crude product, which was purified by column chromatography (petroleum ether:ethyl acetate = 3:1 to 0:1) using TLC (petroleum ether:ethyl acetate = 0:1, RF = 0.53) to give compound 9-3. 1 H NMR (400 MHz, CDCl3) δ ppm 7.16 (d, J = 7.60 Hz, 4 H) 6.84 (d, J = 8.40 Hz, 4 H) 6.66 (s, 1 H) 5.26 (d, J = 10.42 Hz, 1 H), 4.85 - 4.68 (m, 2 H) 4.39 - 4.20 (m, 4 H) 4.09 - 3.90 (m, 2 H) 3.89 - 3.67 (m, 7 H) 3.66 - 3.42 (m, 2 H) 3.40 - 3.16 (m, 2 H) 3.14 - 2.75 (m, 4 H) 2.34 (d, J = 4.00Hz, 3H) 1.49 (s, 9 H) 1.43 - 1.37 (m, 2 H) 1.19 (m, 2 H), LCMS m / z =828.2[M+H] +

[0359] Step 4: Synthesis of Compound 9-4

[0360] Toluene (6 mL) was added to a dry reaction flask, followed by compound 9-3A (289.51 mg, 2.17 mmol, 28.68 μL, 4 equiv). The reaction was cooled to 0 °C. Sodium tert-butoxide (208.93 mg, 2.17 mmol, 4 equiv) was added, and the reaction was allowed to react for 10 min at 0-5 °C. A solution of compound 9-3 (0.45 g, 543.53 μmol, 1 equiv) in toluene (2 mL) was added, and the reaction was allowed to react for 0.5 h at 0-5 °C. The reaction solution was washed with saturated ammonium chloride (20 mL × 2), followed by saturated brine (20 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give compound 9-4, which was used directly in the next step without further purification. 1 H NMR (400 MHz, CDCl3) δ ppm 7.15 (d, J = 7.60 Hz, 4 H) 6.84 (d, J = 8.40 Hz, 4 H) 6.62 (d, J = 7.20 Hz, 1 H) 5.29 - 5.04 (m, 3 H) 4.29 (d, J = 14.80 Hz, 4 H) 3.80 (s, 6 H) 3.44 - 3.34 (m, 2 H) 3.30 - 3.21 (m, 1 H) 3.06 - 2.79 (m, 2 H) 2.68 - 2.52 (m, 5 H) 2.47 (s, 3 H) 2.42 - 2.27 (m, 5 H) 2.25 - 2.08 (m, 5 H) 1.49 (s, 9 H) 1.38 (d, J = 6.40 Hz, 2 H) 1.14 (d, J = 6.80 Hz, 1 H). LCMS m / z =897.3[M+H] +

[0361] Step 5: Synthesis of Compound 9-5

[0362] Dichloromethane (15 mL) was added to a dry reaction flask, followed by compound 9-4 (0.6 g, 668.91 μmol, 1 equiv.) and trifluoroacetic acid (3 mL). The reaction mixture was allowed to react at 15 °C for 2.5 h. Additional trifluoroacetic acid (0.5 mL) was added, and the mixture was allowed to react for an additional hour. Additional trifluoroacetic acid (0.5 mL) was added, and the mixture was allowed to react for an additional hour. The reaction solution was slowly added to saturated sodium bicarbonate solution (80 mL) and extracted with dichloromethane (30 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product, which was purified by column chromatography (dichloromethane:methanol = 100:0-1:1) followed by TLC (dichloromethane:methanol = 5:1) to give compound 9-5. 1 H NMR (400 MHz, CDCl3) δ ppm 6.59 (d, J = 8.40 Hz, 1 H) 5.29 - 5.07 (m, 2 H) 4.75 - 4.67 (m, 1 H) 4.52 - 4.38 (m, 1 H) 4.32 - 4.16 (m, 1 H) 4.08 - 3.87 (m, 3 H) 3.66 - 3.26 (m, 4 H) 3.25 - 2.8 (m, 6 H) 2.72 - 2.59 (m, 1 H) 2.54 (d, J = 2.00 Hz, 3 H) 2.44 - 2.26 (m, 3H) 2.11 - 1.86 (m, 1 H) 1.52 (d, J = 6.80 Hz, 1 H) 1.26 (d, J = 6.80 Hz, 2 H). LCMS m / z =557.3[M+H] +

[0363] Step 6: Synthesis of Compounds 9A and 9B

[0364] Dichloromethane (5 mL) was added to a dry reaction flask, followed by acrylic acid (21.75 mg, 301.85 μmol, 20.72 μL, 1.2 equiv.) and N,N-diisopropylethylamine (97.53 mg, 754.62 μmol, 131.44 μL, 3 equiv.). The reaction was cooled to -60 °C, and O-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (114.77 mg, 301.85 μmol, 1.2 equiv.) was added. The reaction was allowed to react at -60 °C for 10 min. Compound 9-5 (0.14 g, 251.54 μmol, 1 equiv.) was added, and the mixture was allowed to react for an additional 1 h. The reaction solution was diluted with dichloromethane (10 mL), washed with saturated ammonium chloride solution (10 mL × 2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The product was purified by high-performance liquid chromatography (HPLC) column (Phenomenex Luna C18 80 × 40 mm × 3 μm; mobile phase: [HO (0.04% HCl)-ACN]; acetonitrile %: 20% to 32%, 7 min), lyophilized, and then subjected to chiral separation by SFC (SFC column: DAICEL CHIRALCEL OD (250 mm × 30 mm, 10 μm); mobile phase: [0.1% NH3HO MEOH]; MeOH %: 60% to 60%, 9 min) to obtain compound 9A (time to peak on chiral column: 1.594 min). SFC analysis method (Column: Chiralcel OD-3, 50 × 4.6 mm) ID, 3 μm; Mobile phase: A (CO2) and B (methanol, containing 0.05% diisopropylamine); Gradient: B% = 5–50%, 3 min; Flow rate: 3.4 mL / min; Wavelength: 220 nm; Pressure: 1800 psi. Optical purity: 100%. 1H NMR (400 MHz, CDCl3) δ ppm 6.71 - 6.49 (m, 2 H) 6.42 - 6.28 (m, 1 H) 5.77 (d, J = 10.80 Hz, 1 H) 5.50 to 5.04 (m, 3 H) 4.71 (s, 3 H) 4.49 - 4.22 (m, 2 H) 4.03 (s, 3 H) 3.78 (d, J = 9.20 Hz, 1 H) 3.64 (s, 1 H) 3.51 - 3.17 (m, 4 H) 3.14 - 3.00 (m, 4 H) 2.64 - 2.48 (m, 1 H) 2.40 (d, J = 4.00 Hz, 4H) 1.16 (d, J = 10.40 Hz, 3 H). LCMS m / z =611.3[M+H] + ) and compound 9B (time to peak on chiral column: 1.903 min), SFC analytical method (column: Chiralcel OD-3, 50 × 4.6 mm ID, 3 μm; mobile phase: A (CO2) and B (methanol, containing 0.05% diisopropylamine); gradient: B% = 5–50%, 3 min; flow rate: 3.4 mL / min; wavelength: 220 nm; pressure: 1800 psi; optical purity: 100%). 1 H NMR (400 MHz, CDCl3) δ ppm 6.69 - 6.54 (m, 2 H) 6.42 - 6.30 (m, 1 H) 5.77 (d, J = 10.80 Hz, 1 H) 5.47 - 5.01 (m, 3 H) 4.71 (s, 3 H) 4.49 - 4.23 (m, 2 H) 4.03 (s, 3 H) 3.94 - 3.72 (m, 1 H) 3.64 (s, 1 H) 3.53 - 3.22 (m, 4 H) 3.14 - 3.01 (m, 4 H) 2.62 - 2.49 (m, 1 H) 2.40 (d, J = 4.00Hz, 4H) 1.16 (d, J = 10.40 Hz, 3 H). LCMS m / z =611.3[M+H] + ) was obtained.

[0365] Example 10 [ka] Step 1: Synthesis of Compounds 10-1A and 10-1B

[0366] Compound 8-9 (9 g, 15.27 mmol, 1 equiv.) was dissolved in ethanol (100 mL) and water (20 mL), followed by the addition of 2-methyl-2-thioisourea sulfate (42.49 g, 152.65 mmol, 10 equiv.) and sodium bicarbonate (25.65 g, 305.31 mmol, 11.87 mL, 20 equiv.). The reaction solution was stirred at 30 °C for 4 hours. 100 mL of saturated ammonium chloride solution was added to the reaction solution. The mixture was extracted with ethyl acetate (100 mL × 2), washed with 80 mL of saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give the crude product, which was purified by column (petroleum ether: ethyl acetate = 10%-20%-30%) with TLC (petroleum ether: ethyl acetate = 0:1), and then separated by SFC (column: DAICEL CHIRALCEL AD (250 mm * 50 mm, 10 μm); mobile phase: [0.1% NH3.HO EtOH]; EtOH%: 45%-45%, 6.3 min) to give compound 10-1A (time to peak: 1.665) and compound 10-1B (time to peak: 2.446).

[0367] Step 2: Synthesis of Compound 10-2

[0368] Compound 10-1A (2 g, 3.18 mmol, 1 equiv.) was dissolved in dichloromethane (20 mL) and N,N-diisopropylethylamine (1.23 g, 9.53 mmol, 1.66 mL, 3 equiv.) was added. The reaction mixture was cooled to 0-10 °C, and triflic anhydride (1.34 g, 4.76 mmol, 786.11 μL, 1.5 equiv.) was slowly added. The reaction mixture was allowed to react at this temperature for 15 minutes. Saturated aqueous ammonium chloride solution (15 mL) was added to the reaction mixture, and the layers were separated. The aqueous phase was extracted with dichloromethane (15 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give the crude product. The crude product was purified by column chromatography (PE / EtOAc = 100 / 1 to 0 / 1) followed by TLC (PE / EtOAc = 10 / 1) to give compound 10-2. LCMS m / z = 762.2 [M+H] +

[0369] Step 3: Synthesis of Compound 10-3

[0370] N,N-Dimethylformamide (2 mL) was added to a dry reaction flask, followed by compound 10-2 (0.16 g, 210.05 μmol, 1 equiv.), N,N-diisopropylethylamine (81.44 mg, 630.15 μmol, 109.76 μL, 3 equiv.), and compound 10-2A (50.48 mg, 252.06 μmol, 1.2 equiv.). The reaction mixture was stirred at 50 °C under nitrogen for 1 h. TLC (petroleum ether:ethyl acetate = 3:1) showed the disappearance of the raw material and the appearance of a new spot. Methyl tert-butyl ether (10 mL) was added to the reaction solution. The mixture was washed with saturated ammonium chloride solution (20 mL × 2), followed by saturated brine (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give compound 10-3, which was used directly in the next step without purification. 1H NMR (400 MHz, CDCl3) δ ppm 7.12 (d, J = 8.80 Hz, 4 H) 6.81 (d, J = 8.80 Hz, 4 H) 6.60 (d, J = 8.80 Hz, 1 H) 5.19 (d, J = 8.00 Hz, 1 H) 4.72 (s, 2 H) 4.37 - 4.22 (m, 4 H) 3.88 (d, J = 13.2 Hz, 1 H) 3.77 (s, 6 H) 3.71 - 3.56 (dd, J = 12.80, 13.20 Hz, 2 H) 3.40 (dd, J = 12.40, 12.40 Hz, 1 H) 3.31 (m, 2 H) 3.20 (s, 1 H) 3.03 - 2.91 (m, 2 H) 2.50 (s, 3 H) 2.35 - 2.25 (m, 3 H) 1.46 (s, 9 H) 1.13 (d, J = 6.80 Hz, 3 H)

[0371] Step 4: Synthesis of Compound 10-4

[0372] Dichloromethane (5 mL) was added to a dry reaction flask, and compound 10-3 (0.21 g, 258.64 μmol, 1 equiv.) and m-chloroperoxybenzoic acid (66.95 mg, 310.37 μmol, 80% purity, 1.2 equiv.) were added. The reaction mixture was allowed to react at 15 °C for 0.5 h. Sodium thiosulfate solution (15 mL, 10%) was added to the reaction solution. The mixture showed a negative reaction with starch-KI paper. The mixture was then extracted with dichloromethane (15 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product, which was purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to 0:1) followed by TLC (petroleum ether:ethyl acetate = 0:1) to give compounds 10-4 and 10-4A. 1H NMR (400 MHz, CDCl3) δ ppm 7.20 (s, 4 H), 6.84 (d, J = 8.80 Hz, 4 H), 6.79 - 6.62(s,1 H), 5.24 (d, J = 10.80 Hz, 1 H), 4.87 - 4.74 (m, 2 H), 4.36 (s, 4 H), 3.99 - 3.83 (m, 3 H), 3.83 - 3.71 (m, 7 H), 3.62 - 3.43 (m, 2 H), 3.40 - 3.27 (m, 3 H), 3.22 - 3.06 (m, 2 H), 2.92 (d, J = 5.20 Hz, 1 H), 2.34 (s, 3 H), 1.49 (s, 9 H), 1.16 (d, J = 6.80 Hz, 3 H). LCMS m / z =828.2M+H] +

[0373] Step 3: Synthesis of Compound 10-5

[0374] Toluene (1 mL) was added to a dry reaction flask, and compound 1-11A (38.95 mg, 338.19 μmol, 4 equiv.) was added. The reaction system was cooled to 0 °C. Sodium tert-butoxide (32.50 mg, 338.19 μmol, 4 equiv.) was added, and the mixture was allowed to react for 10 min. A toluene (1 mL) solution of a mixture of compound 10-4 (0.07 g, 84.55 μmol, 1 equiv.) and 10-4A (71.35 mg, 84.55 μmol, 1 equiv.) was added, and the mixture was allowed to react for 0.5 h. 10 mL of ethyl acetate was added to the reaction solution, and the mixture was then washed with 10 mL of saturated ammonium chloride solution and saturated brine, respectively. The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to give compound 10-5, which was used directly in the next step without purification. LCMS m / z = 879.3 [M+H] +

[0375] Step 4: Synthesis of Compound 10-6

[0376] Dichloromethane (5 mL) was added to a dry reaction flask, followed by the addition of compound 10-5 (0.16 g, 182.03 μmol, 1 equiv.) and trifluoroacetic acid (1.25 mL). The reaction was stirred at 18° C. for 1.5 hours. Additional trifluoroacetic acid (0.25 mL) was added, and the mixture was allowed to react for another 1.5 hours. Water (5 mL) was added to the reaction solution. The aqueous phase was collected, adjusted to pH 8 with saturated sodium bicarbonate solution, and extracted with dichloromethane (20 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give compound 10-6, which was used directly in the next step without purification. LCMS m / z=539.2 [M+H] +

[0377] Step 5: Synthesis of Compound 10

[0378] Dichloromethane (5 mL) was added to a dry reaction flask, followed by acrylic acid (5.54 mg, 76.87 μmol, 5.28 μL, 2 equiv.), compound 10-6 (23 mg, 38.43 μmol, 90% purity, 1 equiv.), and N,N-diisopropylethylamine (14.90 mg, 115.30 μmol, 20.08 μL, 3 equiv.). The reaction was cooled to -60 °C, and O-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (17.54 mg, 46.12 μmol, 1.2 equiv.) was added. The mixture was then stirred for 0.5 h. The reaction mixture was combined with a batch of compound 10-6 (19.49 mg) and processed. Water (5 mL) was added to the reaction solution, and the layers were separated. The organic phase was concentrated under reduced pressure and separated using a high-performance liquid chromatography column (Phenomenex Luna C18 80*40mm*3μm column; [HO (0.04% HCl)-ACN]; acetonitrile %: 20%-40%, 7 min) to obtain compound 10. LCMS m / z = 593.4 [M+H] +

[0379] Example 11 [ka] Step 1: Synthesis of Compound 11-2

[0380] N,N-Dimethylformamide (2 mL) was added to a dry reaction flask, followed by compound 10-2 (0.16 g, 210.05 μmol, 1 equiv.), N,N-diisopropylethylamine (81.44 mg, 630.15 μmol, 109.76 μL, 3 equiv.), and compound 11-1 (54.02 mg, 252.06 μmol, 1.2 equiv.). The reaction was allowed to react at 50 °C under nitrogen for 1 h. The mixture was combined with a batch of compound 10-2 (50 mg) and treated. Methyl tert-butyl ether (10 mL) was added to the reaction solution. The mixture was washed with saturated ammonium chloride solution (10 mL × 2), followed by saturated brine (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give compound 11-2, which was used directly in the next step without purification. 1 H NMR (400 MHz, CDCl3) δ ppm 7.14 (d, J = 8.80 Hz, 4 H), 6.84 (d, J = 8.40 Hz, 4 H), 6.62 (d, J = 8.80 Hz, 1 H), 5.19 (br d, J = 8.00 Hz, 1 H), 4.76 (s, 2 H), 4.37 - 4.22 (m, 5 H), 3.80 (s, 7 H),3.58 - 3.35 (m, 3 H), 3.22 (s, 2 H), 3.04 - 2.93 (m, 1 H), 2.52 (s, 3 H), 2.38 - 2.30 (m, 3 H), 1.49 (s, 9 H), 1.34 (dd, J = 6.80, 6.40 Hz, 6 H)

[0381] Step 2: Synthesis of Compound 11-3

[0382] Dichloromethane (5 mL) was added to a dry reaction flask, and compound 11-2 (0.20 g, 242.14 μmol, 1 equiv.) and m-chloroperoxybenzoic acid (62.68 mg, 290.57 μmol, 80% purity, 1.2 equiv.) were added. The reaction mixture was allowed to react at 15 °C for 0.5 h. The mixture was combined with a batch of compound 11-2 (50 mg) and treated. Sodium thiosulfate solution (15 mL, 10%) was added to the reaction solution, and the mixture showed a negative reading on starch-KI paper. The mixture was extracted with dichloromethane (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product, which was purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to 0:1) followed by TLC (petroleum ether:ethyl acetate = 0:1) to give a mixture of compound 11-3 and compound 11-3A. 1 H NMR (400 MHz, CDCl3) δ ppm 7.17 (d, J = 6.40 Hz, 4 H) 6.84 (d, J = 8.40 Hz, 4 H) 6.67 (s, 1 H) 5.23 (d, J = 11.20 Hz, 1 H) 4.90 - 4.74 (m, 2 H) 4.32 (d, J = 12.00 Hz, 4 H) 3.84 - 3.75 (m, 9 H) 3.68 - 3.39 (m, 3 H) 3.31 - 3.10 (m, 3 H) 2.89 (d, J=10.40 Hz, 2 H) 2.34 (d, J=3.60 Hz, 3 H) 1.49 (s, 9 H) 1.42 - 1.29 (m, 6 H). LCMS m / z =842.2[M+H] +

[0383] Step 3: Synthesis of Compound 11-4

[0384] Toluene (1 mL) was added to a dry reaction flask, and compound 1-11A (46.51 mg, 403.82 μmol, 4 equiv.) was added. The reaction mixture was cooled to 0 °C. Sodium tert-butoxide (38.81 mg, 403.82 μmol, 4 equiv.) was added, and the mixture was allowed to react for 10 minutes. A toluene (1 mL) solution of a mixture of compound 11-3 (0.085 g, 100.96 μmol, 1 equiv.) and compound 11-3A (86.62 mg, 100.96 μmol, 1 equiv.) was added, and the reaction mixture was stirred for 0.5 hours. The mixture was combined with a batch of compound 11-3 (10 mg) and treated. 10 mL of ethyl acetate was added to the reaction solution, and the mixture was then washed with 10 mL of saturated ammonium chloride solution and saturated brine, respectively, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give compound 11-4, which was used directly in the next step without purification. LCMS m / z=893.4 [M+H] +

[0385] Step 4: Synthesis of Compound 11-5

[0386] Dichloromethane (5 mL) was added to a dry reaction flask, and compound 11-4 (0.13 g, 145.57 μmol, 1 equiv.) and trifluoroacetic acid (1.25 mL) were added. The reaction was allowed to react at 18° C. for 1.5 h. Additional trifluoroacetic acid (0.25 mL) was added, and the mixture was allowed to react for another 1.5 h. The mixture was combined with a batch of 11-4 (15 mg) and treated. Water (5 mL) was added to the reaction solution. The aqueous phase was collected, adjusted to pH 8 with saturated sodium bicarbonate solution, and extracted with dichloromethane (20 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give compound 11-5, which was used directly in the next step without purification. LCMS m / z=553.2 [M+H] +

[0387] Step 5: Synthesis of Compound 11

[0388] Dichloromethane (5 mL) was added to a dry reaction flask, and acrylic acid (14.08 mg, 195.44 μmol, 13.41 μL, 2 equiv.), compound 11-5 (60.00 mg, 97.72 μmol, 90% purity, 1 equiv.), and N,N-diisopropylethylamine (37.89 mg, 293.16 μmol, 51.06 μL, 3 equiv.) were then added. The reaction was cooled to -60 °C. O-(7-Azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (44.59 mg, 117.26 μmol, 1.2 equiv.) was added. The mixture was then stirred for 0.5 h. The reaction mixture was combined with a batch of compound 11-5 (20 mg) and treated. Water (5 mL) was added to the reaction solution. The layers were separated. The organic phase was concentrated under reduced pressure and purified by high-performance liquid chromatography (HPLC) column {column: Phenomenex luna C18 80*40mm *3μm; mobile phase: [HO (0.04% HCl)-ACN]; acetonitrile%: 15%-40%, 7 min} to obtain compound 11. 1 H NMR (400 MHz, CD3OD) δ = 6.92 - 6.75 (m, 1H), 6.74 - 6.70 (m, 1H), 6.33 - 6.24 (m, 1H), 5.88 - 5.77 (m, 1H), 5.28 - 5.18 (m, 1H), 4.82 - 4.63 (m, 2H), 4.56 - 4.43 (m, 1H), 4.42 - 4.23 (m, 1H), 4.01 - 3.81 (m, 2H), 3.79 - 3.59 (m, 2H), 3.57 - 3.41 (m, 1H), 3.32 - 3.20 (m, 5H), 3.17 - 3.02 (m, 3H), 2.84 (m, 2H), 2.51 - 2.35 (m, 3H), 2.31 - 1.99 (m, 3H), 1.49 - 1.29 (m, 6H). LCMS m / z =607.5[M+H] +

[0389] Example 12 [ka] Step 1: Synthesis of Compound 12-2

[0390] N,N-Dimethylformamide (2 mL) was added to a dry reaction flask, followed by compound 10-2 (0.2 g, 262.56 μmol, 1 equiv.), N,N-diisopropylethylamine (101.80 mg, 787.69 μmol, 137.20 μL, 3 equiv.), and compound 9-1A (63.10 mg, 315.07 μmol, 1.2 equiv.). The reaction was allowed to react at 50 °C under nitrogen for 30 min. Additional compound 9-1A (30 mg, 0.6 equiv.) was added, and the mixture was allowed to react for an additional 30 min. Saturated ammonium chloride solution (10 mL) was added to the reaction solution, and the mixture was extracted with methyl tert-butyl ether (5 mL). The organic phase solution was washed successively with saturated ammonium chloride solution (10 mL) and saturated brine (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give compound 12-2, which was used directly in the next step without purification. 1 H NMR (400 MHz, CDCl3) δ ppm 7.14 (d, J = 8.80 Hz, 4 H) 6.84 (d, J = 8.40 Hz, 4 H) 6.62 (d, J = 8.80 Hz, 1 H) 5.21 (d, J = 7.20 Hz, 1 H) 4.78 - 4.63 (m, 2 H) 4.38 - 4.15 (m, 4 H) 4.00 - 3.82 (m, 2 H) 3.80 (s, 6 H) 3.73 - 3.60 (m, 1 H) 3.48 - 3.33 (m, 1 H) 3.22 (s, 2 H) 3.16 - 2.80 (m, 3 H) 2.51 (s, 3 H) 2.38 - 2.30 (m, 3 H) 1.49 (s, 9 H) 1.38 (d, J = 6.80 Hz, 3 H). LCMS m / z =812.3[M+H] +

[0391] Step 2: Synthesis of Compound 12-3

[0392] Dichloromethane (5 mL) was added to a dry reaction flask, followed by compound 12-2 (0.18 g, 221.70 μmol, 1 equiv.) and m-chloroperoxybenzoic acid (57.39 mg, 266.03 μmol, 80% purity, 1.2 equiv.). The reaction was allowed to react at 15 °C for 0.5 h. The mixture was combined with a batch of compound 12-2 (30 mg) and treated. Sodium thiosulfate solution (10 mL, 10%) was added to the reaction solution, and the mixture showed a negative reading on starch-KI paper. The mixture was extracted with dichloromethane (3 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product, which was purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to 0:1) followed by TLC (petroleum ether:ethyl acetate = 0:1) to give compound 12-3. 1 H NMR (400 MHz, CDCl3) δ ppm 7.17 (br s, 4 H) 6.84 (br d, J = 8.40 Hz, 4 H) 6.67 (br s, 1 H) 5.25 (br d, J = 9.60 Hz, 1 H) 4.89 - 4.64 (m, 2 H) 4.32 (br d, J = 10.40 Hz, 4 H) 4.09 - 3.86 (m, 3 H) 3.84 - 3.68 (m, 7 H) 3.64 - 3.51 (m, 1 H) 3.37 - 2.97 (m, 4 H) 2.95 - 2.81 (m, 3 H) 2.34 (br d, J = 3.60 Hz, 3 H) 1.49 (s, 9 H) 1.41 (br s, 3 H). LCMS m / z =828.2[M+H] +

[0393] Step 3: Synthesis of Compound 12-4

[0394] Toluene (1 mL) was added to a dry reaction flask, followed by compound 12-3A (66.52 mg, 471.06 μmol, 3 equiv). The reaction was cooled to 0° C., and then sodium tert-butanol (45.27 mg, 471.06 μmol, 3 equiv) was added. The mixture was stirred for 10 minutes, and then a solution of compound 12-3 (0.13 g, 157.02 μmol, 1 equiv) in toluene (0.5 mL) was added. The mixture was stirred for 0.5 hours. The mixture was combined with a batch of compound 12-3 (20 mg) and treated. 10 mL of ethyl acetate was added to the reaction solution. The mixture was then washed with 10 mL of saturated ammonium chloride solution and saturated brine, respectively, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give compound 12-4, which was used directly in the next step without purification. LCMS m / z=905.3 [M+H] +

[0395] Step 4: Synthesis of Compound 12-5

[0396] Dichloromethane (6 mL) was added to a dry reaction flask, followed by compound 12-4 (0.18 g, 198.89 μmol, 1 equiv.) and trifluoroacetic acid (1.5 mL). The reaction was stirred at 18° C. for 3.5 hours. Water (5 mL) was added to the reaction solution. The aqueous phase was collected, adjusted to pH 8 with saturated sodium bicarbonate solution, and extracted with dichloromethane (20 mL×2). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give compound 12-5, which was used directly in the next step without purification. LCMS m / z=565.2 [M+H] +

[0397] Step 5: Synthesis of Compound 12

[0398] Dichloromethane (5 mL) was added to a dry reaction flask and stirred. Acrylic acid (11.49 mg, 159.40 μmol, 10.94 μL, 2 equiv.), compound 12-5 (50 mg, 79.70 μmol, 90% purity, 1 equiv.), and N,N-diisopropylethylamine (30.90 mg, 239.10 μmol, 41.65 μL, 3 equiv.) were added. The reaction was cooled to -60 °C, and O-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (36.37 mg, 95.64 μmol, 1.2 equiv.) was added. The mixture was then stirred for 0.5 h. The reaction mixture was combined with a batch of compound 12-5 (20 mg) and treated. Water (5 mL) was added to the reaction solution. The layers were separated. The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product, which was then purified using a high-performance liquid chromatography (HPLC) column (Phenomenex Luna C18, 80 x 40 mm, 3 μm column; mobile phase: [HO (0.04% HCl)-ACN]; acetonitrile content: 15% to 40%, 7 min) to obtain compound 12 (time to peak: 1.509). SFC analytical method (Column: Chiralcel OD-3, 50 x 4.6 mm ID, 3 μm column; mobile phase: A (CO2) and B (methanol, containing 0.05% diisopropylamine); gradient: B% = 5 to 50%, 3 min; flow rate: 3.4 mL / min; wavelength: 220 nm; pressure: 1800 psi) was used. Optical purity: 99.4%. 1H NMR (400 MHz, CD3OD) δ = 6.89 - 6.71 (m, 1H), 6.71 - 6.65 (d, J = 8.8 Hz, 1H), 6.32 - 6.19 (m, 1H), 5.84 - 5.75 (m, 1H), 5.26 - 5.15 (m, 1H), 4.68 - 4.60 (m, 1H), 4.52 (s, 2H), 4.50 - 4.45 (m, 1H), 4.39 - 4.32 (m, 1H), 4.27 - 4.16 (m, 1H), 4.15 - 3.89 (m, 2H), 3.76 - 3.61 (m, 2H), 3.60 - 3.32 (m, 2H), 3.28 - 3.13 (m, 3H), 3.09 - 3.00 (m, 1H), 2.96 - 2.85 (m, 1H), 2.38 - 2.32 (m, 3H), 2.32 - 2.24 (m, 2H), 2.24 - 2.12 (m, 4H), 2.12 - 2.03 (m, 2H), 1.42 - 1.31 (m, 3H). LCMS m / z =619.3[M+H] +

[0399] Example 13

change

[0400] N,N-Dimethylformamide (4 mL) was added to a dry reaction flask, followed by compound 10-2 (220 mg, 288.82 μmol, 1 equiv.) and compound 13-1 (115.69 mg, 577.64 μmol, 2 equiv.). The mixture was stirred, and then N,N-diisopropylethylamine (111.98 mg, 866.45 μmol, 150.92 μL, 3 equiv.) was added. The reaction was heated to 50° C. and stirred for 1 h. The reaction solution was extracted with ethyl acetate (30 mL), washed once with saturated ammonium chloride (15 mL) and once with saturated brine (15 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give crude compound 13-2, which was used directly in the next step without purification. LCMS m / z=812.2 [M+H] +

[0401] Step 2: Synthesis of Compound 13-3

[0402] Dichloromethane (10 mL) was added to a dry reaction flask, and compound 13-2 (200.00 mg, 246.33 μmol, 1 equiv.) was added. The mixture was stirred, and m-chloroperoxybenzoic acid (60.01 mg, 295.59 μmol, 85% purity, 1.2 equiv.) was added. The reaction was stirred at 25 °C for 1 h. The reaction solution was diluted with dichloromethane (20 mL), then washed once with 5% sodium thiosulfate (10 mL) and once with saturated brine (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product, which was purified by column chromatography (petroleum ether:ethyl acetate = 90:10 to 50:50) followed by TLC (petroleum ether:ethyl acetate = 1:1) to give compound 13-3. LCMS m / z = 828.3 [M+H] +

[0403] Step 3: Synthesis of compound 13-4

[0404] Toluene (5 mL) was added to a dry reaction flask, followed by compound 1-11A (112.68 mg, 978.35 μmol, 4.5 equiv). The mixture was stirred. Sodium tert-butoxide (94.02 mg, 978.35 μmol, 4.5 equiv) was then added, and the reaction was cooled to 0 °C and stirred for 10 min. Compound 13-3 (180 mg, 217.41 μmol, 1 equiv) was then added, and the reaction was stirred at 0 °C for 1 h. The reaction mixture was combined with a batch of compound 13-3 (60 mg) and treated. The reaction solution was extracted with ethyl acetate (30 mL). The organic phase solution was washed once with saturated ammonium chloride solution (10 mL) and once with saturated brine (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give crude compound 13-4, which was used directly in the next step without purification. LCMS m / z=879.3[M+H] +

[0405] Step 4: Synthesis of compound 13-5

[0406] Dichloromethane (5 mL) was added to a dry reaction flask, followed by compound 13-4 (260 mg, 295.79 μmol, 1 equiv). The mixture was stirred. Potassium acetate (2.82 g, 24.70 mmol, 1.83 mL, 83.50 equiv) was added, and the reaction was stirred at 20 °C for 2 h. Water (30 mL) was added to the reaction solution, and the layers were separated. The aqueous phase was adjusted to pH 9 with saturated sodium bicarbonate and then extracted with ethyl acetate (15 mL × 2). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product of compound 13-5, which was used directly in the next step without purification. LCMS m / z = 539.2 [M+H] +

[0407] Step 5: Synthesis of Compound 13

[0408] Dichloromethane (5 mL) was added to a dry reaction flask, followed by acrylic acid (10.84 mg, 150.40 μmol, 10.32 μL, 1 equiv.), compound 13-5 (90 mg, 150.40 μmol, 90% purity, 1 equiv.), and N,N-diisopropylethylamine (58.31 mg, 451.19 μmol, 78.59 μL, 3 equiv.). The mixture was stirred. The reaction was cooled to -60 °C, and O-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (68.62 mg, 180.47 μmol, 1.2 equiv.) was added. The mixture was stirred for 0.5 h. The reaction mixture was combined with a batch of compound 13-5 (30 mg) and processed. Water (5 mL) was added to the reaction solution, and the layers were separated. The organic phase solution was directly concentrated under reduced pressure to give the crude product, which was purified by high-performance liquid chromatography (HPLC) using a Welch Xtimate C18 column (100 × 25 mm × 3 μm column; mobile phase: [HO (0.05% HCl)-ACN]; acetonitrile content: 15%–45%, 8 min) to give compound 13 (time to peak: 1.683). SFC analysis was performed using a Chiralcel OD-3 column (50 × 4.6 mm ID, 3 μm column; mobile phase: A (CO2) and B (methanol, containing 0.05% diisopropylamine); gradient: B% = 5–50%, 3 min; flow rate: 3.4 mL / min; wavelength: 220 nm; pressure: 1800 psi; optical purity: 95.48%). 1H NMR (400 MHz, CD3OD) δ = 6.87 - 6.73 (m, 1H), 6.68 (d, J = 8.4 Hz, 1H), 6.25 (dd, J = 3.8, 16.6 Hz, 1H), 5.78 (d, J = 11.6 Hz, 1H), 5.20 (dd, J = 4.0, 11.2 Hz, 1H), 4.83 - 4.75 (m, 2H), 4.74 - 4.61 (m, 2H), 4.60 - 4.45 (m, 2H), 4.32 (d, J = 13.0 Hz, 1H), 4.17 - 3.92 (m, 1H), 3.90 - 3.80 (m, 1H), 3.71 - 3.57 (m, 2H), 3.55 - 3.42 (m, 1H), 3.39 - 3.32 (m, 1H), 3.27 - 3.18 (m, 2H), 3.04 (s, 3H), 2.99 - 2.85 (m, 2H), 2.41 - 2.30 (m, 4H), 2.22 - 1.95 (m, 3H), 1.11 (d, J = 6.6 Hz, 3H), LCMS m / z =593.3[M+H] +

[0409] Example 14

change

[0410] N,N-Dimethylformamide (4 mL) was added to a dry reaction flask, followed by compound 10-2 (220 mg, 288.82 μmol, 1 equiv.), compound 14-1 (123.79 mg, 577.64 μmol, 2 equiv.), and N,N-diisopropylethylamine (111.98 mg, 866.45 μmol, 150.92 μL, 3 equiv.). The mixture was stirred. The reaction was stirred at 50° C. for 1 h. The reaction solution was extracted with ethyl acetate (30 mL). The combined organic phase solution was washed once with saturated ammonium chloride solution (15 mL) and once with saturated brine (15 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was then concentrated under reduced pressure to give crude compound 14-2, which was used directly in the next step without purification. LCMS m / z=826.3 [M+H] +

[0411] Step 2: Synthesis of compound 14-3

[0412] Dichloromethane (10 mL) was added to a dry reaction flask, followed by compound 14-2 (350.18 mg, 423.97 μmol, 1 equiv.), and the mixture was stirred. m-Chloroperoxybenzoic acid (109.75 mg, 508.77 μmol, 80% purity, 1.2 equiv.) was added, and the reaction was stirred at 25 °C for 1 h. A more polar major spot was detected. The reaction solution was diluted with dichloromethane (10 mL), then washed once with 5% sodium thiosulfate (10 mL) and once with saturated brine (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 90:10 to 50:50) followed by TLC (petroleum ether:ethyl acetate = 0:1) to give compound 14-3. LCMS m / z = 842.3 [M+H] +

[0413] Step 3: Synthesis of compound 14-4

[0414] Toluene (5 mL) was added to a dry reaction flask, followed by compound 1-11A (98.73 mg, 857.24 μmol, 4.5 equiv.) and stirring. Sodium tert-butoxide (82.38 mg, 857.24 μmol, 4.5 equiv.) was then added, and the reaction was cooled to 0 °C and stirred for 10 min. A solution of compound 14-3 (160.39 mg, 190.50 μmol, 1 equiv.) in toluene (2 mL) was added, and the reaction was stirred at 0 °C for 1 h. The reaction mixture was combined with a batch of compound 14-3 (50 mg) and treated. The reaction solution was extracted with ethyl acetate (30 mL). The organic phase solution was collected, washed once with saturated ammonium chloride solution (10 mL) and once with saturated brine (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give crude compound 14-4, which was used directly in the next step without purification. LCMS m / z=893.4[M+H] +

[0415] Step 4: Synthesis of compound 14-5

[0416] Dichloromethane (5 mL) was added to a dry reaction flask, followed by compound 14-4 (260 mg, 291.15 μmol, 1 equiv). The mixture was stirred. Trifluoroacetic acid (2.77 g, 24.31 mmol, 1.8 mL, 83.50 equiv) was added, and the reaction was stirred at 20° C. for 2 hours. The reaction solution was diluted with dichloromethane (20 mL), and then water (20 mL) was added. The layers were separated. The aqueous phase was adjusted to pH 8 with saturated sodium bicarbonate and then extracted with ethyl acetate (20 mL × 2). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product of compound 14-5, which was used directly in the next step without purification. LCMS m / z=553.2 [M+H] +

[0417] Step 5: Synthesis of Compound 14

[0418] Dichloromethane (5 mL) was added to a dry reaction flask, followed by acrylic acid (10.56 mg, 146.58 μmol, 10.06 μL, 1 equiv.), compound 14-5 (90 mg, 146.58 μmol, 90% purity, 1 equiv.), and N,N-diisopropylethylamine (56.83 mg, 439.73 μmol, 76.59 μL, 3 equiv.). The mixture was stirred, and the reaction was cooled to −60° C. O-(7-Azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (66.88 mg, 175.89 μmol, 1.2 equiv.) was added. The mixture was then stirred for 0.5 h. Water (5 mL) was added to quench the reaction, and the layers were separated. The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to give the crude product. The crude product was purified by high performance liquid chromatography column {Column: Welch Xtimate C18 100*25mm*3μm; Mobile phase: [H2O (0.05% HCl)-ACN]; Acetonitrile%: 15%~45%, 8 min} to obtain compound 14. 1 H NMR (400 MHz, CDCl3)6.69 - 6.62 (m, 1H), 6.62 - 6.48 (m, 1H), 6.47 - 6.34 (m, 1H), 5.91 - 5.76 (m, 1H), 5.34 (s, 1H), 5.25 - 5.14 (m, 1H), 5.10 - 4.99 (m, 1H), 4.86 - 4.64 (m, 2H), 4.62 - 4.30 (m, 2H), 4.21 - 4.11 (m, 1H), 4.06 - 3.93 (m, 2H), 3.90 - 3.73 (m, 2H), 3.71 - 3.59 (m, 1H), 3.57 - 3.49 (m, 3H), 3.47 - 3.33 (m, 1H), 3.28 - 3.15 (m, 2H), 3.09 - 2.92 (m, 1H), 2.50 - 2.35 (m, 4H), 2.26 - 2.09 (m, 2H), 1.43 - 1.32 (m, 4H), 1.31 - 1.25 (m, 2H), LCMS m / z =607.4[M+H] +

[0419] Example 15 [ka] Step 1: Synthesis of Compound 15-2

[0420] N,N-Dimethylformamide (3 mL) was added to a dry reaction flask, and compound 10-2 (200 mg, 262.56 μmol, 1 equiv.) was added. The mixture was stirred. N,N-Diisopropylethylamine (101.80 mg, 787.69 μmol, 137.20 μL, 3 equiv.) and compound 15-1 (78.88 mg, 393.84 μmol, 1.5 equiv.) were added. The reaction was allowed to react at 50° C. for 30 minutes. The mixture was combined with a batch of compound 10-2 (10 mg) and treated. The reaction solution was poured into saturated aqueous ammonium chloride (5 mL) and extracted with ethyl acetate (5 mL×3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give crude compound 15-2, which was used directly in the next step without purification. LCMS m / z=812.2 [M+H] +

[0421] Step 2: Synthesis of compound 15-3

[0422] Dichloromethane (3 mL) was added to a dry reaction flask, followed by compound 15-2 (0.24 g, 295.59 μmol, 1 equiv.). The mixture was stirred. m-Chloroperoxybenzoic acid (66.95 mg, 310.37 μmol, 80% purity, 1.05 equiv.) was added, and the reaction was allowed to react at 25° C. for 30 minutes. The reaction solution was quenched with aqueous sodium sulfite (5 mL, 5%). The layers were separated. The aqueous phase was extracted with dichloromethane (5 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product. The aqueous phase was detected by starch-potassium iodide test paper and shown to be non-oxidizing. The aqueous phase was discarded. The crude product was purified by column chromatography (petroleum ether:ethyl acetate=50:1 to 0:1) by TLC (petroleum ether:ethyl acetate=1:1, product Rf=0.51) to give compound 15-3.1 H NMR (400 MHz, CDCl3) δ = 7.17 - 7.06 (m, 4H), 6.83 - 6.72 (m, 4H), 6.71 - 6.60 (m, 1H), 5.24 - 5.10 (m, 1H), 4.87 - 4.64 (m, 2H), 4.44 - 4.17 (m, 4H), 3.98 - 3.81 (m, 2H), 3.78 - 3.69 (m, 6H), 3.67 - 3.43 (m, 2H), 3.20 - 2.97 (m, 4H), 2.88 - 2.78 (m, 3H), 2.32 - 2.20 (m, 3H), 1.47 - 1.37 (m, 9H), 1.32 - 1.23 (m, 3H). LCMS m / z =828.3 M+H] +

[0423] Step 3: Synthesis of compound 15-4

[0424] Toluene (1 mL) was added to a dry reaction flask, and compound 15-3 (180 mg, 217.41 μmol, 1 equiv.) was added. The mixture was stirred. The reaction was cooled to 0-5°C, and sodium tert-butoxide (2.68 mg, 652.23 μmol, 3 equiv.) was added. The mixture was stirred for 10 min. A solution of compound 1-11A (75.12 mg, 652.23 μmol, 77.44 μL, 3 equiv.) in toluene (0.3 mL) was added to the above reaction solution, and the reaction was allowed to react at 0-5°C for 30 min. The reaction solution was poured into saturated aqueous ammonium chloride (5 mL) and extracted with ethyl acetate (5 mL × 3). The organic phases were combined, washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give crude compound 15-4, which was used directly in the next step without purification. LCMS m / z=879.4[M+H] +

[0425] Step 4: Synthesis of compound 15-5

[0426] Dichloromethane (4 mL) was added to a dry reaction flask, and compound 15-4 (160 mg, 182.03 μmol, 1 equiv.) was added. The mixture was stirred. The reaction was cooled to 0-5° C. Trifluoroacetic acid (1.23 g, 10.81 mmol, 800.00 μL, 59.36 equiv.) was added, and the mixture was stirred for 4 h. The reaction solution was added to saturated aqueous sodium bicarbonate (10 mL). The layers were separated. The mixture was extracted with dichloromethane (5 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product of compound 15-5, which was used directly in the next step without purification. LCMS m / z=539.2 [M+H] +

[0427] Step 5: Synthesis of Compound 15

[0428] Dichloromethane (10 mL) was added to a dry reaction flask, followed by compound 15-5 (0.06 g, 111.40 μmol, 1 eq.) and acrylic acid (16.06 mg, 222.81 μmol, 15.29 μL, 2 eq.). The mixture was stirred. N,N-diisopropylethylamine (28.80 mg, 222.81 μmol, 38.81 μL, 2 eq.) was then added, and the reaction was cooled to -60 °C. O-(7-Azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (63.54 mg, 167.11 μmol, 1.5 eq.) was added, and the reaction was allowed to react at -60 °C for 0.5 h. The mixture was combined with a batch of compound 15-5 (20 mg) and treated. Dichloromethane (5 mL) was added to the reaction solution. The reaction solution was washed with saturated ammonium chloride solution (5 mL × 2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified using a high-performance liquid chromatography column (column: Phenomenex Luna C18 200 x 40 mm x 10 μm; mobile phase: [HO (0.04% HCl)-ACN]; acetonitrile: 1% to 50%, 8 min). One drop of aqueous ammonia was added to the fraction solution, making the solution alkaline. The solution was concentrated to remove the organic solvent and lyophilized to obtain compound 15. 1H NMR (400 MHz, CD3OD) δ = 7.24 - 7.07 (m, 2H), 6.80 (dd, J = 10.8, 16.8 Hz, 1H), 6.71 (d, J = 8.6 Hz, 1H), 6.24 (d, J = 16.8 Hz, 1H), 5.79 (d, J = 11.7 Hz, 1H), 5.24 - 5.16 (m, 1H), 4.76 (d, J = 13.8 Hz, 3H), 4.57 (dd, J = 7.2, 12.5 Hz, 2H), 4.07 - 3.86 (m, 3H), 3.73 (s, 1H), 3.17 (d, J = 11.4 Hz, LCMS m / z =593.2[M+H] +

[0429] Example 16 [ka] Step 1: Synthesis of Compound 16-2

[0430] N,N-Dimethylformamide (3 mL) was added to a dry reaction flask, and compound 10-2 (200 mg, 262.56 μmol, 1 equiv.) was added. The mixture was stirred. N,N-Diisopropylethylamine (101.80 mg, 787.69 μmol, 137.20 μL, 3 equiv.) and compound 16-1 (78.02 mg, 393.84 μmol, 1.5 equiv., 2HCl) were added, and the reaction mixture was reacted at 50° C. for 30 minutes. The mixture was combined and treated. The reaction solution was poured into saturated aqueous ammonium chloride (15 mL) and extracted with ethyl acetate (10 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product of compound 16-2, which was used directly in the next step without purification. LCMS m / z=737.2 [M+H] +

[0431] Step 2: Synthesis of compound 16-3

[0432] N,N-Dimethylformamide (3 mL) was added to a dry reaction flask, and compound 16-2 (230 mg, 312.15 μmol, 1 equiv.) was added. The mixture was stirred. N,N-Diisopropylethylamine (121.03 mg, 936.46 μmol, 163.11 μL, 3 equiv.) and di-tert-butyl dicarbonate (74.94 mg, 343.37 μmol, 78.88 μL, 1.1 equiv.) were added, and the reaction mixture was reacted at 20°C for 10 hours. The reaction solution was poured into saturated aqueous ammonium chloride (15 mL) and extracted with ethyl acetate (10 mL x 2). The organic phases were combined, washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product. The crude product was purified by column chromatography (petroleum ether:ethyl acetate=100:1-0:1) followed by TLC (petroleum ether:ethyl acetate=3:1) to give compound 16-3. 1 H NMR (400 MHz, CDCl3) δ = 7.16 (d, J = 8.4 Hz, 4H), 6.85 (d, J = 8.6 Hz, 4H), 6.64 (d, J = 8.0 Hz, 1H), 5.22 (d, J = 7.2 Hz, 1H), 4.90 - 4.68 (m, 2H), 4.61 (s, 1H), 4.41 - 4.21 (m, 4H), 4.04 (s, 1H), 3.80 (s, 6H), 3.71 (s, 1H), 3.50 (d, J = 11.0 Hz, 2H), 3.30 (s, 1H), 3.24 - 3.02 (m, 2H), 2.90 (d, J LCMS m / z =837.2[M+H] +

[0433] Step 3: Synthesis of compound 16-4

[0434] Dichloromethane (0.3 mL) was added to a dry reaction flask, and compound 16-3 (230 mg, 274.81 μmol, 1 equiv.) was added. The mixture was stirred. m-Chloroperoxybenzoic acid (61.37 mg, 302.29 μmol, 85% purity, 1.1 equiv.) was added, and the reaction was allowed to react at 20 °C for 1 h. The reaction solution was poured into 5% aqueous sodium sulfite solution (5 mL), and the layers were separated. The aqueous phase was extracted with dichloromethane (5 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product. The aqueous phase was tested with starch-potassium iodide paper and shown to be non-oxidizing. The aqueous phase was discarded. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 100:1 to 0:1) followed by TLC (petroleum ether:ethyl acetate = 1:1) to give compound 16-4. LCMS m / z=853.2[M+H] +

[0435] Step 4: Synthesis of compound 16-5

[0436] Toluene (2 mL) was added to a dry reaction flask, and compound 16-4 (158 mg, 185.24 μmol, 1 equiv.) was added. The mixture was stirred. The reaction was cooled to 0° C. Sodium tert-butoxide (35.60 mg, 370.49 μmol, 2 equiv.) was added. The mixture was stirred for 15 minutes, and compound 12-3A (65.40 mg, 463.11 μmol, 2.5 equiv.) was added. The reaction was allowed to react at 0° C. for 30 minutes. The reaction solution was poured into saturated aqueous ammonium chloride (5 mL) and extracted with ethyl acetate (5 mL×3). The organic phases were combined, washed with saturated brine (3 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product of compound 16-5, which was used directly in the next step without purification. LCMS m / z=930.4 [M+H] +

[0437] Step 5: Synthesis of compound 16-6

[0438] Dichloromethane (5 mL) was added to a dry reaction flask, and compound 16-5 (0.18 g, 193.54 μmol, 1 equiv.) was added. The mixture was stirred. Trifluoroacetic acid (1 mL) was then added, and the reaction was allowed to react at 18° C. for 3 hours. Water (10 mL) was added to the reaction solution, and the mixture was extracted. The layers were separated. The aqueous phase was collected, adjusted to pH 8 with saturated sodium bicarbonate solution, and extracted with dichloromethane (20 mL×2). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product of compound 16-6, which was used directly in the next step without purification. LCMS m / z=590.2 [M+H] +

[0439] Step 6: Synthesis of Compound 16

[0440] Compound 16-6 (62.77 mg, 106.46 μmol, 1 equiv.), 2-fluoroacrylic acid (19.17 mg, 212.92 μmol, 2 equiv.), and N,N-diisopropylethylamine (41.28 mg, 319.38 μmol, 55.63 μL, 3 equiv.) were dissolved in DCM (5 mL), and the mixture was cooled to −60° C. O-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (48.58 mg, 127.75 μmol, 1.2 equiv.) was added. The mixture was stirred for 0.5 h. The reaction solution was combined with a batch of compound 16-6 (20.92 mg) and treated. 5 mL of water was added to the reaction solution. The layers were separated. The organic phase was concentrated and purified by high-performance liquid chromatography column {column: Phenomenex luna C18 80*40mm*3μm; mobile phase: [HO (0.04% HCl)-ACN]; acetonitrile%: 20%~40%, 7 min} to obtain compound 16. 1H NMR (400MHz, CD3OD) δ = 6.73 (d, J=8.6 Hz, 1H), 5.45 - 5.21 (m, 3H), 4.87 - 4.80 (m, 2H), 4.57 (s, 2H), 4.19 (br d, J=13.7 Hz, 1H), 3.98 (br d, J=13.1 Hz, 1H), 3.75 - 3.66 (m, 2H), 3.56 - 3.49 (m, 1H), 3.37 (s, 3H), 3.32 - 3.27 (m, 2H), 3.26 - 3.11 (m, 1H), 3.06 - 2.87 (m, 1H), 3.06 - 2.87 (m, 1H), 3.06 - 2.87 (m, 1H), 2.44 - 2.03 (m, 12H). LCMS m / z =662.4[M+H] +

[0441] Example 17 [ka] Step 1: Synthesis of Compound 17-2

[0442] N,N-Dimethylformamide (30 mL) was added to a dry reaction flask, followed by compound 10-2 (2.8 g, 3.68 mmol, 1 equiv). The mixture was stirred. N,N-Diisopropylethylamine (1.43 g, 11.03 mmol, 1.92 mL, 3 equiv) and compound 16-1 (873.80 mg, 4.41 mmol, 1.2 equiv, 2HCl) were added, and the reaction was allowed to react at 50 °C under nitrogen for 1 h. The mixture was combined with a batch of compound 10-2 (0.2 g) and treated. Methyl tert-butyl ether (30 mL) was added to the reaction solution, and the mixture was washed twice with saturated ammonium chloride solution (30 mL × 2) and twice with saturated brine (30 mL × 2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give crude compound 17-2, which was used directly in the next step without purification. 1H NMR (400 MHz, CDCl3) δ ppm 7.15 (d, J = 8.80 Hz, 4 H), 6.84 (d, J = 8.40 Hz, 4 H), 6.63 (d, J = 8.40 Hz, 1 H), 5.22 (dd, J = 11.20, 4.00 Hz, 1 H), 4.71 (s, 2 H), 4.36 - 4.20 (m, 4 H), 4.06 (d, J = 12.80 Hz, 1 H), 3.80 (s, 6 H), 3.61 - 3.50 (m, 2 H), 3.43 (dd, J = 18.80, 11.60 Hz, 2 H), 3.27 - 3.15 (m, 2 H), 3.12 - 2.98 (m, 2 H), 2.85 - 2.66 (m, 2 H), 2.53 (s, 3 H), 2.38 - 2.31 (m, 3 H), LCMS m / z =737.2[M+H] +

[0443] Step 2: Synthesis of compound 17-3

[0444] Dichloromethane (25 mL) was added to a dry reaction flask, and compound 17-2 (2.3 g, 3.12 mmol, 1 equiv.) was added. The mixture was stirred. The reaction was cooled to 0 °C. Triethylamine (789.67 mg, 7.80 mmol, 1.09 mL, 2.5 equiv.) and trifluoroacetic anhydride (983.42 mg, 4.68 mmol, 651.27 μL, 1.5 equiv.) were added, and the reaction was allowed to react at 0-5 °C for 0.5 h. The mixture was combined with a batch of compound 17-2 (0.3 g) and treated. The reaction solution was washed with saturated ammonium chloride solution (20 mL × 2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give crude compound 17-3, which was used directly in the next step without purification. 1H NMR (400 MHz, CDCl3) δ ppm 7.15 (d, J = 8.40 Hz, 4 H), 6.84 (d, J = 8.40 Hz, 4 H), 6.65 (br d, J = 8.40 Hz, 1 H), 5.29 - 5.20 (m, 1 H), 4.77 (s, 2 H), 4.38 - 4.24 (m, 4 H), 4.05 - 3.88 (m, 2 H), 3.80 (s, 6 H), 3.78 - 3.60 (m, 2 H), 3.59 - 3.37 (m, 2 H), 3.14 - 2.99 (m, 2 H), 2.98 - 2.93 (m, 1 H), 2.91 - 2.86 (m, 1 H), 2.78 (t, J = 6.80 Hz, 1 H), 2.53 (s, 3 H), 2.39 - 2.30 (m, 3 H), LCMS m / z =833.1[M+H] +

[0445] Step 3: Synthesis of compound 17-4

[0446] Dichloromethane (30 mL) was added to a dry reaction flask, and compound 17-3 (2.6 g, 3.12 mmol, 1 equiv.) was added. The mixture was stirred. m-Chloroperoxybenzoic acid (697.20 mg, 3.43 mmol, 85% purity, 1.1 equiv.) was added, and the reaction mixture was allowed to react at 18 °C for 0.5 h. The reaction mixture was combined with a batch of compound 17-3 (0.2 g) and treated. Sodium thiosulfate solution (20 mL, 10%) was added to the reaction mixture, and the mixture showed a negative reading on starch-KI paper. The mixture was extracted with dichloromethane (20 mL × 2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product, which was purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to 0:1) followed by TLC (petroleum ether:ethyl acetate = 0:1) to give compound 17-4. 1H NMR (400 MHz, CDCl3) δ ppm 7.15 (d, J = 8.40 Hz, 4 H), 6.84 (d, J = 8.40 Hz, 4 H), 6.66 (d, J = 8.40 Hz, 1 H), 5.27 (d, J = 9.20 Hz, 1 H), 4.93 - 4.982 (m, 2 H), 4.38 - 4.24 (m, 4 H), 4.10 - 3.99 (m, 2 H), 3.98 - 3.88 (m, 1 H), 3.87 - 3.68 (m, 8 H), 3.67 - 3.54 (m, 1 H), 3.54 - 2.98 (m, 3 H), 2.93 - 2.79 (m, 4 H), 2.78 - 2.65 (m, 1 H), 2.35 (d, J = 3.60 Hz, 3 H), LCMS m / z =849.1[M+H] +

[0447] Step 4: Synthesis of compound 17-5

[0448] Toluene (1 mL) was added to a dry reaction flask, and compound 17-4A (78.77 mg, 494.80 μmol, 3 equiv.) was added. The mixture was stirred. The reaction was cooled to 0 °C, and sodium tert-butoxide (47.55 mg, 494.80 μmol, 3 equiv.) was added. The mixture was stirred for 10 min, and then a solution of compound 17-4 (0.14 g, 164.93 μmol, 1 equiv.) in toluene (0.5 mL) was added. The mixture was reacted for an additional 0.5 h. The reaction was combined with a batch of compound 17-4 (20 mg) and treated. The reaction solution was diluted with ethyl acetate (5 mL), washed successively with saturated ammonium chloride (10 mL × 2) and saturated brine (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give crude compound 17-5, which was used directly in the next step without purification. LCMS m / z=848.3[M+H] +

[0449] Step 5: Synthesis of compound 17-6

[0450] Dichloromethane (12 mL) was added to a dry reaction flask, followed by compound 17-5 (160.00 mg, 188.70 μmol, 1 equiv.). The mixture was stirred. Trifluoroacetic acid (2 mL) was then added, and the reaction was allowed to react at 18° C. for 2 hours. The reaction was combined with a batch of compound 17-5 (20 mg) and treated. Water (10 mL) was added to the reaction solution. After extraction, the layers were separated. The aqueous phase was adjusted to pH 8 with saturated sodium bicarbonate solution and extracted with dichloromethane (10 mL×2). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product of compound 17-6, which was used directly in the next step without purification. LCMS m / z=608.3 [M+H] +

[0451] Step 6: Synthesis of Compound 17

[0452] Dichloromethane (5 mL) was added to a dry reaction flask, followed by the addition of compound 17-6 (50 mg, 82.29 μmol, 1 equiv.), 2-fluoroacrylic acid (14.82 mg, 164.58 μmol, 2 equiv.), and N,N-diisopropylethylamine (31.90 mg, 246.87 μmol, 43.00 μL, 3 equiv.). The mixture was stirred. The reaction was cooled to −60° C., and O-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (37.55 mg, 98.75 μmol, 1.2 equiv.) was added. The mixture was then stirred for 0.5 h. The mixture was combined and worked up. Water (5 mL) was added to the reaction solution to quench the reaction mixture, and the layers were separated. The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to give the crude product, which was purified by high-performance liquid chromatography (HPLC) using a Welch Xtimate C18 column (100 × 25 mm × 3 μm; mobile phase: [HO (0.05% HCl)-ACN]; acetonitrile %: 20% to 50%, 8 min) to give compound 17. SFC analysis was performed using a Chiralcel OD-3 column (50 × 4.6 mm ID, 3 μm; mobile phase: A (CO2) and B (methanol, containing 0.05% diisopropylamine); gradient: B% = 5 to 50%, 3 min; flow rate: 3.4 mL / min; wavelength: 220 nm; pressure: 1800 psi; optical purity: 99.21%, time to peak: 1.840). 1H NMR (400 MHz, CD3OD) δ = 6.80 - 6.68 (m, 1H), 5.73 - 5.51 (m, 1H), 5.46 - 5.19 (m, 3H), 5.05 - 4.90 (m, 3H), 4.74 - 4.58 (m, 2H), 4.37 - 4.26 (m, 1H), 4.20 - 4.06 (m, 2H), 4.05 - 3.84 (m, 3H), 3.79 - 3.59 (m, 2H), 3.54 - 3.43 (m, 1H), 3.42 - 3.35 (m, 1H), 3.31 - 3.24 (m, 1H), 3.13 - 2.89 (m, 3H), 2.82 - 2.52 (m, 2H), 2.50 - 2.42 (m, 1H), 2.41 - 2.30 (m, 5H), 2.29 - 2.18 (m, 1H)

[0453] Example 18 [ka] Step 1: Synthesis of Compound 18-1

[0454] 1-11A (194.75 mg, 1.69 mmol, 200.78 μL, 4 equiv) was added to anhydrous toluene (16 mL). The mixture was cooled to 0°C, and sodium tert-butoxide (162.50 mg, 1.69 mmol, 4 equiv) was added. The mixture was reacted at 0-5°C for 10 min. A solution of compound 9-3 (0.35 g, 422.74 μmol, 1 equiv) in toluene (5 mL) was added, and the mixture was reacted at 0-5°C for 0.5 h. The mixture was combined with a batch of compound 9-3 (50 mg) and treated. The reaction solution was washed with 20 mL × 2 saturated ammonium chloride and 20 mL saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give compound 18-1. MS m / z = 879.2 [M+H] +

[0455] Step 2: Synthesis of Compound 18-2

[0456] Compound 18-1 (0.4 g, 455.07 μmol, 1 eq) was added to anhydrous dichloromethane (12 mL), and trifluoroacetic acid (2.4 mL) was added. The mixture was reacted at 25° C. for 1.5 hours. The mixture was combined with a batch of compound 18-1 (50 mg) and treated. Saturated sodium bicarbonate was slowly added to the reaction solution until the pH reached 7-8. The mixture was extracted with 20 mL of dichloromethane, dried over anhydrous sodium sulfate, and filtered. The filtrate was then concentrated to dryness by rotary evaporation to give compound 18-2. LCMS m / z=539.1 [M+H] +

[0457] Step 5: Synthesis of Compounds 18A and 18B

[0458] Compound 18-2 (36.80 mg, 510.60 μmol, 35.04 μL, 1.1 equiv.), acrylic acid (36.80 mg, 510.60 μmol, 35.04 μL, 1.1 equiv.), and N,N-diisopropylethylamine (179.97 mg, 1.39 mmol, 242.55 μL, 3 equiv.) were added to anhydrous dichloromethane (5 mL). The mixture was cooled to -60 °C, and O-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (176.50 mg, 464.18 μmol, 1 equiv.) was added. The mixture was reacted at -60 °C for 30 min. The reaction solution was diluted with 10 mL of dichloromethane, washed with 2 x 10 mL of saturated ammonium chloride, dried over anhydrous sodium sulfate, and filtered. The filtrate was then concentrated. The residue was purified by high-performance liquid chromatography column (column: Phenomenex luna C18 100*40mm*5μm; mobile phase: [HO (0.1% TFA)-ACN]; acetonitrile%: 10%-40%, 8 min), lyophilized, and then subjected to chiral separation by SFC (column: DAICEL Chiralcel OD (250mm*30mm, 10μm); mobile phase: [0.1% NH3HO ETOH]; ethanol%: 50%-50%, 15 min) to obtain compound 18A (time to chiral peak: 1.479). SFC separation method (column: Chiralcel OD-3, 50×4.6mm) ID, 3 μm; Mobile phase: A (CO₂) and B (methanol, containing 0.05% diisopropylamine); Gradient: B% = 5–50%, 3 min; Flow rate: 3.4 mL / min; Wavelength: 220 nm; Pressure: 1800 psi, Optical purity: 100). MS m / z = 593.3 [M+H] + , 11H NMR (400 MHz, CDCl3) δ = 6.66 - 6.50 (m, 2H), 6.36 (d, J = 16.8 Hz, 1H), 5.76 (d, J = 10.0 Hz, 1H), 5.20 (d, J = 7.6 Hz, 1H), 4.58 - 4.53 (m, 1H), 4.45 - 4.20 (m, 2H), 4.01 (s, 3H), 3.85 - 3.23 (m, 6H), 3.04 - 2.86 (m, 2H), 2.67 (s, 2H), 2.47 - 2.33 (m, 3H), 2.22 - 1.53 (m, 8H), 1.23 - 1.04 (m, 3H)) and Compound 18B (time to chiral peak: 1.642), SFC separation method (column: Chiralcel OD-3, 50 × 4.6 mm I.D., 3 μm; mobile phase: A (CO2) and B (methanol containing 0.05% diisopropylamine); gradient: B% = 5 - 50%, 3 min; flow rate: 3.4 mL / min; wavelength: 220 nm; pressure: 1800 psi, optical purity 97.8%). LCMS m / z = 593.3 [M+H] + [[ID=S2]]. 1 1H NMR (400 MHz, CDCl3) δ = 6.72 - 6.48 (m, 2H), 6.35 (dd, J = 1.6, 16.8 Hz, 1H), 5.76 (d, J = 10.4 Hz, 1H), 5.20 (d, J = 7.6 Hz, 1H), 4.83 - 4.57 (m, 3H), 4.18 - 3.99 (m, 3H), 3.94 - 3.5 (m, 2H), 3.5 - 3.2 (m, 2H), 3.11 - 2.75 (m, 6H), 2.43 - 2.35 (m, 3H), 2.35 - 1.80 (m, 8H), 1.38 (d, J = 6.4 Hz, 3H)) was obtained.

[0459] Example 19

Chemical Structure

[0460] Dichloromethane (5 mL) was added to a dry reaction flask, followed by the addition of compound 17-6 (25 mg, 42.40 μmol, 1 equiv.), acrylic acid (6.11 mg, 84.80 μmol, 5.82 μL, 2 equiv.), and N,N-diisopropylethylamine (16.44 mg, 127.20 μmol, 22.16 μL, 3 equiv.). The mixture was stirred. The reaction was cooled to 0 °C, and O-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (19.35 mg, 50.88 μmol, 1.2 equiv.) was added. The mixture was stirred at 20 °C for 3 h. Water (5 mL) was added to quench the reaction, and the layers were separated. The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product, which was purified by high-performance liquid chromatography (HPLC) column (Phenomenex Luna C18 80*40mm*3μm; mobile phase: [HO (0.04% HCl)-ACN]; B%: 18%~34%, 7 min) to obtain compound 19. LCMS m / z=622.2 [M+H] +

[0461] Example 20 [ka] Step 1: Preparation of Intermediate 20-1

[0462] Compound 9-2 (90 mg, 110.85 μmol) was dissolved in dichloromethane (2 mL) and m-chloroperoxybenzoic acid (45.01 mg, 221.70 μmol, 85% content) was added. The reaction solution was stirred at 20°C for an additional 3 hours. The organic solvent was removed under reduced pressure, and the resulting crude product was purified on a preparative thin-layer chromatography plate (developing solvent: dichloromethane:methanol = 20:1) to obtain compound 20-1. MS m / z = 844.4 [M+H] +

[0463] Step 2: Preparation of Intermediate 20-2

[0464] Compound 17-4A (12.26 mg, 77.02 μmol) was dissolved in anhydrous tetrahydrofuran (2 mL) at 20°C. Sodium tert-butoxide (7.40 mg, 77.02 μmol) was added, and the reaction solution was stirred for an additional 30 minutes. A solution of compound 20-1 (50 mg, 59.25 μmol) in tetrahydrofuran (0.5 mL) was added, and the reaction solution was stirred at this temperature for 0.5 hours. The organic solvent was removed under reduced pressure, and the resulting crude product was purified on a preparative thin-layer chromatography plate (developing solvent: dichloromethane:methanol = 10:1) to obtain compound 20-2. MS m / z = 923.6 [M+H] +

[0465] Step 3: Preparation of compound 20-3

[0466] Compound 20-2 (45 mg, 48.75 μmol) was dissolved in anhydrous dichloromethane (2 mL) and trifluoroacetic acid (1.5 mL) was added. The reaction solution was stirred at 20° C. for an additional 2 hours. The solvent was removed under reduced pressure, and the resulting crude product was dissolved in 20 mL of dichloromethane. 3 g of solid sodium bicarbonate was added, and the mixture was stirred at room temperature for an additional 1 hour. The mixture was filtered, and the organic solvent was removed under reduced pressure to give crude product 20-3, which was used directly in the next reaction step without further purification.

[0467] Step 5: Preparation of Compound 20

[0468] Compound 20-3 (20 mg, 34.33 μmol) was dissolved in anhydrous dichloromethane (2 mL) at 20 °C. Diisopropylethylamine (13.31 mg, 102.99 μmol, 17.94 μL) and acryloyl chloride (4.66 mg, 51.49 μmol, 4.20 μL) were added, and the reaction solution was stirred at this temperature for an additional 16 h. The organic solvent was removed under reduced pressure, and the crude product was purified by high-performance liquid chromatography (column: Welch Xtimate C18 100*40 mm*3 μm; mobile phase: [water (0.075% trifluoroacetic acid)-acetonitrile]; acetonitrile: 22%-52%, 8 min) to obtain the trifluoroacetate salt of compound 20. MS m / z = 637.4 [M+H]+

[0469] Biological Assay Data: Assay Example 1: KRAS G12C Assay of the inhibitory effect of compounds on mutant MIA-PA-CA-2 cell proliferation

[0470] 1.1 Purpose of the assay The compound is then added to KRAS G12C IC for growth inhibition of mutant MIA-PA-CA-2 cells 50 were assayed for.

[0471] 1.2 Reagents

[0472] The main reagents used in this assay included CellTiter-Glo (Promega, Cat. No. G7573).

[0473] 1.3 Equipment

[0474] The primary equipment used in this assay was a PerkinElmer EnVision multifunction microplate reader.

[0475] 1.4 Assay Method 1) Adherent cells were digested with trypsin to form a cell suspension, and the cell suspension was counted for subsequent use. 2) An appropriate amount of cells was added to a centrifuge tube and cell culture medium was added to make up the required volume; then the cells were seeded into a 96-well plate at a final density of 2000 cells / well in 100 μL of culture medium. 3) After 24 hours of incubation, compounds were prepared at 10 mM in DMSO and serially diluted 3-fold in nine steps with DPBS (Dulbecco's phosphate-buffered saline); 10 μL was added to each well in duplicate. 10 μL of DPBS / well was added to assay control wells (Con). 4) On the same day, 50 μL of CellTiter Glo was added to another cell culture plate without compound, and the fluorescence value was read by EnVision. The value was recorded as the day 0 value. 5) After 72 hours of incubation of compound-treated cells, the plate was removed and 50 μL of CellTiter Glo was added to the cell plate. The fluorescence value was read by EnVision. 6) Data analysis: The cell inhibition rate of each well was calculated by the following formula:

number

number

[0476] 1.5 Assay Results

[0477] [Table 1]

[0478] The assay results show that the compounds of the present invention inhibit KRAS G12C It was shown to have good inhibitory activity against cell proliferation of the mutant MIA-PA-CA-2 cell line.

[0479] Assay Example 2: H358 Cell Assay

[0480] 2.1 Purpose of the assay The compound is then added to KRAS G12CIC for growth inhibition of mutant H358 cells 50 were assayed for.

[0481] 2.2 Reagents

[0482] The main reagents used in this assay included RPMI-1640 medium, penicillin / streptomycin antibiotics purchased from Vicente, fetal bovine serum purchased from Biosera, CellTiter-Glo (cell viability chemiluminescence detection reagent) reagent purchased from Promega, and NCI-H358 cell line purchased from Cell Bank of the Chinese Academy of Sciences.

[0483] 2.3 Equipment

[0484] The primary instrument used in this assay was the Nivo multilabel analyzer (PerkinElmer).

[0485] 2.4 Assay Method: 1) NCI-H358 cells were seeded into a white 96-well plate, with each well containing 80 μL of cell suspension and 4000 NCI-H358 cells. The cell plate was incubated overnight in a carbon dioxide incubator. 2) The compounds to be assayed were serially diluted 5-fold using a multichannel pipette to obtain nine concentrations, namely, 2 mM to 5.12 nM. Assays were performed in duplicate. 78 μL of medium was added to the intermediate plate, and then 2 μL of the serially diluted compounds was transferred to each well of the intermediate plate according to their corresponding positions. After thorough mixing, 20 μL per well was transferred to the cell plate. The compound concentrations transferred to the cell plate ranged from 10 μM to 0.0256 nM. The cell plate was incubated in a carbon dioxide incubator for 5 days. Another cell plate was prepared, and the signal value of the cell plate was read as the maximum value (Max value, as calculated below) on the day of compound addition and incorporated into data analysis. 25 μL of cell viability chemiluminescence detection reagent was added to each well of the cell plate, and the plate was incubated at room temperature for 10 minutes to stabilize the fluorescent signal. The plate was read using a multi-label analyzer. 3) 25 μL of cell viability chemiluminescence detection reagent was added to each well of the cell plate, and the plate was incubated at room temperature for 10 minutes to stabilize the fluorescent signal. The plate was read using a multi-label analyzer.

[0486] Data Analysis:

[0487] Convert raw data into percentage inhibition using the formula (Sample - Min) / (Max - Min)*100% to IC 50 The values ​​can be obtained by four-parameter curve fitting (GraphPad Prism's "log(inhibitor) vs. response -- variable slope" mode). The inhibitory activity of the compounds of the present invention against NCI-H358 cell proliferation is shown in Table 2.

[0488] [Table 2]

[0489] Conclusion: Some of the compounds of the present invention showed good inhibitory activity on the proliferation of NCI-H358 cells.

[0490] Assay Example 3: Metabolic Stability of Hepatocytes Purpose of the assay: The metabolic stability of the assay compounds was assayed in CD-1 mouse, SD rat, beagle dog, cynomolgus monkey and human hepatocytes, respectively.

[0491] Assay Procedure: Several 96-well sample precipitation plates were prepared and labeled T0, T15, T30, T60, T90, T120, T0-MC, T120-MC, and blank substrate, respectively. The recovery and incubation media were removed in advance and placed in a 37°C water bath for pre-warming. Cryopreserved hepatocytes were removed from the liquid nitrogen tank and immediately immersed in a 37°C water bath (approximately 90 seconds). After the cryopreserved hepatocytes were thawed and loosened, they were poured into a centrifuge tube containing 40 mL of recovery medium, and the tube was gently inverted to resuspend the cells in the recovery medium. The cells were centrifuged at 100 × g for 5 minutes at room temperature, and the supernatant was removed. The hepatocytes were resuspended in an appropriate volume of incubation medium, and cell viability was calculated by trypan blue staining. 198 μL of hepatocyte suspension (0.51 × 10 6 198 μL of hepatocyte-free incubation medium was added to the T0-MC and T120-MC incubation plates as a culture medium control. All incubation plates were preincubated in a 37°C incubator for 10 minutes. Then, 2 μL of working solution of the assay sample and control compound were added, respectively, and the mixture was thoroughly mixed. The incubation plate was immediately placed on a shaker in the incubator to initiate the reaction, and the timer was started simultaneously. Two duplicate samples were prepared for each compound at each time point. The incubation conditions were 37°C, saturated humidity, and 5% CO2. In the assay system, the final concentration of the assay sample was 1 μM, the final concentration of the control sample was 3 μM, and the final concentration of hepatocytes was 0.5 × 10 6The final concentrations of cells / mL and total organic solvents were 0.96%, and the final concentration of DMSO was 0.1%. At the end of the corresponding incubation time points, the incubation plates were removed, and 25 μL of the compound and control compound / cell mixtures were added to sample plates containing 125 μL of stop solution (200 ng / mL tolbutamide and labetalol in acetonitrile). For blank sample plates, 25 μL of hepatocyte-free incubation medium was added directly. After sealing, all sample plates were shaken at 600 rpm for 10 minutes and then centrifuged at 3220 × g for 20 minutes. The supernatants of the assay and control samples were diluted 1:3 with ultrapure water. All samples were thoroughly mixed and analyzed by LC / MS / MS.

[0492] The assay results are shown in Table 3.

[0493] [Table 3]

[0494] Conclusion: Metabolic assays in hepatocytes of various species demonstrate that the compounds of the present invention have good metabolic stability.

[0495] Assay Example 4: In vitro stability assay in liver microsomes Purpose of the assay: The metabolic stability of the assay compounds in liver microsomes from CD-1 mice, SD rats, beagle dogs, cynomolgus monkeys, and humans was assayed, respectively.

[0496] Assay procedure: Two 96-well incubation plates were prepared, designated T60 and NCF60 incubation plates, respectively. 445 μL of microsome working solution (liver microsomal protein concentration of 0.56 mg / mL) was added to the T60 and NCF60 incubation plates, respectively, and then the incubation plates were pre-incubated in a 37°C water bath for approximately 10 minutes.

[0497] After preincubation, 5 μL of working solution of the assay sample or control compound was added to the T60 incubation plate and NCF60 incubation plate, respectively, and the mixture was mixed thoroughly. 50 μL of potassium phosphate buffer was added to each well of the NCF60 incubation plate to initiate the reaction. 180 μL of stop solution (200 ng / mL tolbutamide and 200 ng / mL labetalol in acetonitrile) and 6 μL of NADPH-regenerating system working solution were added to the TO stop plate, and 54 μL of sample was transferred from the T60 incubation plate to the TO stop plate (production of TO sample). 44 μL of NADPH-regenerating system working solution was added to each well of the T60 incubation plate to initiate the reaction. 54 μL of microsome working solution, 6 μL of NADPH-regenerating system working solution, and 180 μL of stop solution alone were added to a blank plate. Therefore, in the samples of assay compounds or control compounds, the final reaction concentrations of the compounds, testosterone, diclofenac, and propafenone were 1 μM, the concentration of liver microsomes was 0.5 mg / mL, and the final reaction concentrations of DMSO and acetonitrile in the reaction system were 0.01% (v / v) and 0.99% (v / v), respectively.

[0498] After incubation for an appropriate time (e.g., 5, 15, 30, 45, and 60 minutes), 180 μL of stop solution (200 ng / mL tolbutamide and 200 ng / mL labetalol in acetonitrile) was added to each sample well of each stop plate. 60 μL of sample was removed from the T60 incubation plate to stop the reaction. All sample plates were shaken well and then centrifuged at 3220 × g for 20 minutes. 80 μL of supernatant was then removed from each well, diluted with 240 μL of pure water, and analyzed by liquid chromatography-tandem mass spectrometry. All samples were injected into the liquid chromatography-tandem mass spectrometry system and analyzed.

[0499] [Table 4]

[0500] Conclusion: The metabolic stability assay in liver microsomes showed that the compounds of the present invention have good metabolic stability.

[0501] Assay Example 5: Stability assay in plasma Purpose of the assay: The stability of the assay compounds in CD-1 mice and human plasma, respectively, was assayed.

[0502] Assay Procedure: Frozen plasma was thawed for 10-20 minutes. After the plasma was completely thawed, it was placed in a centrifuge and centrifuged at 3220 x g for 5 minutes to remove any suspended matter and sediment. 96-well incubation plates were prepared and designated T0, T10, T30, T60, and T120. 98 μL of blank plasma from mouse, rat, dog, monkey, and human samples was added to the corresponding incubation plates, followed by 2 μL of working solution of the compound or control compound in duplicate. All samples were incubated in a 37°C water bath. The final incubation concentrations of the compounds and the control compounds bisacodyl, enalapril maleate, procaine, and probansain were 2 μM, and the final organic phase content was 2.0%. At the end of each incubation time point, the corresponding incubation plate was removed, and 400 μL of 200 ng / mL tolbutamide and labetalol in acetonitrile was added to each corresponding sample well to precipitate proteins. All sample plates were sealed, shaken vigorously, and then centrifuged at 3220 × g for 20 minutes. 50 μL of the supernatant was removed and diluted with 100 μL of ultrapure water. All samples were thoroughly mixed and then analyzed by LC / MS / MS.

[0503] [Table 5]

[0504] Conclusion: The compounds of the present invention had good stability in human and mouse plasma.

[0505] Assay Example 6: Stability Assay in Whole Blood Purpose of the assay: The stability of the assay compounds in CD-1 mice, SD rats, beagle dogs, and cynomolgus monkey whole blood was assayed, respectively.

[0506] Assay Procedure: On the day of the assay or the day before, fresh whole blood from CD-1 mice, SD rats, beagle dogs, and cynomolgus monkeys was collected using the anticoagulant EDTA-K2. Before starting the assay, whole blood was mixed 1:1 (v:v) with PBS, and the mixture was prewarmed in a 37°C water bath for 10–20 minutes. 96-well incubation plates were prepared and designated T0, T30, T60, and T240, respectively. In the corresponding incubation plates, including the T0, T30, T60, and T240 incubation plates, 2 μL of working solution of compound or control compound was mixed in duplicate with 98 μL of blank whole blood from mice, rats, dogs, monkeys, and humans. All samples were incubated in a 37°C water bath. The final incubation concentration of the compound was 5 μM, and the final incubation concentration of the control compound was 2 μM. At the end of each incubation period, the corresponding incubation plate was removed, and 100 μL of ultrapure water was immediately added to the corresponding sample well and mixed thoroughly. Proteins were precipitated by adding 800 μL of a 200 ng / mL solution of tolbutamide and labetalol in acetonitrile. The sample plate was sealed, shaken vigorously, and then centrifuged at 3220 × g for 20 minutes. 150 μL of the supernatant was removed and analyzed by LC / MS / MS.

[0507] [Table 6]

[0508] Conclusion: The stability assay in whole blood of various species showed that the compounds of the present invention have good stability in whole blood.

[0509] Assay Example 7: Protein Binding Rate Assay Assay Objective: Protein binding rates of the assay compounds in plasma from CD-1 mice, SD rats, beagle dogs, cynomolgus monkeys, and humans were determined by equilibrium dialysis.

[0510] Assay procedure: Plasma samples with a 2 μM compound concentration were prepared using the five plasma samples described above, placed in a 96-well equilibrium dialysis apparatus, and dialyzed against phosphate buffer at 37±1°C for 4 hours. Warfarin was used as a control compound in this assay. The concentrations of the assay compounds in the plasma and dialysis buffer were determined by LC-MS / MS.

[0511] [Table 7]

[0512] Conclusion: Plasma binding assays in various species showed that the compounds of the present invention have high protein unbound rates in plasma.

[0513] Assay Example 8: In vivo Pharmacokinetic Assay 1) Pharmacokinetics of the test compound after oral administration and intravenous injection in SD rats

[0514] The assay compounds were mixed with a 5% dimethyl sulfoxide / 95% (10% hydroxypropyl-β-cyclodextrin) solution. The mixture was vortexed and sonicated to prepare a 1 mg / mL clear solution, which was then filtered through a microporous membrane for further use. Male SD rats aged 7 to 10 weeks were selected and administered the candidate compound solution intravenously or orally. Whole blood was collected at regular intervals and prepared to obtain plasma. Drug concentrations were analyzed by LC-MS / MS, and pharmacokinetic parameters were calculated using Phoenix WinNonlin software (Pharsight, USA). The assay results are shown in Table 8.

[0515] [Table 8]

[0516] Note:Vd ss , u is the apparent volume of distribution under unbound plasma proteins (Vd ss ,u=Vd ss / PPB(unbound%));C max,u and AUC 0-last,u is the corresponding value under unbound plasma protein (C max,u =C max ×PPB(unbound %);AUC 0-last,u =AUC 0-last ×PPB (unbonded %))

[0517] Conclusion: PK assays showed that the compounds of the present invention have high unbound plasma exposure and good oral bioavailability in rats.

[0518] 2) Pharmacokinetics of the test compounds in CD mice by oral administration and intravenous injection

[0519] The assay compounds were mixed with a 5% dimethyl sulfoxide / 95% (10% hydroxypropyl-β-cyclodextrin) solution. The mixture was vortexed and sonicated to prepare a 1 mg / mL clear solution, which was then filtered through a microporous membrane for further use. Male CD mice aged 7 to 10 weeks were selected and administered the candidate compound solution intravenously or orally. Whole blood was collected at regular intervals and prepared to obtain plasma. Drug concentrations were analyzed by LC-MS / MS, and pharmacokinetic parameters were calculated using Phoenix WinNonlin software (Pharsight, USA). The assay results are shown in Table 9.

[0520] [Table 9]

[0521] Note:Vdss , u is the apparent volume of distribution under unbound plasma proteins (Vd ss ,u=Vd ss / PPB(unbound%));C max,u and AUC 0-last,u is the corresponding value under unbound plasma protein (C max,u =C max ×PPB(unbound %);AUC 0-last,u =AUC 0-last ×PPB (unbonded %))

[0522] Conclusion: PK assays show that the compounds of the present invention have high unbound plasma exposure and good oral bioavailability in mice.

[0523] Assay Example 9: In vivo Pharmacodynamic Assay In vivo pharmacodynamic assay of human pancreatic cancer Mia PaCa-2 cells in a subcutaneously transplanted tumor model in Balb / c nude mice

[0524] 1. Cell culture and tumor tissue preparation

[0525] Cell culture: Human pancreatic cancer Mia PaCa-2 cells (ATCC-CRL-1420) were cultured in vitro in monolayer in DMEM medium supplemented with 10% fetal bovine serum and 2.5% horse serum at 37°C in a 5% carbon dioxide incubator. Cells were passaged twice weekly by routine digestion with trypsin-EDTA. When cell saturation reached 80%-90% and the required cell number was reached, cells were harvested, counted, and resuspended in an appropriate volume of PBS. Matrigel was added at a 1:1 ratio to 25 × 10 6 A cell suspension with a cell density of 0.05 cells / mL was obtained.

[0526] Cell inoculation: 0.2mL (5×10 6 Mia PaCa-2 cells (+Matrigel, 1:1 in volume) were inoculated subcutaneously into the right dorsal region of each mouse. The mean tumor volume was 190 mm. 3 When tumor volume reached 10, mice were randomized into groups based on tumor volume and treatment was initiated according to the protocol in Table 10.

[0527] [Table 10]

[0528] NOTE: PO indicates oral administration; QD indicates once daily.

[0529] 2. Tumor Measurements and Assay Indicators

[0530] Tumor diameters were measured twice weekly with a vernier caliper. Tumor volume was calculated using the formula: V = 0.5a × b 2 (where a and b represent the long and short diameters of the tumor, respectively).

[0531] The antitumor efficacy of the compounds was evaluated by TGI (%) or relative tumor growth rate T / C (%). Relative tumor growth rate T / C (%) = TRTV / CRTV × 100% (TRTV: RTV of the treatment group; CRTV: RTV of the negative control group). Relative tumor volume (RTV) was calculated according to tumor measurement results, using the formula RTV = Vt / V0 (where V0 was the mean tumor volume measured at the time of administration (i.e., D0) for each group, and Vt was the mean tumor volume at a given measurement). For TRTV and CRTV, data from the same day were used.

[0532] TGI (%) reflected the tumor growth inhibition rate. TGI (%) = [(1 - (mean tumor volume at the end of treatment in the treatment group - mean tumor volume at the start of treatment in the treatment group)) / (mean tumor volume at the end of treatment in the vehicle control group - mean tumor volume at the start of treatment in the vehicle control group)] × 100%.

[0533] 3. Assay Results

[0534] The assay results are shown in Figures 1 and 2.

[0535] The results on day 22 of administration are shown in Table 11.

[0536] [Table 11]

[0537] Conclusion: The compound of the present invention had a significant tumor-inhibiting effect. Moreover, the body weight of the mice in each dose group was stable, and there was no obvious intolerance.

Claims

1. Formula (III) 【Chemical 1】 or a pharmaceutically acceptable salt thereof, wherein T １ is O; R １ is selected from phenyl, naphthyl, and indazolyl, where phenyl, naphthyl, and indazolyl are optionally selected from 1, 2, 3, 4, or 5 R ａ is substituted with; R ２ does not exist; R ３ is C １－３ alkyl, where C １－３ Alkyl is one, two or three R ｃ is substituted with; R ４ is H and C １－３ alkyl, wherein C １－３ Alkyl may optionally have one, two or three R ｄ is substituted with; R ５ , R ６ and R ７ are each independently selected from H, F, Cl, Br, and I; R ８ is H and CH ３ Selected from: R ａ are each independently F, Cl, Br, I, OH, or NH ２ , C.N., C.H. ３ , C.F. ３ and OCH ３ Selected from: R ｃ are each independently tetrahydropyrrolyl, wherein said tetrahydropyrrolyl is optionally substituted with 1, 2, or 3 R; R ｄ are each independently F, Cl, Br, I, OH, or NH ２ and CN; R is independently F, Cl, Br, or CH ３ Selected from: However, the following compounds are not included: 【Chemistry 2】 【Chemistry 3】 A compound or a pharmaceutically acceptable salt thereof.

2. R １ is phenyl, naphthyl, and 【Chemistry 4】 wherein phenyl, naphthyl, and 【Chemistry 5】 optionally one, two or three R ａ Is it replaced by Or, R １ but 【Chemistry 6】 2. The compound of claim 1, selected from: or a pharmaceutically acceptable salt thereof.

3. R ｃ but 【Chemistry 7】 Selected from:

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof.

4. R ３ is CH ３ where CH ３ One, two or three R ｃ Is it replaced by Or R ３ but 【Chemistry 8】 2. The compound of claim 1, selected from: or a pharmaceutically acceptable salt thereof.

5. R ４ is CH ３ where CH ３ optionally one, two or three R ｄ Is it replaced by Or, R ４ is CH ２ CN, or a pharmaceutically acceptable salt thereof.

6. The compound 【Chemistry 9】 Selected from; The compound 【Chemistry 10】 Selected from; or, The compound 【Chemistry 11】 【Chemistry 12】 Selected from: A compound or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising the compound of any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition for treating a KRAS-related disease, comprising the compound of any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof.

Images